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Abstract 
ABSTRACT 
This thesis addresses the use of two general methods involving transition-metal 
catalyzed cyclization for the synthesis of nitrogenous heterocycles. The amino-Heck 
reaction was applied to the synthesis of spiroimines, pyrroles and simple and amino 
acid-based imidazoles while ring-closing metathesis was applied to the synthesis of 
seven- and six-membered lactam analogues of cyclic urea HlY protease inhibitors. The 
lactams were further derivatized to epoxides, and to cis-diols using Sharpless 
asymmetric dihydroxylation. 
Chapter One describes the significance of nitrogenous heterocycles in life and society 
with examples from peptidomimetics, synthetic and medicinal chemistry. The various 
approaches used in the design of peptidomimetics are then reviewed. The amino-Heck 
reaction and ring closing metathesis, used for the synthesis of nitrogenous heterocycles, 
are introduced briefly with an explanation of the catalytic pathways involved in these 
two processes. 
Chapter Two gives a description of the role of palladium in organic and heterocyclic 
syntheses with applications to carbon-carbon and carbon-nitrogen bond formation. 
Palladium-catalyzed carbon-nitrogen bond formations are discussed in detail. The 
Amino-Heck reaction, an important new method for the formation of heterocycles from 
olefinic oxime derivatives, is then reviewed and discussed in terms of its applications 
towards the synthesis of various nitrogenous heterocycles. 
Chapter Three describes the first domino-mode Amino-Heck reaction towards the 
synthesis of spirobicyclic and tricyclic imines. Cephalotaxine and its ester derivatives, 
harringtonine and homoharringtonine, have displayed powerful activity against chronic 
myelogenous leukaemia. l-Azaspiro[ 4.4Jnonane, which makes the core structure of 
Cephalotaxine, and its analogues 3.18a-d, were synthesized by a domino Amino-Heck 
reaction of the dienyl ketone O-pentafluorobenzoyl oximes. The domino Amino-Heck 
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reaction of a trienyl ketone O-pentafluorobenzoyl oxime was also undertaken for the 
synthesis of a diastereomeric mixture of spirotricyclic imines 3.18g and 19. 
Chapter Four extends the scope of the Amino-Heck reaction to the synthesis of 
trisubstituted imidazoles. Various derivatives of imidazoles 4.13a-c were synthesised 
starting from simple non-peptide aldoximes. The generality of the reaction was further 
extended to the synthesis of optically-active a-amino acid-based imidazoles 4.22a-c 
from a-amino aldoximes. The reaction proceeds with little or no racemization as 
determined by coupling of the (S)-Phe-based imidazole 4.22a with (S)-N-Boc alanine to 
give a single diastereoisomer 4.24 (95% de, determined by IH and J3C NMR). The C-
terminal amino acid-based imidazoles have found applications as potential cis-amide 
bond isosteres in pepetidomimetics. The reaction works well for the synthesis of both 
simple and amino acid-based imidazoles from olefinic derivatives of the respective 0-
pentafluorobenzoyl amidoximes. 
Chapter Five describes a further application of the Amino-Heck reaction from 
propargylic type derivatives of ketoximes to the synthesis of 2,5-disubstituted pyrroles. 
Various domino processes, e.g. transmetallation, intermolecular Heck reaction and 
carbonylation with sequential treatment with alcohols, were attempted for termination 
of the living palladium(II) complexes that were generated from oxidative addition of 
palladium into the N-O bond of the oxime followed by triple bond insertion reactions. 
Termination under Amino-Heck reaction conditions gave the corresponding pyrroles, 
whereas the amino-Heck-carbonylation-termination with alcohols sequence led to the 
synthesis of 5-aryl-2-pyrroloesters. 
Chapter Six presents a detailed overview of ring-closing metathesis. The development 
and functional group tolerance of ruthenium, molybdenum and other catalysts, and their 
use in the synthesis of peptidomimetics and non-peptidomimetics-based nitrogenous 
heterocycles are reviewed. Ring-closing metathesis from diene, ene-yne, ene-yne-ene 
and diyne precursors are discussed in detail. In addition, other miscellaneous 
applications ofRCM are described. 
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Chapter Seven describes a versatile ring-closing metathesis approach to the synthesis of 
seven-membered lactam analogues of cyclic urea HN protease inhibitors. The lactams 
7.30, 7.40 and 7.48 were synthesized in good to excellent yields and derivatization of 
the double bond of lactams to epoxides (7.31, 7.41 and 7.49 respectively) and diols 
[(7.32 and 7.33), 7.42 and 7.50 respectively] was carried out successfully. The syn-
stereoselectively of the N-t-Boc group was determined in the asymmetric 
dihydroxylation of the lactam 7.30. The enhancement in the syn-directing effect of the 
N-t-Boc group by C-4 (R)-phenyl group in lactam 7.40 and C-7 (S)-benzyl group in 
lactam 7.48 was determined by the synthesis of a single diastereoisomer (7.42 and 7.50) 
from the con-esponding lactam. The reinforcement of the syn-stereoselectivity by C-7 
(S)-benzyl group ofthe lactam 7.48 was further confirmed from the synthesis of a single 
diastereoisomer 7.50 by canying out the asymmetric dihydroxylation of 7.48 in the 
absence ofligands. 
Abbreviations 
ABBREVIATIONS 
AD Asymmetric dihydroxylation 
[a]o specific rotation 
Amino-Heck 
Boc tert-butyloxycarbonyl 
brs broad singlet (in NMR) 
BOP benzotriazol-l-yloxy-tris( dimethyl amino )phosphonium 
hexafluorophosphate 
COSY correlation spectroscopy 
0 chemical shift 
d doublet (in NMR) 
DCM dichloromethane 
dd doublet of doublets (in NMR) 
DIBALH diisobutylaluminium hydride 
DlEA N,N-diisoprpoylethylamine 
DMAP 4-N,N-dimethylaminopyridine 
DMF N,N-dimethylformamide 
ethyl acetate 
EDCl 1-[3-( dimethyl amino )propyl]-3-carbodiimide hydrochloride 
electronic impact ionisation (in mass spectrometery) 
eqmv. equivalents 
electro spray ionisation (in mass spectrometery) 
FTlR fourier transform infrared 
h hour(s) 
HHT 
HlV 
HMBC 
HOBT 
Hexane 
homoharringtonine 
human immunodeficiency virus 
heteronuclear multiple bond correlation (in NMR) 
I-hydroxybenzotriazole 
Abbreviations 
HRMS 
HSQC 
Hz 
J 
LiHMDS 
LRMS 
m 
Micro. 
mm 
NEM 
NMO 
NMP 
NMR 
PE 
ppm 
RCM 
RCAM 
RCEYM 
RCEYEM 
rt 
s 
t 
TEA 
TFA 
THF 
TLC 
high resolution mass spectroscopy 
heteronuclear single quantum correlation (in NMR) 
hertz (in NMR) 
coupling constant 
lithium bis(trimethylsilyl)amide 
low resolution mass spectrometry 
multiplet (in NMR) 
microanalysis 
minute(s) 
N-ethylmaleimide 
4-methylmorpholine-N-oxide 
I-Methyl-2-pyrrolidinone 
nuclear magnetic resonance 
petroleum ether (bp 50-70 DC) 
parts per million 
ring-closing metathesis 
ring-closing alkyne metathesis 
ring-closing ene-yne metathesis 
ring-closing ene-yne-ene metathesis 
room temperature 
singlet (in NMR) 
triplet (in NMR) 
triethylamine 
trifluoroacetic acid 
tetrahydrofuran 
thin-layer chromatography 
Acknowledgements 
ACKNOWLEDGEMENTS 
In the name of ""LIlLU.., ..... JL. the most merciful and almighty gave me the courage, 
energy and patience to complete this study. 
There are many people, whose inspiration, assistance, support, guidance and love 
enabled me to complete this project. Firstly, my sincere thanks go to my main 
supervisor Professor Andrew Abell for allowing me to work on my PhD research 
project in collaboration with the University of Tokyo, Japan. Professor Abell's excellent 
supervision, guidance, tremendous support and extreme patience enabled me to achieve 
my goals with great confidence. Without Prof. Abell's support, it would have been 
difficult for me to do collaborative research in Japan especially at the time when we 
were newly married. 
Very special thanks to my overseas associate supervisor, Professor Koichi Narasaka for 
giving me an opportunity to work in his lab. It was a wonderful experience to work in a 
totally different environment. However, Professor Narasaka's constant encouragement 
and kind supervision enabled me to adjust to the Japanese culture and long-hour 
working environment. My special thanks also go to Dr. Mitsuru Kitamura, research 
associate at the University of Tokyo Japan, for his friendly advice, positive criticism 
and technical assistance. 
To Dr Owen Curnow, my associate supervisor, University of Canterbury for his 
guidance and efforts in reading this thesis. 
A big thanks to all staff members in Chemistry Department, particularly Bruce Clark 
and Rewi Thompson. I also owe thanks to Abell's group, especially Micheal Edmonds 
and Axel Neffe for their assistance in proof reading, and Blair Stuart for modelling 
studies. 
Acknowledgements 
Special thanks must go to all members of Prof. Abell and Prof. Narasaka's groups for 
their valued friendships and support. 
I am also very grateful to my loving parents for their constant prayers and 
encouragements over these many years of my studies. At this time, I can't forget my 
loving brother Inamullah lilian, and sisters for their constant support during my study. 
I must not forget my brother in law Muhammad Ikram Khan and his wife Shabana for 
their help, support and encouragement. 
I am also grateful to Canterbury University for awarding me a doctoral scholarship. 
Thanks must go to all my friends in Pakistan, especially Khadija Shahid, Safia Liaqat, 
Humaira Nadeem, Salma, Tehmina Hayat, Gulnaz, Tasleem, Aliya Mustafeez, Kulsoom 
and Mumlikat. 
Last but not the least my thanks go to my loving husband Dr Mohammad Zaman for his 
patience, endless support and encouragement. 
Dedication 
DEDICATION 
I dedicate this piece of work to my two loving children HAIDER ZAMAN KHAN and 
MAMUNA ZAMAN KHAJ\J. 
CHAPTER 
GENERAL INTRODUCTION 
Chapter 1 2 
Introduction 
Many N-heterocyclic compounds occur naturally and their functions are often of 
fundamental importance to living systems: biochemical reactions that involve N-
heterocyclic systems are important in many physiological processes, such as provision of 
energy, transmission of nerve impulses, sight, metabolism and transfer of hereditary 
information. The reason that nature utilises so many nitrogenous heterocyclic compounds 
lies in their remarkable properties. Nitrogen-containing heterocycles can behave like acids 
(the NH group of pyrroles) , bases (the N group of pyridine), or be amphoteric (imidazoles). 
Another important property of N-heterocylic compounds is their ease of coordination with 
metal atoms. This can be seen in natural compounds like haeme and chlorophyll, which are 
important components in photosynthesis and oxygen transport in plants and animals. N-
heterocycles are also able to participate in hydrogen bonding. For example, polypeptide 
helical chains and the double helical structure of DNA are stabilized by such interactions. 
Due to these striking properties, N-heterocycles have found wide-spread applications as 
key components of a large number of biologically-active natural products. Examples 
include antibiotics such as penicillin and cephalosporin, alkaloids such as vinblastine, 
ellipticine, morphine and reserpine, and marine natural products like sceptrin and ageliferin 
and fungal natural product like cyclosporine A and FK506, all exhibiting interesting 
biological properties. However, synthetic N-heterocyclics have also found widespread use 
in pharmaceuticals as anticancer agents, analeptics, analgesics, hypnotics and vasopressor 
modifiers, in agrochemicals as pesticides, insecticides and herbicides, in material sciences 
as polymers, dyestuffs, photographic sensitizers and developers, antioxidants and 
vulcanization accelerators in the rubber industry. 
The successful application of heterocyclic systems in these and many other areas, and their 
significance in applied chemistry, arise from their very complexity. This ensures numerous 
novel compounds with a range of physical, chemical and biological properties, displaying a 
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broad spectrum of reactivity and stability. A good deal of effort has, therefore, gone into 
the synthesis of this biologically diverse and important class of compounds. What follows 
is a detailed overview of the significance of heterocyclic systems in peptides and proteins. 
1.2 N-Heterocydes in Peptides and Proteins 
Peptides and proteins are a particularly important class of natural compounds, because of 
their role in a wide variety of processes that are fundamental to living organisms. Cellular 
membrane walls, supporting and protective tissues, and muscle fibres are among many 
examples of living structural materials made up of proteins. Twenty primary amino acids 
exist in nature, and each contains an amino group, a carboxylic acid and a sidechain group, 
R, attached to a central carbon (Figure l.la). Amino acids are linked together by 
condensation of the amino group of one amino acid with the carboxyl group of another to 
form an amide or peptide (CONH) bond (Figure l.lb). Proteins are derived from the 
combination of the twenty primary amino acids to give an infinite number of possible 
sequences within the polypeptide ehain. 
R 
H~ ;OH 
H2N' If 
o 
(a) 
amide linkage 
~ 
RI 0 R2 0 
""NAN)lNAN~ 
H H H H 
(b) 
Figure 1.1: a) general structure of the plimary amino acid. b) a peptide chain joined by amide linkage. 
The common ammo acids differ only in the nature of the R groups. Histidine (1.1), 
tryptophan (1.2) and proline (1.3) are among the primary amino acids whose sidechains are 
derived from N-heterocyclic residues, are depicted in Figure 1.2. 
Chapter 1 
R 
H,~ JOH 
H2N" If R 
o 
\~N ~_J 
N 
H 
1.1 
\~ ~~T~ N 
H 
1.2 
Figure 1.2: Heterocycle-based primary amino acids. 
~C02H 
H 
1.3 
4 
Several additional non-protein amino acids have evolved from the diverse metabolism of 
plants and microorganisms, some of which are biochemically important. For example, 
histamine 1.4, derived from histidine by enzymatic decarboxylation, is the cause of 
allergies in mast cells. It also dilates blood vessels, increases the permeability of capillaries, 
and constricts bronchial air passages (Figure 1.3). Similarly, serotonin (1.5), derived from 
tryptophan by enzymatic hydroxylation at C-5 followed by decarboxylation, acts as a 
neurotransmitter and a regulator (Figure 1.3). 
H0'CUJ I~ I NH 
N 2 
H 
1.4 1.5 
Figure 1.3: Biochemically important derivatives of histidine and tryptophan. 
Enzymes, nature's biocatalysts, are of crucial importance in chemical and physiological 
processes in organisms. The tertiary structure of an enzyme defines clefts, pockets and/or 
trenches on the surface. The active site of an enzyme is a cleft into which a specific 
substrate enters. The imidazole ring of histidine (1.1) is often associated with catalytic 
activity because of its acid base properties and ability to participate in hydrogen bonding. 
The high basicity of the imidazole ring of histidine enables it to form strong hydrogen 
bonds and also to abstract a proton from an acid, such as water or an alcohol. The imidazole 
ring can catalyze a nucleophilic addition to a carbonyl group through 'general base 
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catalysis'. Such catalysis is best illustrated by the hydrolytic cleavage of a peptide bond in a 
protein or polypeptide by a class of enzymes named proteases (see Scheme 1.1). 
RI 0 RI 0 ~N~(~YL Protease ~OH + H2N~ """"""N 
H 0 R2 H2O H 0 R? 
1.6 1.7 1.8 
Scheme 1.1: Hydrolysis of the peptide 1.6 by a protease to give fragments 1.7 and 1.8. 
A histidine residue is a constituent of the active site of many enzymes, e.g. serine proteases, 
where it plays a key catalytic role (Fig.1.5). The mechanism of amide bond hydrolysis by 
serine proteases involves a catalytic triad of amino acids denoted as Ser195, His57 and 
Asp 102 (Figure 1.5). The numbers 195, 57 and 102 represent the position of the 
corresponding amino acid in the polypeptide chain.1 Figure 1.4 illustrates the mechanism of 
a serine protease catalyzed hydrolysis of a peptide bond. 
The nucleophilicity of the hydroxyl group of Ser195 in enhanced by charge transfer from 
His57 and Aspl02. Attack on the carbonyl group of the substrate 1.6 then occurs to form a 
tetrahedral complex 1.9. The oxyanion of 1.9 is stabilized by hydrogen bonding to NH 
groups in an active site region termed the 'oxyanion hole'. The complex 1.9 is transformed 
to an acyl intermediate 1.10 along with the formation of the C-terminal fragment 1.8. 
Hydrolysis of 1.10 by an active site water molecule then occurs with the release of N-
terminal fragment 1.7 and regeneration of the catalytic triad (see Figure 1.4). 
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1.6 
Rl 
~HN~OH 
1.7 0 
6 
Oxyanion hole 
1.10 
Figure 1.4: Serine protease catalyzed hydrolysis ofthe peptide 1.6. 
Serine proteases are involved in a large number of physiological processes such as 
digestion and blood clotting, peptide hormone processing, fertilization, cell destruction and 
defense mechanisms. 
1.3 Peptidomimetics2 
The use of peptides as drugs is problematic due to their poor pharmacological properties 
such as low metabolic stability, vulnerability of the peptide bonds to hydrolysis, poor 
pharmacokinetics and poor oral bioavailability. Thus, a potent peptide may be active in 
Chapter 1 7 
vitro, but not in vivo because of the above mentioned reasons. In order to circumvent these 
problems, considerable efforts have been invested in modification or non-peptide 
surrogates of biologically active peptides, These surrogates are referred to as 
peptidomimetics. 
Peptidomimetics are designed on the basis of the conformational, topochemical and 
electronic properties of a native peptide and its receptor,3 The design of a peptidomimetic 
as a potential bioactive substance, therefore, is of crucial importance and depends on two 
main structural factors; a favourable conformation with respect to spatial position of the 
active site, and the placement of certain structural elements in the defined positions so that 
the desired interactions can occur. What follows here is a discussion of various strategies 
that are usual1y employed in peptidomimetics design. 
1.3.1 Conformational Restriction 
A key principle in peptidomimetics design is the formation of conformationally-restricted 
ligands which mimic the bioactive conformation of the native peptide. The required 
bioactive conformation can be stabilized by incorporation of additional structural elements 
to enforce rigidity, The introduction of these rigid structural features in defined positions 
increases its affinity by lowering the entropy cost exhibited by a peptidomimetic upon 
binding to a receptor. Conformational restriction is always achieved by fixing a peptide 
bond into a cis or trans geometry. The pioneering research by Pauling and Corey on the 
structure of peptides and proteins revealed that the peptide bond is rigid and planar such 
that the H atom attached to the nitrogen is always trans to the carbonyl group due to the 
partial double bond character of the amide bond. The rate of interconversion between the 
cis and trans geometdes is slow as a result of limited rotation about the amide bond 
(Scheme 1.2). 
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slow 
--
trans cis 
Scheme 1.2 
The conformation of the amide bond, therefore, is of crucial importance to the binding of a 
peptide-based ligand to a receptor. An example is the Phe-Pro cleavage site in the 
substrates of HIV protease, a site distinct to retroviral proteases. Initial studies of HIV 
protease suggested that a cis-conformation was preferred at this position in substrates that 
bind in the active site of the enzyme. This resulted in the development of the potent HIV 
protease inhibitor JG-365 (1.11), a compound that contains a modified peptide bond to 
include a hydroxyethylamine isostere in place of the key phenylalanine residue4 (Figure 
1.5). 
(Ph / t 
ACHNSer-LeU-Asn-NH~N~ 
OH ~, 
o Ile-Val-OMe 
Figure 1.5: Hydroxyethylamine-based HlV Protease inhibitor JG-365 (1.11). 
X-ray crystal studies of 1.11 bound to HIV protease5 showed that the inhibitor binds to the 
active site in a pseudo-cis conformation about the C-C bond adjacent to the proline residue. 
The torsion angle about this bond is 11°, indicating the conformation to be essentially 
planar. However, while JG-365 is a potent inhibitor in vitro, it fails to inhibit HIV protease 
in cellular assays due to its peptide character. What follows is a discussion about the 
various approaches that have been used to develop conformational restriction in a 
peptidomimetic. 
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1.3.1.1 Introduction of Conformation~Stabilizing Rings 
A classical approach in the design of peptidomimetics is the introduction of confonnation-
stabilizing rings. The introduction of rigid rings into a peptide molecule can improve the 
potency by locking the ligand in a preferred bioactive conformation, thus enhancing its 
activity for its associated receptor molecule (e.g. an enzyme active site). The ring can be 
incorporated within a single amino acid residue, e.g. 1.126 and 1.13,7 or between tw08,9 or 
more amino acid residues (1.14 & 1.15), as shown in Figure 1.6. 
BOC'N£) 
H yo 
MeO 
1.12 1.13 1.14 
Figure 1.6: Some bridged amino acids. 
Aromatic N-heterocydes (e.g. pyrroles, imidazoles and tetrazoles) have commonly been 
used to get the preferred cis conformation of the peptide bond. Research in this laboratory 
has focussed on the synthesis of different heterocycle-based amino acids that stabilize the 
cis geometry of the amide bonds. Abell et al. have reported the stereoselective synthesis of 
1,2-disubstituted pyrrole mimetics (e.g. 1.14, see Figure 1.6) in which a peptide bond is 
locked into a cis geometry by a planar aromatic pyrrole ring. 8 The same author and co-
workers have also reported a-methylene tetrazole-based dipeptidomimetics as illustrated by 
compound 1.159 in Figure 1.6. 
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Modification of the Side of Amino Acid 
A well-known strategy in peptidomimetics design is to modify the side chains of natural 
amino acid residues to give unnatural derivatives. Compounds 1.16 and 1.17 are examples 
of constrained mimetics of phenylalanine (see Figure 1.7) that have been incorporated into 
potent peptidomimetics ligands of the angiotensen II receptor. 10 Another example involves 
tyrosine analogue 1.18, whereby the introduction of methyl groups at the 2', 6', and {3-
positions hinders the rotation about the Cil-C, bond (Figure 1.7).11 This has been shown to 
favour the formation of bioactive conformations in peptides (methionine-enkephalin)11 and 
has been used to study the effects of restricted rotation of the peptide bond in peptide-
protein complexes (e.g. oxytocin and neurophysin).12 
~ HO~ 
N a COzH HzN a COzH 
H 
Phenylalanine 1.16 1.17 Tyrosine 1.18 
Figure 1.7: Sidechain modified amino acids. 
1.3.3 Modification of the Peptide Backbone 
A modification in the peptide backbone usually means the exchange of sterically- or 
electronically-equivalent stmctural units and the introduction of additional stmctural 
fragments. 13 These modifications bring a tremendous change in the peptide characteristics, 
such as proteolytic stability, while still retaining the key sterie and electronic characteristics. 
The most common modifications are listed in Table 1.1. 
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Table 1.1: General modifications of a peptide backbone 
aza thio 
-§]- ~ 
alkyl reduced 
--@]- -§]-
bora n=12 
-i p=Oe~R) t-
-1 BeOR) r-
Studies in this laboratory have shown that the phenylalanine-based inhibitor (Figure 
1.8) constrains the peptide backbone to adopt a similar conformation to that of JG-365 
(1.11) by incorporation of a tetrazole moiety as a cis-amide bond isostere. The tetrazole 
moiety constrains the peptide such that the torsion angle about the C-tetrazole bond is 
approximately 13°, which is very close to the equivalent C-C bond in the bioactive 
conformation of 1.11. Consequently, compounds of type 1.15, that contain a modified 
tetrazole backbone, have been found to be good inhibitors of HIV protease.8 Similarly, the 
amide bond can also be locked into a cis geometry by the incorporation of an imidazole 
ring to make biologically important peptidomimetics of type 1.19. 
~Ph 1: Ph, N-N AoHNSe<-L,u-AM-NH ,N~ Chz, ( ,·V·:N 
OH ~. j'j~N o lle-Val-OMe yo 
BnO 
1.11 1.15 1.19 
Figure 1.8: mtroduction of conformational restriction by the incorporation of a tetrazole or imidazole ring. 
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Another ex amp Ie is modification of the backbone of the tetrapeptide Cys-V al-TIe-Met (1.20, 
see Figure 1.9), that inhibits Famesyltransferase (a heterodimeric metalloenzyme) in 
vitro (IC50 = 340 nM). Inhibition of this enzyme is an important target in cancer therapy.14 
Unfortunately, 1.20 is inactive in whole cell assays due to its poor membrane pelmeability 
and metabolic stability, features typical of peptides. Therefore, to improve its inhibitory 
activity, the peptide backbone was modified by replacing Val-TIe-Met with a 
conformationally restricted 4-amino-3'-carboxy phenyl group to give 1.21. 
HS HN )-5 
HzN OH 
1st phase modification 
HS 
OH 
1.20 
2nd phase modification 
A 
1.22 
Rl CN, N02, NH2 
R2 CH3 
Figure 1.9: Modification in the peptide backbone of 1.20 to give better inhibitors, 1.21 and 1.22. 
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Further modification by replacement of the 4-amino-3' -carboxy phenyl group with a 
biphenyl moiety led to an improvement in the inhibitory activity of the Famesyltransferase 
inhibitors. 1s In particular, the replacement of the cystein residue of 1.20(C) with an N-
benzyl substituted imidazole ring to give the inhibitor (ICso = 1-10 JiM) resulted in a 
substantial increase in the whole cell inhibitory activity. This is attributed to the increased 
binding ability of the inhibitor (through the imidazole group) to the Zn2+ ion in the 
active site of the enzyme. 1S 
1.4 Cyclic Peptidomimetics 
The incorporation of bridging rings is another strategy for the design of conformationally 
constrained peptidomimetics. An example is the de novo design of cyclic urea inhibitors of 
HN protease. Based on the C2-symmetry of the HN protease dimer, peptidomimetics-
based inhibitors of type 1.23, containing a diol moiety, were developed and found to be 
good inhibitors of HI V protease (Figure 1.1Oa). However, diols of this type experienced the 
characteristic drawbacks of pep tides, i.e. poor solubility and poor bioavailability. To reduce 
the peptidic character of the HN protease inhibitors, Lam et al. 16 utilised a 3D computer 
programme to develop the cyclic structures shown in Figure 1.10. The first model stmcture 
was a phenyl-ring based structure (Figure 1. lOb ), but later on this was rej ected as a phenyl 
ring might not position all parts of the inhibitor properly. This was replaced by a 
cyclohexanone ring (Figure 1.1 Oc) with the carbonyl oxygen as a structural water mimic. 
The six-membered ring was enlarged in the next step to a seven-membered ring cyclic urea 
scaffold containing a diol moiety, as the SAR studies of linear inhibitors containing diols 
were found to show better potency than the corresponding mono-ol inhibitors. The final 
synthetic target was a cyclic urea scaffold to replace the structural water molecule, as well 
as the basic stmctural motifs necessary to bind in the active site of the HIV protease (Figure 
1.10d). This resulted in the development of cyclic urea analogues of HN protease 
inhibitors. The subsequent synthesis of cyclic ureas led to potent and highly bioavailable 
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HIV protease inhibitors e.g. DMP 323 (Figure 1.10d). A number of cyclic urea-based HIV 
protease inhibitors have since been synthesized and have proved to be better inhibitors by 
exhibiting high bioavailability and good pharmacokinetics in humans. 16 Figure 1.10e 
illustrates the enhanced H-bonding interactions to the active site residues, resulting from 
the cyclic nature of the urea mimic. Compounds ofthis type are discussed further in chapter 
seven. 
R 0 Phe OR R lIe (,I 1;J~ 
NJl ~ J... ,N : ~ RO ~ = N- Y '(lIN ~ ~:N 0 lIe R OR Phe 0 R 
(a) 
(c) 
(e) 
-N 
"-
AsP29 
1.23 
IIle 50 
--N 
, 
, 
, 
'50 Ile, 
N-
, 
, 
, 
MeO 
OR 
RO OMe 
(b) 
(d) DMP 323 
Figure 1.10: Steps (a-d) involved in the design of cyclic urea inhibitors ofRN protease. (e) enhanced 
R-bonding ofDMP 323 with RlV protease inhibitor. 
Chapter 1 15 
Examples of the use of cyclic amino acids are found in the seven-membered cyclic lactams 
1.24-1.26 which dimerize in non-polar solvents to give {3-turn peptide mimetics l7 (Figure 
1.11). 
O~""Q 
-NH HN '" 
NHBoc 
)\'''''y -N 
H HNi NHBoc BOCO~ 'BOC).ri ('X 
° ° ° X=H,N3 1.24 1.25 1.26 
Figure 1.11: Some p-tum inducing cyclic amino acids. 
{3-Peptides (derived from (3-amino acids) are biologically- and structurally-important 
compounds. Unlike peptides derived from a-amino acids, {3-peptides exhibit high resistance 
to peptidase hydrolysis and have the ability to adopt stable secondary structures such as 
helices, sheets, and turns. Research carried out in this laboratory has resulted in the 
synthesis of cyclic 5-7 membered {3-Peptides 1.27-1.29 (Figure 1.12) via ReM 
methodology which has been discussed in section 1.5.2. l8 What follows here is a discussion 
about the applications of heterocyclic compounds in pharmaceuticals and other fields. 
1.5 
CbzHN-Y 
C02Me 
1.27 
~ 
CbZHNY 
C02Me 
1.28 
BOclmQ 
C02Me 
1.29 
Figure 1.12: Cyclic p-peptidomimetics. 
N -Heterocycles Fields 
Besides their abundance in nature, N-heterocyclic compounds are of importance as building 
units in pharmaceuticals. Examples include allopurinol 1.30 (gout therapeutic)/9 sildenafil 
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1.31 (inhibitor of type V cGMP phosphodiesterase, Viagra), tubersidin 1.32 (anticancer 
agent), abacavir 1.33 (anti HN agent), acyclovir 1.34 (antiviral agent for the treatment of 
Herpes) and eprosartan (antihypertensive agent) (Figure 1.13). Heterocyclic 
nitroimidazole pharmaceuticals, such as metroindazole 1.36 and tinidazole 1.37, work as 
magic bullets for the treatment of trichomonas infections (see Figure 1.13). 
° 
"1:J N N 
H 
1.33 
1.31 
N N 0 
1.32 OH OH 
o ~~ 
HN N 1/\ :r N S A I ~ ~N.o COH 
H1N N N ~ 2 l.O~OH ~ 
1.34 1.35 .0 C02H 
J[N 
°2N N~ J[~ °2N N~ ~OH 
1.36 
~S02Et 
1.37 
Figure 1.13: Heterocycle-based pharmaceuticals. 
In addition, N-heterocyclic compounds like tJ-lactams make up the core structure of 
antibiotics, such as penicillin G 1.38 and Cephalosporin C 1.39. o-Lactams (e.g. 1.4020 & 
have found applications as HN protease inhibitors (Figure 1.14). 
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H 
Phg)r~ 
1.38 
° Ph~/"'....Ph 
III,,/, Ph 
H 
OH 
1.40 
1.39 
Ph 
OR 
1.41 
Figure 1.14: Some ~ and I) lactams containing biologically- important compounds. 
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Heterocycles also make the key cores of herbicides, fungicides, dyes (e.g. acridin yellow G 
1.42 & purple coloured cyanine dye 1.43) and pigments (e.g. haemin 1.44, obtained from 
haemoglobin) (see Figure 1.15). 
1.42 1.43 
C02H H02C 
1.44 
Figure 1.15: Heterocycle-based dyes and pigment. 
What follows is a brief overview of the two general methods of metal-catalyzed ring 
closure reactions for the synthesis of N-heterocycles that have been used in the research 
work described in this thesis. 
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1 Metal-Catalyzed as a Vle'UU]IO for the 
of Heterocycles 
Transition metal catalyzed reactions offer some of the most attractive methodologies for 
synthesizing heterocycles. They allow the convenient construction of complex molecules 
under mild conditions. A number of methods involving transition metal catalyzed synthesis 
ofN-heterocyc1es have been reported and reviewed,z2 The two general methods used in this 
thesis for the preparation of peptide and non-peptide N-heterocyclic compounds are 
introduced briefly in the following two subsections. 
Palladium-Catalyzed Amino-Heck (A-H) Cyclization from Olefinic Oximes 
The amino-Heck (A-H) reaction, developed recently by Narasaka et al. has emerged as an 
attractive and powerful tool for the synthesis of a variety ofN-heterocyc1es.23 The reaction 
involves an intramolecular cyclization of an olefinic oxime in the presence of a 
palladium(O) catalyst (e.g. Pd(PPh3)4), a base, and a polar solvent, such as DMF (Scheme 
1.3). The reaction proceeds in a fashion very similar to an intramolecular version of the 
Mizoroki-Heck reaction,z4 The reaction, which is usually carried out at mild temperatures 
with various derivatives of oxime starting materials bearing electron-rich and electron-
deficient olefins, works in the presence and/or absence of additives,zs 
Pd cat 
X=C,N 
Scheme 1.3. Palladium-catalyzed amino-Heck reaction. 
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The utility of this reaction lies in the generation of an alkylidenepalladium(II) aminyl 
intermediate which could be used for the synthesis of various nitrogenous heterocycles. A 
schematic representation of the mechanism is illustrated in scheme 1.4. 
R = alkyl, aryl 
R' C6FsCOCI 
X C,N H-Pd-OR 
xS· --1~ 
R X R X 
Pd(O) 
+ 
base 
Pd-OR' RJ~ 
Scheme 1.4: Catalytic cycle of the amino-Heck reaction. 
The pioneering work in this area by Tsutsui et at. revealed that the geometry of the oxime 
does not affect the reaction: pyrrole derivatives from both E and Z oximes have been 
prepared in very good yields.2o The reaction can also be carried out from both terminal and 
branched olefinic oxime derivatives. A more detailed discussion on A-H cyclization will be 
described in chapter 2 of the thesis. 
1.6,2 Ring-Closing Metathesis (RCM) 
Ring closing metathesis (ReM) has emerged as a new and powerful technique over the past 
decade for the synthesis of a wide range of peptide and non-peptide heterocycles and 
carbocycles. The power of this reaction lies in its ability to form a ring from a molecule 
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containing two olefins under mild reaction conditions and with good functional group 
tolerance. The reaction involves joining together two carbon-carbon double bonds, in the 
presence of a transition metal catalyst to form a new carbon-carbon double bond (Scheme 
1.5). 
RCM 
Scheme 1.5: Ring Closing Metathesis reaction. 
The reaction can be carried out at room temperature and in a variety of solvents. A number 
of stable, well-defined and functional group tolerant metal carbene catalyst systems allow a 
wide scope of syntheses. The catalytic cycle involved in the reaction is depicted in Scheme 
1.6 below. 
R 
Ru-----/ 
Scheme 1.6: Catalytic cycle of the Ring Closing Metathesis of dienes. 
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The most commonly used catalysts for ReM are the ruthenium-based compounds 
developed by Grubbs et at. 26 and molybdenum-based compounds developed by Schrock et 
al. 27 Ruthenium-based catalysts are usually preferred over the molybdenum-based catalysts 
which are sensitive to air, moisture and other impurities. 
ReM of nitrogen-containing compounds, with applications towards the preparation of 
heterocycles, alkaloids and peptidomimetics, has been the focus of much research and has 
recently been reviewed?S Research in this laboratory has focused on the synthesis of 
constrained peptidomimetics and carbocyc1es from CL- and (3- amino acids. 
Recently, Gardiner et at. synthesized the CL,CL-disubstituted tetrahydropiperidine mimic 1.46 
from the diene using ReM methodology and successively derivatized it to the 
diastereoisomeric mixture of diols (1.47) and dibromo derivatives (1.48),29 as illustrated in 
Scheme 1.7. 
1.45 1.46 
Scheme 1.7: Ring closure and derivatization of diene 1.45. 
o Ph 
o y 
MeO "" i' 
Ph 
MeO "" i' 
Ph 
N 
OH 
OH 
1.47 
Br 
Br 
1.48 
Humphries and co-workers synthesized the o-lactam 1.50 from the diene linker 1.49 and 
transformed it to allylic alcohol 1.51 (as depicted in Scheme 1.8),30 analogues of which 
have been reported to be inhibitors ofHIV protease.21 
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0 0 0 
PV"NXPh PV"&Ph PV"~Ph Ph",,,,,~ "" .. .. Ph"",' h- ., Ph"",' 
OR 
1.49 1.50 1.51 
Scheme 1.7: Ring closure by ReM and derivatization of diene 1.49. 
A more detailed discussion about RCM, catalysts used in RCM, and its applications in 
organic synthesis will be presented in chapter 6. 
1.7 Research Work described in this Thesis 
This thesis covers two general areas that utilise A-H and RCM chemistry for the synthesis 
of biologically-important N-heterocyclic compounds: chapters 2-5 cover A-H chemistry for 
the synthesis of N-heterocyclic compounds, and chapters 6 and 7 cover RCM-based 
syntheses. 
The next chapter describes a more detailed specific background to the synthesis of N-
heterocycles from olefinic oximes by using the palladium-catalyzed A-H cyclization 
reaction. The extension of this synthetic methodology to various types of N-heterocycles is 
also presented. 
Chapter 3 describes the synthesis of spiro bicyclic imines from dienyl oxime precursors. 1-
azaspiro[4.4]nonane, the base skeleton of the biologically active alkaloid cephalotaxin, and 
its synthetic analogues, have been prepared from dienyl ketoxime derivatives using the A-H 
reaction. This methodology has also proven to work in a domino manner for the synthesis 
of tricyclic spiroimines. 
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Chapter 4 describes the extension of the same methodology to the synthesis of imidazoles. 
Applications described involve the preparation of aliphatic and <x-amino acid based 
imidazoles (as amide bond replacements) from aliphatic and a-amino aldoxime precursors. 
The reaction proceeds well without racemization of the stereo centre of the starting <x-amino 
aldoxime. 
Chapter 5 highlights the synthesis of pyrrole derivatives by A-H cyclization of prop argyl 
type derivatives of ketoximes. Several attempts were made to terminate the living alkenyl 
palladium(II) complexes by different methods involving the use of organometallic reagents, 
intermolecular Heck reaction and carbonylation-termination with alcohols. The A-
Hlcarbonylation-termination via alcohols sequence was applied to the synthesis of 2,5-
disubstituted pyrroles. 
Chapter 6 provides an overview of olefin metathesis and its various types. In particular, a 
detailed introduction about the RCM technique, the different catalysts used in RCM (as 
well as their functional group tolerance capability), and its various applications to peptide 
and non-peptide N-heterocycles are described. 
Chapter 7 of the thesis presents a versatile and convenient ring-closing metathesis approach 
to the preparation of <x-amino acid-based seven-membered lactams, and their derivatization 
to diols (using Sharpless asymmetric dihydroxylation reactions), and to epoxides. The 
RCMldihydroxylation sequence allows access to diol-containing lactam analogues of cyclic 
ureas, which could prove to be potent HIV inhibitors. 
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2.1 Introduction 
Palladium chemistry has undergone considerable progress in the past three decades in the 
field of organic synthesis. 1 Organopalladium complexes have been used extensively in the 
recent development of efficient industrial processes2 because of the stability, low toxicity 
and the ability of palladium to exist in a variety of oxidation states. Common examples of 
palladium catalysts are the air stable complex dichlorobis(triphenylphosphine)palladium(II) 
[Pd(PPh3)2Ch] and the air sensitive complex tetrakis(triphenylphosphine)palladium(O) 
[Pd(PPh3)4]. The actual catalytic species appears to be 'bis(triphenylphosphine), 
palladium(O) ['Pd(PPh3h'],3 or some other in situ generated analogue; they are strictly 
defined as the 'pre-catalysts'. 
One of the major contributions of palladium catalysts is the formation of C-C bonds 
through coupling reactions. The most commonly used reaction for C-C bond fonnation is 
the Mizoroki-Heck reaction concurrently reported by Mizoroki4a and Heck4b in the early 
1970s. The Mizoroki-Heck reaction mainly involves the fundamental reactions of 
organometallic chemistry i.e., oxidative addition, olefin insertion, t3-hydrogen elimination 
and reductive elimination. The mechanism of the reaction is illustrated in Scheme 2.1. 
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Scheme 2.1: Catalytic cycle of Mizoroki-Heck reaction. 
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The first step involves the oxidative addition of an organic halide to fonn an akylpalladium 
complex, which then undergoes alkene inseliion to fonn a second alkylpalladium(II) 
intennediate. Syn-elimination of ~-hydrogen from the second palladium intennediate 
affords a new alkene molecule and a palladium hydride. Reductive elimination of 
palladium(II) to palladium(O) occurs from palladium hydride to complete the catalytic cycle. 
Other principal palladium-catalyzed reactions5 include Negishi coupling, Suzuki coupling, 
Stille coupling, Sonogashira coupling and the Tsuji-Trost reaction, as summarized in 
Scheme.2. 2. 
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Heck Reaction 
+ RX 
[Pd] ,. 
Negishi couplings 
1 R2 
R3X 
[Pd] R~o + CO, base ,. 
R3 
Suzuki couplings 
+ ArB(OHh [Pd] ,. 
Stille couplings 
+ ArSnR3 
[Pd] ,. 
Sonogashira couplings 
+ H R 
[Pd] ,. 
Tsuji-Trost Reaction 
y~ Nu [Pd] ,. Nu~ 
Scheme 2.2: Palladium-catalyzed reactions. 
2.2 Palladium in Heterocyclic Chemistry 
Palladium chemistry involving heterocycles has its unique characteristics arising from the 
heterocycles' inherently different propeliies from carbocycles. A novel example that 
illustrates the striking difference between a carbocyclic and heterocyclic arene is the 
heteroaryl Heck reaction (inter- or intramolecular), which occurs onto a heteroaryl substrate. 
Heterocycles, including thiazoles, oxazoles, imidazoles, pyrroles and indoles are "A'VvJ,J,,'IL 
substrates for intermolecular Heck reactions, whereas, examples of carbocyclic substrates 
are rare.6 In contrast, intramolecular Heck reactions of carbocyclic substrates have been 
well-precedented.7 
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In fact, the intramolecular verSIOn of the Heck reaction has been extremely fmitful, 
enabling elegant total synthesis of complex molecules.8 An intramolecular Heck reaction 
has been used as a key step in the synthesis of (-)-allonorsecurinine and securinine9 (2.2) 
ii'om a vinyl iodide (2.1, Scheme 2.3). 
I 
90 DC, 14h 
2.1 2.2 
n =1 88% 
n=278% 
Scheme 2.3: futramolecular Heck reaction for the synthesis of2.2. 
Another brilliant example of the intramolecular Heck reaction is the cyclization of a 
pentacyclic lactam 2.3 with a pendant vinyl iodide moiety to give cyclic product 2.4 10 
(Scheme 2.4). 
N~OTBS 
I 
2.3 
Pd(OAc)z, (0.3 eq.) 
BU4NCl, DIVIF, K2C03 
70 DC, 3h, 74% 
Scheme 2.4: futramolecular Heck reaction of 2.3. 
OTBS 
2.4 
An intramolecular heteroaryl Heck reaction was also the key step in the synthesis of 5-
butyl-l-methyl-1H-imidazo[4,5-c] quinolin-4(5H)-one 2.6 which is a potent antiasthmatic 
dmg11(Scheme 2.5). 
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Scheme 2.5: Intramolecular Heck cyclization for the synthesis of 2.6. 
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In addition, the Mori-Ban indole synthesis involves the oxidative addition/cyclization 
process and stoichiometric carbopalladation using a Pd(II) species as well, typically from 
Pd(OAch (Seheme 2.6).12 
RCL~ 
N 
I 
X 
1-2 eq. Pd(OAc)2 
HOAc, reflux, 60-80% 
Scheme 2.6: Synthesis of in doles by MOli-Ban methodology. 
The scope of this protocol is limited in most cases due to the consumption of a 
stoichiometric equivalents of expensive Pd(OAc)2. However, progress has been made 
towards a catalytic version of the Mori-Ban synthesis by Knolker's group in their synthesis 
of indoles. 13 eupric acetate is used as a reoxidant of Pd(O) to Pd(II), as in Wacker's 
reaction. 
In summary, Pd-catalyzed C-C bond formation has numerous applications in SCIence. 
Compared to the considerable amount of research on C-C bond formation, little attention 
has been paid to the palladium-catalyzed direct C-N bond formation. What follows is an 
overview of Pd-cata]yzed C-N bond synthesis. 
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of Pd-Catalyzed C-N Bond Formation 
The first example of a Pd-catalyzed C-N bond formation was provided by Kosugi et al. 14 in 
1983. They reported Pd-catalyzed transamination of aryl halides with aminostannanes 
leading to C-N bond formation (Scheme 2.7). 
Pd cat. 
Scheme 2.7: Pd-catalyzed transamination of ary halides with tin amides. 
Unforttmately, the toxicity, thermal and moisture sensitivity, and the commercial non-
availability of the aminostannanes limits the scope of this reaction. Moreover, its use is 
also limited to dialkyl aminostannanes and electron neutral aryl halides. In 1984, a Pd-
mediated reaction involving a C-N bond synthesis was carried out by Boger et al. 15 via 
intramolecular amination of an aryl halide in the cyclization of the ring skeleton of 
lavendamycin 2.8 (Scheme 2.8). 
Me02C 
H2N 
Br 
2.7 
COzMe 
Me 
MeOzC 
Me 
2.8 
Scheme 2.8: Synthesis of2.8 via Pd-catalyzed intramolecular amination on.7. 
Guram and Buchwald16 then extended the ability ofN,N-diethylaminostannanes to undergo 
transamination reactions by generating tin amides in situ as outlined in Scheme 2.9. The 
reactions proceeded with 80% yield or greater was still not practical because stoichiometric 
amounts of tin were required. 
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lEt 
BU3SnN, 
Et 
HNR1R2 
R3-Q-Br 
,., 
Scheme 2.9: Pd-catalyzed transamination of ary halides by generating ill situ tin amides. 
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Amination under tin-free conditions was finally achieved independently by both 
Buchwaldl7 and Hartwig groups18 in 1995. These amination reactions were carried out by 
the reaction of an aryl halide with combination of an amine and an alkoxide, or a silylamide 
base, thus avoiding the isolation or generation of a tin amide in situ. The general reaction 
conditions are: bulky tris o-tolyl phosphine as ligand, a palladium catalyst, and 100 DC in 
toluene. Both groups report amination reactions using the above-mentioned conditions with 
a variety of substrates. A catalytic cycle for this process which is supp0l1ed by mechanistic 
studies,19 is illustrated in Scheme 2.10. 
ArH 
Ar 
/ 
LnPdll 2.11 
'NR'(CH2)R 
HO-t-Bu 
HN(R')CH2R 
/Ar 
L PdIl 
n "-O-t-Bu 
2.10 
Scheme 2.10: Catalytic cycle of the amination of my I halides. 
2.9 
Na-O-t-Bu 
-],\aX 
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Oxidative addition of palladium(O) to aryl halide results in the fOlmation of complex 
which then reacts with an alkoxide or a silyl amide base to form an intelmediate palladium 
alkoxide species 2.10. This alkoxide species then undergoes ligand exchange with an amine 
to form the active amidopalladium complex 2.11 that undergoes reductive elimination of 
the amine. 
A side reaction involved in catalytic cycle depicted in Scheme 2.10, is the (J-hydrogen 
elimination reaction from the aryl amidopalldium complex 2.11 to give the 
arylpalladium(II) complex that undergoes reductive elimination to give an imine, a 
reduced arene, and Pd(O). Hartwig et al. 21 studied the effect of steric and electronic 
properties of ligands and halides on the relative rates of (J-hydrogen elimination and 
reductive elimination of amine as summarized 
in Scheme 2.11. 
x o Br~ 
LnPd(O) 1 
X r~1 LnPd~ 
'Br 
reductive 
elimination 
R2R1 N-OX 
yX accelerated by £5" 1. X = electron-withdrawing RzR1N 2. R = electron-donating & larger LnPd ~ 3. L = Large 
P-hY~ 
elimination 
N,R2 
+R~H 
Scheme 2.11: Factors controlling the selectivity for amination vs B-H elimination. 
This field has also gained significant interest over the past decade, and has been reviewed 
by many research groupS.22 What follows is a discussion on the Pd-mediated C-N bond 
synthesis £i'om oximes, including introduction of the A-H reaction. 
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C-N Bond Formation via Pd-Mediated 
Advent of Amino-Heck Reaction 
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of Oximes: 
Oximes and their derivatives are widely used in organic synthesis as key intermediates in 
the preparation of a variety of heterocyc1es.23 Murahashi et ai. reported the transformation 
of a,JJ-unsaturated ketoxime 2.13 into isoxazole 2.14 on treatment with an equimolar 
amount ofPdCh(PPh3)2 in the presence of 5 equivalents ofNaOPh in benzene.24a Later on, 
they also reported the formation of pyridine derivative 2.15 in very low yields from 2.13 by 
Pd-catalyzed reactions24b (Scheme 2.12). 
PdC12(PPh3kl\'aOPh N-O ~ ~ A 2.14 j) N ~ PdClrNa2C03 OH 
B N 
2.13 2.15 
Schem 2.12: Synthesis ofpyridines and isoxazoles ii'om ketoximes. 
Frederickson et al. also used palladium(II) salts in a oxime-nitrone-isoxazolidine cascade.25 
They reported the formation of cyclic nitrone 2.17 from o,E-unsaturated oxime 2.16 
(Scheme 2.13). Here, the oxime directly attacks the olefinic moiety which is activated by 
coordination to palladium(II) complexes. 
C02Et CX\ 
? 
OH 
2.16 
@ 
I Q 
2.17 
Scheme 2.13: Synthesis of cyclic nitrones from 6-g unsaturated oximes. 
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Narasaka et al. recently rep0l1ed the so-called Amino-Heck reaction, which is an 
intramolecular palladium-catalyzed cyclization (similar to Mizoroki-Heck reaction) of the 
olefinic derivatives of oximes, resulting in the synthesis of N -heterocycles?6 They 
suggested the formation of an alkylideneaminopalladium(II) intermediate, similar to the 
Sp2 -carbopalladium species in an intramolecular Heck reaction. Tsutsui et al. can-ied out the 
reaction of an equimolar amount of 4,4' -bis(hifluoromethyl) benzophenone O-methyl 
sulfonyl oxime 2.18 and Pd(PPh3)4 in THF at room temperature to unravel the mechanism 
involved in such reactions26a (Scheme 2.14). 
2.18 2.19 2.20 
Scheme 2.14: Synthesis of2.20 by the oxidative addition ofPd to the N-O bond of the oxime 2.18. 
A 4,4' -bis(trifluoromethylphenyl)methylideneamine 2.19 was isolated after quenching the 
reaction with a pH 9 buffer, and this was hydrolyzed to benzophenone 2.20 on treatment 
with an acid. Imine formation indicates that oxidative addition ofPd(O) to the N-O bond of 
oxime occurs, giving the intermediate diarylmethylideneaminopalladium(II) species that 
hydrolyzes to benzophenone via imine 2.19. The formation of such an intermediate could 
not be observed directly in the above reaction, but Pombeiro et al. 27 have repOlted the 
isolation of a similar intermediate in the oxidative addition of an acetone oxime 2.21 to a 
rhenium(I) complex 2.22 (Scheme 2.15). 
",OR 
N )l 
Me Me 
2.21 
trans-[RelcI(N 2)( dppe hl 
TI[BF41-Tl[HS04J 
TRF 
N",[ReIII(OH) (dppeh][BF41 
)l 
Me Me 
2.22 
Scheme 2.15: Oxidative addition ofRe(I) to the N-O bond of acetone oxime 2.22. 
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Buchwald28a and Hartwig's28b groups have also reported previously the isolation of an 
alkylideneaminopalladium(II) species generated from arylpalladium(II) halides and 
diphenylmethylideneamine via ligand exchange processes (Scheme 2.16). 
Ar-X 
Pd(O) 
Ar-Pd-X 
base 
ligand exchange 
(II) 
Pd-Ar N' 
P~Ph 
1-Pd(O) 
Scheme 2.16: Synthesis of alyl imine via diphenylmethylidene Pd(II) intelmediate. 
The formation of an alkylideneaminopalladium(II) intermediate has also been suggested by 
Uemura et al. in their ring-opening reactions of cyclobutanone oximes29 as shown in 
Scheme 2.17. 
O=N-OCOPh 
2.23 
Pd(O) (II) 
O=N-Pd-X 
2.24 
Scheme 2.17: Alkylideneaminopalladium(II) intelmediate in the ling-opening reaction of 2.23. 
Tsutsui et al. 30 synthesised various derivatives of pyrroles by carrying out an intramolecular 
amino Heck reaction of 'Y,o-unsaturated O-pentafluorobenzoyloximes. The suggested 
catalytic cycle for this A-H cyclization is depicted in Scheme 2.18. Oxidative addition of 
the N-O bond of oxime 2.25 to palladium(O) occurs to afford the alkylideneamino-
palladium(II) intermediate 2.26. Olefin insertion into this species leads to the intermediate 
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VIa (1-hydrogen elimination from 2.28 gives rise to palladium hydride and the 
dihydropyrrole which isomerises to the final product pyrrole 2.29 in good yield. 
.tOR N 
Ph~ 
:6 Ph 
2.29 
base-HOR) 
H-Pd-OR 
P Ph 
r,j 
Ph 
Pd(O) 
+ 
base 
;SrPd- OR N \ 
Ph 
2.28 
.tOR 
N 
~ Ph 
2.25 
(II) 
~Pd-OR 
N 
Ph~ 
2.26 
2.27 
Scheme 2.18: Palladium catalyzed synthesis ofpYlToles from oximes. 
The palladium hydride species then releases Pd(O) by reductive elimination to complete the 
catalytic cycle. The reaction is unaffected by the stereochemistry of oximes and work well 
with both E and Z oximes?6a What follows is a literature review revealing the significance 
of the A-H reaction in the synthesis ofN-heterocycles. 
Applications of A-H reactions to synthesis of 
The A-H reaction has successfully been used for the synthesis of functionalized pyrroles 
from various O-pentafluorobenzoyloximes as summarized in Table 2.1.30 
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Table 2.1: Synthesis of pynoles by A-H cyclization of O-pentafluorobenzoyloximes. 
JPCOC6Fs 
[ R,rf.:3] 
R4 
N R3 :ttR3 Rl~R4 ii • Rl 
RZ RZ 
Entry Rl RZ R3 R4 % Yield 
CHzCHzPh H H H 75 a 
2 Ph H Me H 80 b 
3 COzEt H H H 45 b 
4 Ph H H Me 65 c 
5 COzMe H H COzEt 78 b 
6 Ph H H COzEt 88 b 
Reagents and Conditions: i) 10 mol% Pd(PPh3)4' Et3N, DMF, 80 DC. ii) isomerisation by 
a) A-H reaction conditions. b) Me3SiCl, DCM. c) Si0z, DCM. 
Several O-substituted oximes were examined, and only O-pentafluorobenzoyl derivatives 
were found to give the best result as it is thought to suppress the competing Beckmann 
rearrangement of oximes.3o The reaction works well from both aliphatic and aromatic 
oxime substrates, containing electron rich and/or electron deficient olefins as depicted in 
Table 2.1. 
The A-H reaction has also successfully been applied to the synthesis of pyrroles and 
pyridines from /',o-unsaturated O-pentafluorobenzoyl oxime 2.30.31 Pyrrole 2.31 was 
obtained as the major product when the reaction was can1ed out under the optimum 
conditions of A-H reaction, and treatment of the crude reaction mixture with pyn"olidine 
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(Scheme 2.19). However, canying out the reaction in the presence of 5 eq. (n-Bu)4NCl as 
an additive, and further treatment of the crude reaction mixture with pyrrolidine gave 
pyridine 2.32 as the major product as shown in Scheme 2.19. 
Me 
i, ii ~OM' 
Ph 
2.30 2.31 
Reagents and conditions: 
i) a) 10 mol% Pd(PPh3)4, DMF, 80 DC, TEA, 1h. b) pyrrolidine 69% 
ii) a) 10 mol% Pd(PPh3)4, DMF, 80 DC, (n-Bu)4NC1, TEA, 3h. b) pyrrolidine 11 % 
+ 
Ph 
1:-!~ N 
2.32 
7% 
58% 
Scheme 2.19: Synthesis of pyrrole 2.31 and pyridine 2.32 from ketooxime 2.30 using either conditions i or ii. 
Various pyridine derivatives have been synthesized using the above reaction conditions 
(Figure 2.1). 
2.33 
~~ ~Ph 
2.34 
D Ph h 
R=Ph, CH3 
2.35 
Figure 2.1: Pytidines fmmed by A-H reactions. 
The reaction also works effectively with conjugated oxime substrate 2.36, to give pyridine 
2.32 in good yield3l (Scheme 2.20). 
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"OCOC6F5 
N 
Ph~ 
2.36 
10 mol% Pd(PPh3)4 
(n-Bu)4NCl, TEA ~(~ Ph~ 
2.32 
Scheme 2.20: Synthesis ofpylidine 2.32 from conjugated dienyl ketoxime 2.36. 
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The same methodology has also been applied to the synthesis of a variety of 1-
azaazulenes.32 It is suggested that the A-H reaction of cycloheptatrienylmethyl ketone 
oxime 2.37 gives 3,4-dihydro-1-azaazulene 2.39 via the cyclic 1f-allyl-Pd intennediate 2.38, 
which is transfonned to 1-azaazulene 2.40 with successive Mn02 oxidation (Scheme 2.21). 
C6F50CO,V 0 
R~ 
Pd cat. 
base 
___ ... R-{Q 
2.37 2.38 
oxidation 
2.40 
Scheme 2.21: Synthesis of 1-azaazulenes via A-H/oxidation sequence. 
2.39 
Various l-azaazulenes have been synthesized VIa A-H/oxidation sequence, and are 
summarized in Table 2.2 below. 
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Table 2.2 Synthesis of l-azaazulenes by A-H cyclization/oxidation of O-pentafluorobenzoyloximes. 
R2 ;):' "N.J'OCOC6FS i,11 I '\ ~ 
R' R2 Time/h % Yield 
Ph H 0.5 78 
2 t-Bu H 0.5 84 
4 H 1.5 63 
6 Ph Me 0.5 52 
7 Ph Ph 0.5 55 
9 ~ H 68 
Reagents and Conditions: i) 10 mol% Pd(dbah, 40 mol% (t-BuhP, TEA, Ms 4A, DMF, 
80-100 GC, 0.5-1 h. ii) Mn02, DCM, reflux, 2h. 
In summary, the A-H reaction has proved to be a very useful reaction in the synthesis ofN-
heterocycles from simple oxime substrates. The reaction works effectively under mild 
conditions, in polar solvents, and in the presence of both electron rich and electron deficient 
olefins. The reaction also works in a domino manner in conjunction with other chemical 
reactions, as exemplified by the synthesis of l-azaazulenes. 
next three chapters cover further applications of A-H reaction to N-heterocycles' 
synthesis, investigated during the course of this research work 
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CHAPTER THREE 
SYNTHESIS OF SPIRO CYCLIC 
AMINO-HECK 
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The biological activity and other unique characteristics ofN-heterocycles have made them 
attractive targets for medicinal and organic chemists. In recent decades, transition metal-
catalyzed routes to N-heterocycles have become increasingly important. Here, the synthesis 
of spirocyclic imines using the domino A-H reaction is presented. 
l-Azaspiro[4.4Jnonane has a ulllque structure! and makes up the core skeleton of 
cephalotaxine 3.1. This class of compounds has been of significant interest to organic 
chemists due to the powerful activity of its ester derivatives, harringtonine 3.2a and 
homoharringtonine 3.2b, against chronic myelogenous leukaemia (Figure 3.1). 
Homoharringtonine has also been investigated in the treatment of chloroquine resistant 
malaria.2 Homoharringtonine is now in phase III clinical trials.3 However, the natural 
sources of this alkaloid are very limited, and the plants from which it is extracted are 
endangered.4 
3.1 R = H, (-) cephalotaxine 
OIl 
R= ~O-
COOMe 
3 .2 a) n = 1: harringtonine 
OMc 
3.2 b) n =2: homo harringtonine 
Figure 3.1: Cephalotaxus alkaloids. 
During the past three decades, many research groups have been involved in the total 
synthesis of cephalotaxine and its derivatives. The main synthetic problem, is the 
construction of the spiro quatemary centre at rings C and D, i.e. the l-azaspiro[4.4]nonane 
skeleton. Therefore, various synthetic techniques have been developed towards the 
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synthesis of this moiety.s For example, Semmelhack et al. 6 rep0l1ed the acyloin 
condensation of 1,1-bis(methoxycarbonylmethyl)pYlTolidine 3,3 to the resulting 3,4 
(Scheme 3.1). 
IX - ~ ---->-R R 
R=C02CR3 
o OCR3 
3.3 3.4 
Scheme 3.l: Synthesis of 3.4 by acylion type condensation. 
Mori et al. 7 have also rep0l1ed the synthesis of the l-azaspiro[4.4Jnonane moiety 3.6 from 
(2 S)-2-( (Z)-3 -Iodo-2-prop en yl )-1-[2-(3 ,4-dimethoxyphenyl )ethyl Jpyrrolidine-2-carbalde-
hyde 3,5 using stannyl anion generated from Me3SiSnBu3 and esF. 
CsF, ooC, 24h 
3.5 
Meo~\, 
R= I 
~ 
MeO 
Scheme 3.2: Synthesis of 3.6 from 3.5. 
3.6 
In 1999, Ikeda et aZ. published a synthesis from unnatural D-proline,8 while Tietze 
perfOlmed an elegant and very efficient asymmetric synthesis based on palladium 
chemistry.9 
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Recently, Planas et al. synthesized an analogue of the same skeleton 3.7 starting from S-(1-, 
naphthyl)-ethylamine in 5 steps in a stereoselective fashion,lo 
a-Naphl l l (CH3 
NH2 
5 steps 
Scheme 3.3: Synthesis of 3.7. 
a-Naphll,(CH3 
R ~ 
3.7 
Herein, a simple and convenient route to the synthesis of l-azaspiro[ 4.4Jnonane analogues, 
using palladium-catalyzed domino A-H reactions is described.11a,llb 
for the Domino A-H reaction 
Narasaka et al. have recently introduced the A-H reaction which involves oxidative 
addition of the N-O bond of oximes to Pd(O) catalysts to generate an 
alkylideneaminopalladium(II) species, which can be used as intermediates in the synthesis 
ofpyrroles from )"o-unsaturated ketone oxime derivatives 12 (Scheme 3.4). 
P d ...... OR 
1 
[ /OR ,,oR Pd, if ! ' ...... N 10 mol% PhJlJ)? Ph~ DMF, 80°C, r.t, TEA Ph 
3.8 3.9 3.10 
[;5:dORl 
'" 
p)J ~ :d Ph 
3.11 3.12 
From E-isomer 85-83% 
R COC6FS From Z-isomer 82% 
Scheme 3.4: Synthesis ofpyrroles via Pd-catalyzed A-H reaction. 
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Thus, I,D-unsaturated ketone OXIme 3.8 reacts with Pd(PPh3)4 to generate the 
alkylideneaminopalladium(II) species 3.9, which then undergoes olefin inseition VIa 
intermediate 3.10 to give a palladium(II) intennediate 3.11. (3-Hydrogen elimination results 
in the fOlmation of dihydropY11'0ie that isomerises to pY11'0ie The reaction is not 
affected by the stereochemistry of oxime and works well from both and Z isomers. 
The outline of our synthetic strategy for the preparation of spiroimines is based on the 
domino cyclization initiated by the generation of alkylideneaminopalladium(II) species B 
from O-pentafluorobenzoyloxime having a dienyl moiety. Thus, if an intermediate 
similar to 3.10 is lacking an appropriate {3-hydrogen (e.g. intermediate C), then the complex 
may be long lived and susceptible to further cyclization in a domino 13 mode to give another 
intermediate D. The second alleene insertion into D will then give intermediate F, {3-
hydrogen elimination from which affords the spiroimine E as illustrated in Scheme 3.5. 
OR' N.J 
R~ 
A 
ffd OR' N I R 
D 
-
POR' 
R 
E 
R alkyl or myl and R' = pentafluorobenzoyl 
Scheme 3.5: Synthetic plan for the synthesis of spiroimines by a domino A-H Teaction. 
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of the dienyl ketoximes for use in the Domino 
The dienyl ketones 3.15a-d were prepared as shown in Scheme 3.6. Aryl or alkyl ketone 
derivatives were synthesized by alkylation of the N,N-dimethylhydrazones with 
bromomethyl-l,5-hexadiene13b 3.14a and successive hydrolysis. 14 The crude dienyl ketone 
derivatives were purified by f1ash column chromatography to give 3.15a (55%), 3.15b 
(62%), (63%), 3,15d (50%) and 3.15g (63%). 
+ Br~ 
i, ii 
3.13 a-d 3.14a 3.1Sa-d 
3.13 a, 3.15 a H 
3.13 b, 3.15 b Ph H 
3.13 c, 3.15 c 
3.13 d, 3.15 d 
Reagents and conditions: i) LDA, THF, Ih; then 2-bromomethyl-l,5-hexadiene 3.14a, -78°C-r.t, 16h. 
Ii) NaOAc, AcOH, THF, water, 1't, 3h 
Scheme 3.6:Synthesis of dienyl ketones 1 Sa-d. 
a-Keto ester and aldehyde were prepared from 2-methylene-5-hexen-l-ol 13b 
(3.14b) as outlined in Scheme 3 Johnson-Claisen rearrangement of 3.14b15 and 
hydrolysis of the ester functionality afforded acid The acid was then transformed to 
the desired a-keto ester by using the methodology of Hangauer Jr.l6 
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o 
i,ii ~ 
----" H02C II __ ii_i_"'Et02C~ 
3.14b 3.14c 3.15e 
j iv, v 
H~ 
3.15f 
Reagents and conditions: i) CH3C(OEt)3, CH3CH2C02H,140oC, 1.5 h. ii) aq. NaOH, MeOH, OOC, 45 min. 
iii) 2LDA, TMEDA, THF, rt, 4h; (EtOOC)2' -78 to -40oC, 1.5 h; aq. NaHC03. iv) NHMe(OMe).HCl, 
M~N(CH2kN=C=N-CH2CH3.HCl, DCM, rt, 16h. v) LiAlH4' _40°C, 20 min. 
Scheme 3.7:Synthesis of aldehyde 3.15e and o:-ketoester 3.15f. 
Aldehyde 3.15ft was prepared from 3.14c by transformation of the carboxyl group of the 
acid to a formyl group in two steps as shown in Scheme 3.7 above. 
The dienyl ketones 3.15a-e were treated with pyridine, NH20H.HCI in EtOH at rt, stilTed 
for 1-3 h and transformed to the corresponding oximes 3.16a-e. The oximes were obtained 
as (E:Z) mixtures of 3.16a (1:1, 97%), 3.16b (8:1.5, 84%), 3.16c (4:2,90%), 3.16d (single 
. isomer, 80%) and 3.16g (9:1, 95%) which were purified by flash column chromatography 
to elute the major isomers first and minor isomers later. The major isomers (or single 
isomer in case of 3.16d) are tentatively assigned thermodynamically more stable E 
configuration. The E-isomers of oximes were observed to be comparatively less polar in all 
examples studied than the corresponding Z-oximes except 3.16a, which was obtained as an 
inseparable mixture of isomers, and 3.16d where a single isomer was formed. 
t The synthesis and domino A-H reaction of a-ketoester derivative 3.17e and aldehyde 
derivative 3.17f were canied out by a colleague, Dr. Mitsuru Kitamura at the University of 
Tokyo, Japan. 
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Isolation of the minor isomers (Z-3.16b-c, Z-3.16g) after column chromatography, and 
analysis by IH and l3 C NMR spectroscopy revealed a slow isomerisation at Ii to the more 
stable E-isomers. 
The oximes [(EZ)-3.16a (1:1), E-3.16b-gJ were then treated with TEA, C6FsCOCl at O°C, 
and stilTed for 1 h to give O-pentafluorobenzoyl oximes [(EZ)-3.17a (1:1), E-3.17b-gJ. 
Purification by flash column chromatography gave (EZ)-3.17a (1: 1, 95%), (E)-3.17b (87%), 
(E)-3.17c (77%), (E)-3.17d (75%) and (E)-3.17g (80%). No isomerisation was observed for 
these oximes [(EZ)-3.17a (1: 1), (E)-3.17b-g] in the pentafluorobenzoyiation step and 
subsequent column chromatography. The EIZ ratios were determined by analysis of IH 
NMR spectra of the corresponding oximes and O-pentafluorobenzoyl oximes. 
3.15 a-f (EZ) - 3.16a, (E) - 3.16a-f (EZ) 3.173, (E) 3.17a-f 
Rl R2 
3.15- 3.17a Ph-(CH2h- H 
3.15 b-3.17b Ph H 
3.15c-3.17c -(CH2)4-
3.15 d-3.17d trlz-f ~ 
3.15 e-3.17c C02Et H 
3.15 f-3.17f H H 
Reagents and conditions: i) Pyridine, ]\'1i20H. HCI, EtOH, rt,1-3 h. ii) C6FsCOCl, TEA, DCM, rt,O 1-2 h. 
Scheme 3.8: Synthesis of oximes 3.16a-f and O-pentafluorobenzoyl oximes 3. 17a-f. 
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In addition to O-pentafluorobenzoyl oXlmes (EZ)-3.17a, (E)-3.17b-g, 0-2,4-dichloro-
benzoyl oxime derivative (1:1) of oxime was also synthesized to 
check the effect of a different O-substituted group on the domino A-II reaction (Scheme 
3.9). O-benzoyl, O-diphenylphosphinoyl and O-trifluoroacetyl groups are reported 
unsuitable for A-II reaction as oximes bearing such groups react slowly and with 
Beckmann rearrangement. 12 
,JOH 
N 
Ph~ 
(EZ)-3.16 a (1:1) 
2,4-dichlorobenzoyl chloride, TEA 
DCM, 1t, OoC, 
(EZ)-3.17h (1:1) 90% 
Scheme 3.9: Synthesis of 0-2,4-dichlorobenzoyl oxime EZ-3.17h. 
3.4 Optimization of reaction conditions for the reaction 
An initial study was canied out on the spirocyclization of the dienyl oxime derivative (EZ)-
3.17a as shown in Table 3.1. Using the optimal conditions of the previous pynole 
synthesis 12, i.e. at 80 DC with 10 mol% Pd(PPh3)4 and TEA in DMF, required 11.5 h to 
consume (E)-3.17a. The desired spiroimine 3.18a was obtained in 60% yield accompanied 
by 34% of ketone 3.15a (entry 1). Although the use of Pd(dba)2 and PPh3 accelerated the 
reaction, the yield of cyclized product 3.18a was not improved, but a larger amount of the 
ketone 3.15a was obtained (entry 2). 
To improve the yield of the cyclization product 3.18a, it was required to suppress the 
fonnation of ketone 3,15a. The ketone could be fonned either by protonation ofthe initially 
fonned alkyIideneaminopalladium(II) complex B (Scheme 3.5) with the resulting 
Chapter 3 56 
ammonium salt (Et3NH+' C6F sCOO-) and/or contaminated water, or by the reductive 
elimination from palladium hydride species (H-Pd-N=C) generated from B and TEA and 
successive tJ-hydrogen elimination. 17 To check the effect of amine having ~-hydrogen, a 
base having no ~-hydrogen like DABCO was used as a base for the cyclization. The yield 
of 3.18a, however, was not improved and 53% of the ketone 3.15a was formed instead 
(entry 3). 
Table 3.1: The Domino A-H reaction of3.17a. 
,.rOCOC6FS RJl ~ ~~ __ 10_m_ol_%_p_d_c_at ___ 
- ~ - -....- Base, DMF, 80 0 C 
(E:Z= 1:1) 3.17a 
R=CH2CH2Ph 
Entry Pd cat Base 
TEA 
TEA 
ff 
R 
3.18a 
Time/h 
11.5 
1-8 
12 
a) isolated yield. b) n = 2, 4 or 6.c) diazobicyclo[2.2.2]octane 
+ R~ 
3.15a 
3.18a 3.15a 
60 34 
17-53 78-42 
31 53 
Palladium(II) chlorides such as PdCh[P( o-tol)3h, PdCh[P( c-hex)3h, PdCh( dppf) , and 
PdClz(dppp) were not suitable for this cyclization, as the yields of the imine were very low 
i.e. 23%, 30%, 39% and 18% respectively. Therefore, Pd(PPh3)4 was used in further 
optimization. 
The reaction was accelerated at higher temperature (110 DC) and the yield of the spirocyclic 
imine 3.18a was improved to 70% (Table 3.2, entry 1). Of the various bases examined 
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(entry 2-4), the best results were obtained with K2C03, but poor reproducibility was 
observed (entry 4). Therefore, TEA was used as a base for further studies. 
Cyclization proceeded smoothly in polar aprotic solvents (entries 6) compared to non-
polar solvents (entry 7). DMF was found to be more suitable than CH3CN due to the low 
boiling point of CH3CN (entry 8). 
Table 3.2: Optimization of reaction conditions of the Domino A-H reaction of3.17a using Pd(pPh3k a) 
Entry Base (mol amount) Temp/oC Solvent Time!h Yield%b) 3.18a 
TEA (5.0) 110 DMF 0.5 70 22 
2 t-BuOK (2.0) 110 DMF 0.5 22 33 
3 Cs2C03 (2.0) 110 DMF 0.5 53 18 
4 K2C03 (2.0) 110 DMF 60-82 20-5 
5 TEA (5.0) 110 DMF 0.5 70 22 
6 TEA (5.0) 110 DMPUc) 0.5 53 18 
7 TEA (5.0) 110 toluene 2 22 33 
8 TEA (S.O) 110 CII3CN 6.5 45 37 
a) 3.17a: Pd(PPh3)4 1 :0.1. b) Isolated yield. c) DMPU = 1,3-dimethyl-3,4,5,6-tetrahydro-2-
( 11l)-pYlimidinone. 
N ext, the domino A-H reaction of (EIZ 1: 1 )-3,17h was carried out to check the effect of 
a different O-substituted group on A-H reaction. UnfOliunately, only 30% of the cyclic 
imine was formed, along with 40% of the side product ketone 3.15a (Scheme 3.10). This 
result suggests that O-pentafluorobenzoyl group suppresses the competing Beckmann 
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reanangement, as very little or no ketone is fonned during the A-H reaction of the 
conesponding O-pentafluorobenzoyl derivatives of oximes. 
TEA, DMF, 110°C, 
1.5h 
ff R + R~ 
3.18a 30% 3.15a 40% 
Scheme 3.10: The Domino A-H reaction of3.17h. 
Finally, the use of molecular sieves 4 A (MS 4 A) in the reaction resulted in an improved 
yield of 77%, and the formation of ketone was suppressed to a trace amount 
,.rOCOC6FS N 
Ph~~ 
(E:Z)- 3.17a (1:1) 
TEA, DMF, 11 0° C 
MS4A 
Ph~ + 
3.18a 77% 
Scheme 3.11: The Domino A-H reaction of 3.17a in the presence of MS 4A. 
3.15a 
Trace 
(Scheme 3.11). It would seem likely that the molecular sieves trap a trace amount of 
moisture or acidic protons that prevent the protonolysis of the aminopalladium species B 
(Scheme 3.5). 
The product for the domino A-H reaction was clearly characterized from the IH NMR 
spectrum by the absence of the olefinic protons at position 6, 9 and 10 of 3.17a and the 
appearance of methylene protons at position 7 of3.18a (Figure 3.2). 
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X-H 
6-Ha 
6-Hb 
9-H 
lO-Ha' 
10-Hb' 
d ppm (multiplicity) 
4.66 (8), 4.68 (s) 
4.70 (s), 4.71 (s) 
5.96-5.78 (m) 
4.88 (dd) 
4.96 (dd) 
TEA, DMF, 1100 C 
MS4A 
3.18a 
X-H 8 ppm (multiplicity) 
7-CH2 4.87 (s) 
Figure 3.2: Comparison of IH NMR resonances for 3.17a and 3.18a. 
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In addition, the l3C NMR spectral data and elemental analysis reports also confirmed the 
stlUcture and mass of the product 3.18a. 
The Domino A-H reactions of O-pentafluorobenzoyl oximes 
The scope of the palladium-catalyzed domino cyclization was extended as shown in Table 
3.3 by using the optimum conditions from previous study described in section 3.4 i.e. 10 
mol% of Pd(PPh3)4 and 5 molar amounts of TEA as a base in DMF in the presence of MS 
4A at 110°C. 
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Table 3.3: Synthesis of spirocyclic imines by the domino A-H cyclization of O-pentafluorobenzoyl 
oximes.a) 
entry cxime product Yield(%)b 
(82) 
3.17b 
64 (1:1)d) 
3.17c 
3 
~ 80 (1: l)d 
3.17d 3.'8df! 
,.rOCOC6FS N N 
4 Et02C~ I (76) Et02C 
3.17e 3.18e 
a) Isolated yields, b) time=lh, c) determined by IH nmr d) time=20 min 
60 
Phenyl ketone OXIme E-3.I7b cyclized smoothly to 3.1Sb in 82% yield (entry 1). 
Cyclohexanone oxime delivative E-3.17c cyclized and gave tricyclic imine 3.ISc as a 1: 1 
diasterioisomeric mixture (1: 1, based on analysis of 1 H NMR spectrum) in moderate yield 
(entry 2). Similarly, the tetracylic imine 3.1Sd was obtained as a diasterioisomeric mixture 
(1: 1, determined fi:om IH NMR) in 80% yield by using a tetralone oxime derivative 
(entry 3). Cyclic imine having ethoxycarbonyl group 3.I8e was also synthesized 
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from the oxime derivative of a-keto ester E-3.17e (entry 4). Thus, keto oximes were 
successfully converted to spiroimines. 
In contrast to the ketoximes, the aldoxime E-3.17f did not cyclize and gave exclusively the 
conesponding nitrile 3.20 by Beckmann fragrnentation 18 (Scheme 3.12). 
TEA, DMF, 110 DC 
NC~ 
3.17f 3.20 85% 
Scheme 3.12: Beckmann fragmentation of3.17f under A-H reaction conditions. 
The nitrile 3.20 is probably formed via generation of the alkylideneaminopalladium(II) 
intermediate and successive fi'agrnentation,19 as depicted in Figure 3.3. 
3.t7f 
Pd(O) 
r base 
~ base-H 
3.3: Plausible mechanism for the formation of nitrile 3.20. 
3.20 85% 
Thc nitrile formation from the alkylideneaminopalladium(II) intermediate is also suppmied 
by a recent repmi by Uemma et al., who have reported a palladium-catalyzed nitrile 
synthesis20 from cyc1obutanone O-acyloximes (Figure 3.4). 
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CN 
Y 
Ph 
/Pd~OCOPh 
? 
Ph 
CN 
+ Y 
Ph 
y-OCOPh 
Ph 
3.4: ninile fonnation £i'om cyc1obutanone O-acyloxime 
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FUliher extension of the domino A-H reaction of the dienyl oxime to a trienyl olefinic 
oxime 3.17g resulted in the formation of a diastereomeric mixture (3:4, based on analysis 
of lH NMR spectrum) oftricyc1ic imine 3.18g and 3.19 as shown in Scheme 3.13. 
Ph Ph)XJ(f 
TEA, DMF, 110° C 
(E)-3.17g 3.18 3.19 77% (3:4) 
Scheme 3.13: The Domino A-H reaction of3.17g. 
Preparative thin layer chromatography allowed for the separation of the diastereomeric 
mixture and the diastereomer with high Rf value was obtained as the major fraction in 44% 
yield and characterized while the second isomer was obtained in 33% yield and was also 
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characterized by lH, l3C NMR spectroscopy. The reaction afforded the tricyclic imine in a 
combined yield of 77%. (Configuration of the isomers was not assigned). 
All spiroimines (3.1Sa-g, 3.19) were characterized by lH, BC NMR spectroscopy, and 
microanalysis or mass spectrometry. The charactelistic l3C NMR chemical shifts for 
methylene protons-attached carbon, C-7, and spirocentre C-5 and C=N are summarized in 
Table 3.4. 
Table 3.4: Characteristic BC chemical shifts of the spiroimines. 
Compound # 2-C=N C-5 C-7 CH2=C-7 
3.18a 175.2 82.1 150.9 106.1 
3.18b 170.6 82.8 151.0 106.l 
3.18c 177.1 80.5,80.6 151.0 106.0, 106.1 
3.18d 171.5 80.9,80.9 151.0,151.1 105.9, 106.1 
Bicyclic spiroimines (3.17a-d) exhibited the chemical shifts for C-5 within the range of 
±2.5 ppm between 80.5 and 82.8 ppm, whereas C-7 resonated just with a difference of 0.2 
ppm. Likewise, the C bearing the methylene protons also resonated with a minor difference 
of only 0.1 ppm. The chemical shifts for the imino carbons (C=N) for 3.18b and 
were observed ppm upfield compared to 3.18a and 3.1Sc. This could be attributed to 
charge delocalization by the phenyl group u- to C=N in 3.1Sb and 3.1Sd, which make these 
carbon less electron deficient and hence an upfield chemical shift is observed. 
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The characteristic NMR chemical shifts for the trispiranes (3.18g, 3.19) are shown in 
Table 3.5. The chemical shifts for major isomer for C=N, C-5, C-9 and C(9)=CH2 exhibits 
the same pattem of chemical shifts as for C=N, C-5, C-7 and C(7)=CHz for bicyclic 
spiranes (3.17a-d), but the minor isomer exhibits the chemical shifts for 
26ppm and 9.1 ppm downfield. 
Table 3.5: Characteristic l3C chemical shifts of the spiroimines 3.18g and 19. 
Ph 3 Ph 
3.18g and 19 
Compound # C=N C-5 C-7 C-9 
major 169.5 83.3 50.0 105.4 152.8 
minor 169.0 109.3 50.0 114.5 152.5 
3.6 Conclusion and Work 
C-7 about 
In summary, the domino reaction has proven to be a convenient and general method 
for the preparation of spiroimines from dienyl or trienyl ketone O-pentafluorobenzoyl 
oximes. The reaction proceeds by treatment with a catalytic amount of Pd(PPh3)4, TEA, 
and MS 4A via the formation of alkylideneaminopalladium(II) intem1ediates generated in 
situ by the oxidative addition of oximinoesters to the Pd(O) complex. By increasing the 
olefinic moiety in the starting material, polycyclic imines can be easily constructed in one 
pot synthesis by the use of palladium-catalyzed domino A-H cyc1izations. 
Chapter 3 65 
Future work in this area could involve carrymg out the domino A-H reaction m an 
asymmetric manner by treatment of (R) or (S) BINAP in combination with palladium 
catalysts. The ester derivative of the spirocyclic imine 3.18e could also be used in a 
multistep synthesis to the total synthesis of cephalotaxine as depicted in Scheme 3.12. 
Et02ClM. steps 
.. 
3.18e O~X < I ~ 
o OR 
X= Br or I 
o OMe 
3.1 
Scheme 3.14: Proposed total synthesis ofCephalotaxine 3.1 from 3.18e. 
Additionally, by introducing different kinds of olefinic moieties into the substrates, the A-H 
reaction can also be extended to ene-yne type of domino cyclization. 
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FOUR 
TRI-SUBSTITUTED IMIDAZOLES 
AMINO-HECK REACTION 
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4.1 Introduction 
There is an ongoing interest in the development of new methods for the synthesis and 
derivatization of heterocyclic compounds. Imidazoles, an important class ofN-heterocycles, 
have numerous applications in organic synthesis, and are components of an array of 
biomolecules. Here, a further application of the A-H reaction to the synthesis of aliphatic 
and C-terrninal amino acid-based imidazoles as a generalized method is presented. What 
follows is a brief review of some biologically active imidazoles and methods of their 
synthesis. 
An imidazole is a component of the essential amino acid histidine and related compounds, 
and is well known as ligand in many metalloproteases. I The metal ion coordination in these 
complex molecules generally takes place via N(1) or N(3) of imidazole residues as 
exemplified by myoglobin and other heme proteins, carbonic anhydrase, and carboxy 
peptidase. Another example is therrnolysin (TLN), a heat-stable proteolytic enzyme that 
contains two histidine residues coordinated to zinc ion.2a,b A crystal structure2c of the TLN 
is depicted in Figure 4.1: the active site of the enzyme shows a tetrahedral Zn ion bound to 
two histidine residues via N(1) in each case. 
Figure 4.1 : Crystal structure of the metalloprotease TLN highlighting the a - helical structure of the active site 
(yellow) containing two histidines (greenlblue) botmd through their N(l) to tetrahedral Zn2+ (white). 
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The proposed reaction mechanism of peptide bond hydrolysis2a by TLN is illustrated in 
Figure 4.2. 
GlUI43~O 
o 
e 
GlUI43~O 
o 
e 
Free Enzyme 
Enzyme carboxylate complex 
e 
-Asp226 
Tyr157 
Tyrl57 
Michaelis complex 
Tyr157 
Nucleophilic water attack 
Tetrahedral intermediate 
Figure 4.2: Experimentally proposed catalytic cycle for TLN. 
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Four amino acid residues Glu 1 His231, TYT 157 and Asp226 take part in the catalytic 
pathway. The Zn2+ ion is coordinated to a water molecule, His142, His146 and Glu166 in 
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the inactivated form ofTLN. A wide groove exists between the two domains of the enzyme 
to accommodate the extended peptide chain of the substrate thus forming Michaelis 
complex. The carbonyl oxygen of the scissile peptide wedges between His231, Tyr 157 and 
water molecule in the proximity of Zn2+. The water molecule is then displaced towards 
Glu143 resulting in a strong polarization between the negative carboxylate and the 
This increases the nucleophilicity of the water oxygen, to promote attack on the carbonyl 
carbon. The proton accepted by Glu143 is immediately shuttled to the nitrogen of the 
substrate to give a tetrahedral complex, where Zn is pentacoordinated and the peptide C is 
tetrahedral. The formation of hydrogen bonds to His231 and Tyr157 enhances the 
formation of this tetrahedral complex. The negative carboxylate motif of Asp226 helps to 
stabilize the positive charge required for catalysis. Direct cleavage of the peptide C-N bond 
follows with the amine being released in its protonated form. The Glu143 again abstracts a 
proton from water. The catalytic cycle is closed by detachment of the carboxyl product, 
probably by the uptake of the incoming water molecule. 
Other examples of biologically active mimetics containing C-tenninal imidazoles are 
potent and bioavailable endothelin-A (ETA) receptor antagonists (Table 4.1)? Endothelin,4 
a 21-amino acid bicyclic peptide, is a very powerful constrictor of vascular smooth muscle, 
as well as a potent mitogen. It has been reported as a pathogenic factor for a variety of 
diseases, including asthma,5a coronary vasospasm, myocardial infarction,5b pulmonary 
hypertension,5c restenosis, 5d and atherosclerosis.5e Endothelin acts by binding to a family of 
membrane associated, G-protein-coupled receptors.6 There are two subtypes of endothelin 
receptors i.e. ETA and Binding of endothelin to the ETA receptor, which is found in 
vascular smooth muscle cells, triggers vasoconstrictive and proliferative responses. Von 
GeIdel'll et al. have reported the synthesis and SARs results of the highly potent and well-
absorbed C-terminal imidazole based ETA receptor agonists,3 which are summarised in 
Table 4.1. 
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Table 4.1: Activity of C-tenninal imidazole based endothelin antagonists 
Entry p 
H a NIl\ Me 
2 01l\ H 
3 Ot Me 
4 01l\ H 
5 Ot H 
H 
H 
H 
Me 
Bn 
ETA binding 
IC 50 (IlM)a 
0.011 
0.57 
0.28 
23.3 
16.2 
a: IC50s calculated for 11 concentrations from 10-
10 to 10-5 M. 
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Von Geldem et al. 3 have prepared the C-terminal imidazole mimetics by refluxing the 
intermediate a-amido (3-ketoesters in acetic acid and NH40Ac as outlined in Scheme 4.1 on 
the next page. The scope of this method is limited due to incompatibility of other N-
protecting groups (e.g. a Boc group) to such harsh conditions used in step a, and loss of 
stereochemical integrity observed in the final product.3 
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H ~oy 
Cbz-N '-.~. 
N C02Et R2 
H~R2'N~C02Et 
Cbz-N -N 
~ I ~ 
N ...0 
R'1 
ii, iii, iv 
Reagents and conditions: i) NH40Ac, HOAc, ref1ux. ii) H2/10% Pd-C, EtOH. iii) Phe-Leu-OH, Eocr, HOBT, NMM, 
THF, OMF. iv) LiOH, H20, THF, ref1ux 
RI, R2 = see Table 4.1 
Scheme 4.1: Synthesis of Imidazole mimetics using NH40Ac and HOAc. 
73 
C-tenninal imidazole mimetics have been utilized as stable isosteres in peptidomimetics of 
medicinal impOliance. For example introduction of the imidazole ring as replacement of the 
amide bond in 4.1 reduces its peptidic character and thus increasing its bioavailability as 
HN protease inhibitor7 (Figure 4.3). 
D 
.(JY 
BocNH ~ ~ }(~~t 
OR - R N~ U 
4.1 
Figure 4.3: 4.1 contains a C-tenninal imidazole ring. 
The Val based C-tenninal 2-functionalized imidazolinium component of 4.1 is prepared by 
adding nucleophilic organometallics to non-racemic 2-oxazolidinones usmg 2-
phenylglycinol as the source of chirality as depicted in Scheme 4.2. 
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Y Ph 
zr)LCHO 
N 
H 
(Nr~~ 
N H OH 
H 
4.2 
iii,iv fiN Y tL rNH2 
N 
H 4.3 
"~U'6~""~ and conditions: i) Toluene, MS. ii) i-PrCeCI3, THF. iii) HCl. iv) Pb(OAc)4 
Scheme 4.2: Synthesis ofC-terminal Val-based imidazole 4.3. 
This method employs the imidazole carboxaldehyde as the starting material and uses 
uncommon Ce organometallics. The synthesis of 4.3 by the typical method of reacting (S)-
valinal with NH3 in glyoxal trimer hydrate, with retention of configuration at the chiral 
centre, has also been published in the same report. 
Dhanak and co-workers have synthesized of2-functionalized single amino acid C-tenninal 
imidazole mimetic as CCR3 receptor antagonists (Scheme 4.3).8 
-:?'" N02 
~I 
-:?'" N02 
~I 
i, ii 
I ~ H 
~I ~ I ( 
4.4 
Conditions: i) NH3, glyoxal, DMF. ii) aq. KOH, Etl, DMF. 
Scheme 4.3: Synthesis of racemic phenylalanine delived C-terminalimidazole 4.4. 
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Problems regarding racemization have been reported during the preparation of phenyl 
alanine derived C-terminal imidazole mimetic 4.4 by the typical procedure of reacting (S)-
phenyl alaninal with NH3 in glyoxal, and subsequent alkylation in the presence of KOH 
with Etl (Scheme 4.3). 
The results obtained by Dhanak et al. 7 using NH3 and glyoxal for the synthesis of 
terminal imidazole mimetics show epimerization of imidazole, whereas Predgen et al. 8 
have reported the retention of configuration using the same protocoL This vagueness in the 
results obtained by two groups 7,8 limits the generality of this method. Therefore, the 
development of a general and reliable method of synthesis of non-racemic C-terminal 
imidazole mimetics using mild reactions, and compatible with a variety of N-protecting 
groups seems crucial. 
Haberhauer et al. have reported the synthesis of imidazole-containing cyclopeptide 4.1b-c 
as analogue of the naturally occurring 4.1a.9 Other heterocycles such as oxazole, thiazole, 
oxazoline and thiazoline are found in nature in lissoclium class of cyclopeptides (e.g. 
westiellamide 4.1a) obtained from marine sources9 (Figure 4.4). 
4.1a 4.1b 4.h: 
Figure 4.4: LissocliulII cyc10peptide 4.1a and its imidazole analogue 4.1b and 4.1c. 
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The synthesis of non-peptide imidazole-based antagonists of the Angiotensin receptor as 
potent antihypertensives has been repOlted by Carini et al. 10 (Figure 4.5). Angiotensin II, 
an octapeptide produced by the renin-angiotensin system, is a powerful endogenous 
vasopressor. Renin-angiotensin inhibitors have been found to be effective for the treatment 
of human hypertension. These angiotensin convelting enzyme (ACE) inhibitors work by 
blocking the production of angiotensin II from angiotensin I. 
x = single bond, 
CO, 0, S, CH=CH 
(trans) 
Figure 4.5: DeJivatives ofimidazoles as potent hypertensive agents. 
A conventional method for the preparation of 2-substituted aliphatic imidazoles uses the 
reaction of imidazole with an electrophile (e.g. an aldehyde11a or isocyanate, lib Scheme 4.4). 
f~ N + R'CNO 
I 
R 
PhN02 
reflux 
f1 NHR' 
N' l( 
~ ° 
Scheme 4.4: Synthesis of2-substituted imidazoles by the reaction 
of imidazole and isocyanate. 
Recently, Halsta et ai. have reported a synthon of 2-substituted aliphatic imidazoles by 
treating an azolium ylide with reactive carbamoyl and carbonyl compounds. 12 Subsequent 
solvolysis of 4.6 gives 2-substituted imidazoles containing a variety of substituents 
(Scheme 4.5). 
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N (;> 
N 
\ 
4.5 
XCOR 
PhCHO 
DIEA 
(
N OCONR Nu-H IH 
N Ph TFAJTHF 
\ 
4.6 
(
N Nu IH 
N Ph 
\ 
4.7 
Scheme 4.5: Acylation of imidazole 4.5 and solvolysis reaction of 4.6 to give 4.7. 
77 
The diverse applications of imidazole-containing compounds, have made them attractive 
targets for organic and medicinal chemists. Significant efforts have thus gone into 
developing new and efficient methods for the synthesis and functionalization of simple and 
amino acid-based non-racemic imidazoles. We have developed a general Pd-catalyzed 
methodology involving application of A-H reaction to the synthesis of 1,2,4-substituted 
imidazoles. What follows is a discussion about the synthetic strategy and results obtained 
from the synthesis of aliphatic and non-racemic amino acid-based imidazoles. 13 
4.2 Synthetic Plan for the Synthesis of Aliphatic and C-terminal Amino 
Acid Imidazoles 
The proposed synthetic strategy for the synthesis of imidazoles was based on an A-H 
cyclization of O-pentafluorobenzoyl N-alkyl, N-allyl amidoximes. Oxidative addition of 
Pd(O) to the N-O bond of the O-pentafluorobenzoyl amidoxime would occur to give an 
alkylideneamidopalladium(II) species which would add to the olefinic side chain. 
Elimination of a palladium hydride species would then give a dihydroimidazole, which 
would finally isomerise under reaction conditions to the imidazole (Scheme 4.6). 
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Pd(O) 
Base 
.. 
Scheme 4.6: Synthetic plan for the synthesis of irnidazoles. 
4.3 Synthesis of Imidazoles from Aliphatic Aldehydes 
Jil R N 
I 
R' 
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The synthetic steps involved in the synthesis of imidazoles 4.13a-c are outlined in Scheme 
4.7. Reaction of aliphatic aldehydes 4.8a-b with hydroxylamine, in the presence of pyridine, 
gave the aldoximes 4.9a14a (1:1, 75%) and (EIZ) 4.9b 14b (3:2, 72%), respectively. These 
were then separately treated with NCS in dry DMF at 70°C, to give the corresponding 
hydroxamoyl chlorides 4.10a-b, which were coupled in situ with N-allyl benzyl amine 15 in 
DMF to give predominantly 4.11a (63%) and 4.11b (61%) as single isomers, tentatively 
assigned as the E-configuration. t In a separate experiment, 4.9b was treated with NCS and 
the crude product isolated and analysed by 1H NMR to show 4.10b as a single isomer, 
characterized and tentatively assigned the E-configuration. The sample of 4.10b was then 
reacted with N-ally benzyl amine as per the in situ experiment to give the identical isomer 
of 4.11b. Modeling studies of the (EIZ)-amidoximes 4.11a-b also suggested the population 
of the amidoximes 4.10a-b to be in the lower energy (E)-conformation. This is attributed to 
the intramolecular 7r-H bonding between the electron deficient oxime hydrogen (C=NOH) 
and the electron-rich phenyl rings. 
1" O-alkyl hydroxamoyl chlorides are reported to isomerise to the thermodynamically stable 
E-isomers,16 and that these react stereospecifically to give E-amidoximes. 17 
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4.8a-b 
NJOCOC6FS 
v Rl)lN~ 
" 
4.12a-c lph 
Compound i 
4.8a-4.13a 
4.8b-4.13b 
4.8c-4.13c 
Rl 
PhCH2 
Ph(CH2h 
C02Me 
N
JOH 
Rl)lN~ 
lph 
4.11a-c 
IJZl R N 
lph 4.13a-c 
Reagents andc onditions: i) NH20H.HCl, pyridine, EtOH, rt. ii) NCS, DMF, 70° C, 2h. iii) NaN02, HCl, H20, _5° C. 
iv) allyl benzyl amine, DMF, 70° C. v) C6FsCOCl, TEA, DCM, 0 0c. ,,1) Pd(PPh3)4, TEA, DMF, 80° C. 
Scheme 4.7: Synthesis ofimidazoles 4.13a-c. 
Similarly, aliphatic hydroxamoyl chloride 4.10c prepared as an (E/Z) mixture (6:5) from 
glycine methyl ester hydmchloride18 (Scheme 4.7), was also treated with N-allyl benzyl 
amine to give 4.11c (75%) as a 6:5 mixture of isomers. Modeling for (EZ)-4.llc suggested 
that low energy conformers exhibit 1J"-H bonding between the oxime OH and the electron 
rich double bond suggesting 4.11c as Z-configured. However, experimentally both and Z 
isomers are observed for 4.11c suggesting that intramolecular H bonding might also be 
displayed between the hydroxyl H and either oxygen of the methyl ester group. 
The substrates for A-H reaction (4.12a-c) were then prepared by reacting separate samples 
of (E)-4.11a, (E)-4.l1b and (E/Z)-4.llc (6:5) with TEA and pentafluorobenzoyl chloride 
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in DCM at 0 °C to give (E)-4.12a-b as single isomers and (E/Z)-4.12c (4: 1) in 83, 87 and 
88% yields respectively. An N, O-pentafluorobenzoyloxime was chosen for A-H sequence 
since this group is known to suppress the competing Beckmann rearrangement. 13d 
Modeling studies for 4.12a and 4.12b suggested the E isomers of lowest energy, which is 
likely due to 7r-7r stacking between the pentafluorophenyl and the 2-substituted 
phenyl(methyl) and phenyl( ethyl) groups for 4.12a and 4.12b respectively. Low energy 
conformations for 4.12c (4:1) also display 7r-7r stacking between the phenyl ring of the 
benzyl group and the pentafluorophenyl ring, suggesting Z configuration for the major 
Isomer. Assignment of the EIZ Isomer ratios of the amidoximes and 
pentafluorobenzoyloximes is thus, tentatively based on computer modeling as explained 
further in section 4.5. 
The N, O-pentafluorobenzoyl amidoximes 4.12a-b were treated with 10 mol% Pd(PPh3)4 
and 5 equivalents of TEA in DMF, at 80° C for 30 minutes, to give the desired imidazoles 
4.13a-b in 72% and 70% yields respectively. The A-H cyclization of 4.12c was slow 
requiring 3 h to give 30% of the corresponding imidazole 4.13c. The lower yield in this 
case is unlikely to be linked to the presence of two isomers in the substrate 4.12c, since the 
A-H reaction has been reported to be independent of the geometry of the oxime. 13d 
The imidazoles were characterized by lH and l3C NMR spectroscopy. Key observations 
include the difference in chemical shifts for the equivalent C-4 CH3 protons for 4.13a-c is 
~0.04 ppm as depicted in Figure 4.6. Other key equivalent protons are C-1 benzylic protons 
which appear at the same chemical shift for 4.13a and 4.13b whereas chemical shift for the 
same protons in 4.13c is shifted 1.71 ppm downfield due to the proximity of electron 
withdrawing ester group (see Figure 4.6). The difference in chemical shifts for C-5 olefinic 
proton is ±0.24 ppm, and shows the same trend as for C-1 benzyl protons. 
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Compound Benzyl-H U-5 
4.13a 2.22 4.80 6.52 
4.13b 2.23 4.80 6.50 
4.13c 2.18 5.51 6.74 
Figure 4.6: Compalison of the chemical shifts of 4.CU3, I-CH2 and 5-CU protons 
for the imidazoles 4.13a-c 
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The structures of the aliphatic imidazoles were further confirmed by the data obtained from 
2D COSY, HSQCIDEPT and mass spectrometry. 
After successfully using A-H cyc1ization for the synthesis of N-benzyl imidazoles, 
extension of the same methodology was attempted for the synthesis of aliphatic imidazoles 
containing N-carbamoyl substituents. N-Carbamoylation of allyl amine with N-Boc19and N-
Cbzl9 groups was achieved by the literature methods. Simple allyl amine was also used to 
check the possibility of A-H cyclization in the absence of an N-substituent (Scheme 4.8). 
Coupling of the oxime 4.8b could be achieved only with allyl amine to givc amidoxime 
4.14, where as coupling with N-allyl, N-Boc amine and N-allyl, N-Cbz amine was not 
successful (Scheme 4.8). The reason for this could be the reduced nucleophilic character of 
the amine N atom duc to the electron withdrawing effect of I-Boc and Cbz groups. 
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Reagents and conditions: i) NCS, DMF, 70°C, 2h & then allyl benzyl amine, DMF, 70°C. iii) C6FsCOCl, TEA, 
DCM, 0 0C. iV)2 C6FsCOCl, TEA, DCM, 0 0C. v) Pd(PPh3)4, TEA, DMF, 80°C. 
Scheme 4.8: Attepmted N-substitution of 4.14 and A-H reaction of 4.15. 
In addition, bi-pentafluorobenzoylation of the unsubstituted amidoxime derivative 4.14 
could not be achieved, as the reaction of compound 4.14 with 2 equivalents of C6FsCOCI 
and TEA gave only the O-acylated amidoxime derivative 4.15. N-Carbamoylation thus 
seems difficult in the presence of more acidic oxime proton. A-H cyc1ization of the NH 
derivative 4.15 was attempted, but cyc1ization to the desired imidazole did not occur, rather 
4.16 was obtained as the sole product in 80% probably via simple hydrolysis of the 0-
pentafluorobenzoate. This result suggests that the presence of N-substituent seems 
important for the A-H cyc1ization of amidoximes. 
4.4 Synthesis of Imidazoles from a-Amino Aldehydes 
The A-H cyc1ization was next extended to ammo acid-based examples as depicted in 
Scheme 4.9 below. The key starting aldehydes 4.17a-c were prepared by DIBALH 
reduction of (S)-N-Boc-PheOMe, (S)-N-Boc-AlaOMe, and (S)-N-Boc-LeuOMe 
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respectively?O Treatment of each of these aldehydes with hydroxylamine in the presence of 
Na2C03 gave a-amino aldoximes20 (EIZ)-4.18a (79%, 2:1), (EIZ)-4.18b (72%, 3:1), (EIZ)-
4.18c (83%, 3:2) which were purified by column chromatography and recrystallisation. 
4.17a-c ii l4.18a-c, R2 = H 
[ 4.19a-c, R2= CI 1 
Compound 
4.17-4.22a PhCH2 
4.17-4.22 b 
4.17-4.22c 
--;-. [ 4.20a-c, R2 = H 1 
iii I l L 4.21a-c, R2 = OCOC6FS 
R'rJ) 
Boc-NH l 
Ph 
4.22a-c 
Reagents andc onditions: NH20H.HCl, Na2C03' methanol/water (1:1), rt. ii) NCS, DMF, 70° C, 2h & then allyl benzyl 
amine, DMF, 70° C. iii) C6FsCOCl, TEA, DCM, 0° C. iv) Pd(PPh3)4' TEA, DMF, 80° C. 
Scheme 4.9: Synthesis ofimidazoles 4.22a-c derived from a-amino aldehydes 4.17a-c. 
A one-pot treatment of each of these oximes with NCS, as for 4.9a-b in Scheme 4.5, gave 
the hydroxamoyl chlorides 4.19a-c, which reacted in situ with N-allyl benzyl amine to give 
the amidoximes as mixture of isomers (EIZ)-4.20a (2:5), (EIZ)-4.20b (3:8), (EIZ)-4.20c 
(1 :5) based on analysis of lH NMR spectroscopy. Modeling studies conducted for 4.20a-c 
suggested the Z isomers as major products, as they are stabilized by 1f-H bonding between 
oxime the OH and the double bond. These were used in the next step without fmiher 
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purification. Thus, the major isomers of (EIZ)-4.20a-c were assigned as Z-configured based 
on modeling. 
Treatment of (EIZ) t4.20a-c with TEA and pentafluorobenzoyl chloride, as for 4.11a-c, 
gave the substrates (4.2la-c) for the A-H reaction as single isomers in 61, 63 and 31% 
yields respectively. Pentafluorobenzoylamidoximes 4.2la-c were obtained as single 
isomers from (EIZ)-mixture suggesting that the minor isomers might have isomerised to the 
thermodynamically more stable isomers. Molecular modeling suggests >98% population of 
4.2la-c in E-confOlmation stabilized by intramolecular H-bonding between a fluorine and 
NH group in 4.21b and 4.21c, and 7["-7[" stacking between the pentafluorophenyl and the 
phenyl rings in 4.2la. Thus, E-configuration was assigned temporarily to 4.2la-c based on 
molecular modeling, and is discussed further in section 4.5. 
Compounds 4.2la-c were then subjected to the amino Heck reaction conditions to give the 
C-telminal amino acid mimetics 4.22a-c in good yields. In particular, the (S)-Phe-based 
amidoxime derivative 4.2la cyclized smoothly in Ih to give the imidazole derivative 4.22a 
in 70% yield, while (S)-Ala-based 4.22b was isolated in 68% after a comparatively shorter 
reaction time of 30 min. The imidazole derivative of (S)-Leu 4.22c was isolated in 56% 
yield afterl h reaction. The reaction works well, with the crude NMR for all imidazoles 
showing a turnover of 90-95%, but the isolated yields were somewhat lowered due to 
difficulties in separation of the imidazoles and triphenylphosphine oxide fOlmed from the 
decomposition ofPd(PPh3)4 by chromatography. 
The IH NMR data for compounds 4.22a-c show that the t-Bu, CHc:¥, NH, I-benzyl, 4-CH3 
and 5-olefinic protons exhibit the chemical shifts in the same region with a little variation. 
t The assignment of isomers is ambiguous and unimportant as both isomers react in the A-
H reaction. 13d However, Sauve et al. suggested for a-amino amidoximes the Z-isomer to be 
predominant? I 
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Figure 4.7 depicts a comparison of the key lH NMR resonances for 4.22a-c. The nine CH3 
protons of the t-Bu group appear in the same region ~0.02 ppm different from each other. 
The difference in chemical shift for the CHa proton is ~0.09 ppm whereas the variation in 
chemical shifts for NH is ~0.39 ppm. Similar to the aliphatic imidazoles, the CH3 protons 
at C-4 appear approximately at the same position (~ 2.2 ppm) with a negligible difference 
of 0.01 ppm. The benzyl protons for 4.22a appear at 4.67 ppm as a singlet whereas, for 
4.22b-c, these appear as doublet of doublets between 5.08-5.11 and 5.16-5.22 ppm. The the 
olefinic proton appear as a multiplet between 6.35 and 6.52 ppm. All these results confirm 
the structures of imidazoles 4.22a-c. 
t 
~:ro 0 ~{'] It~ ~5,,_ 
/ " 2 Nl Rl) I~
~ 
Compound t-Bu CHa NH CH3 Benzyl-H H-5 
4.22a 1.36 4.95 5.44 2.20 4.67 6.35 
4.22b 1.39 4.91 5.27 2.l9 5.08/5.16 6.52 
4.22c 1.38 4.86 5.05 2.19 5.11/5.22 6.52 
Figure 4.7: Compm1son of the chemical shifts of t-Bu, CHa> NH, 4-CH3' l-CH2 and 5-CH 
protons for the imidazoles 4.22a-c. 
Figure 4.8 depicts key 2D-COSY con-elations for imidazoles 4.22a-c, whose structures 
were further proved by 2D HSQCIDEPT, \3C NMR and mass spectrometry. 
Chapter 4 86 
4.22a 4.22b 4.22c 
Figure 4.8: Key 2D-COSY connectivity data for 4.22a-c. 
Optical rotations were measured for 4.22a-c with [a]2oD of -8.3°, -74.2° and -54.3° 
respectively. The optical purity of the (S)-Phe-based imidazole 4.22a was checked by 
removing the N-Boc group using IN HCI in EtOAc (Scheme 4.10) at rt to give the free 
amine 4.23 (100%). Compound 4.23 was then coupled with (S)-N-Boc alanine under 
standard peptide coupling conditions using EDCl, HOBT and DlPEA to give 4.24 (> 95% 
de, based on analysis of IH and DC NMR spectra). This result suggests that little or no 
racemization has occurred in the preparation of the imidazole. 
~~h ): Ph ):N Ph 
. {NY I~ a b 
'oY HN-I tk d HN-Boc d 'aI, ~ N 0 I 0 H 
~ 
4.22a 4.23 4.24 
and conditions: a) IN HCI, EtOAc, rt, 3h. b) N-t-Boc L-Alanine, EDCI, HOBT, DIPEA, DMF, rt, 16h. 
Scheme 4.10: Deprotection ofBoc from 4.22a and synthesis of 4.24. 
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4.5 Modeling Studies for Assignment of Configuration to the Amid-
oximes and their O-pentafluorobenzoyl Derivatives 
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The EIZ configuration of aliphatic and ammo acid-based amidoximes and their 0-
pentafluorobenzoyl derivatives were tentatively assigned on the basis of modeling studies. 
The Macromodel molecular mechanics programme OPLS2001 forcefield in CHCh was 
used for minimization and confOlmational study. The Clustering programme X cluster was 
subsequently used for sorting and identification of E and Z isomers. Each compound was 
minimized in CHCh by the PRCG method converging on a gradient with a threshold of 
0.05 kJ moriA-I. Each compound was then subjected to a conformational search using the 
MCMM method. Conformers within 21 kJ were saved after 5000 steps. The ensemble of 
each conformer was then subjected to cluster analysis. The comparison atoms used for 
clustering were the oxime C, Nand 0, plus the adjacent C and N atoms on each side. 
4.5.1 Stereochemistry of Aliphatic Amidoximes and O-pentafluorobenzoylamid-
oxirnes 
Table 4.2 highlights the Boltzmann weighted energy (which reflects the relative 
thermodynamic stability) of each isomer for the aliphatic amidoximes and the 
pentafluorobenzoylamidoximes from the modeling studies, which indicates that the low 
energy conformers for 4.11a-b have E configuration. 
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Table 4.2: Boltzmann weighted energy of E:Z ratio for 4.1la-c and 4.12a-c. 
Compound 4.11a 4.11b 4.11c 4.12a 4.12b 4.12c 
Boltzmann 
weighted % 94.5 76.3 0 100 100 0.5 
ofE 
Boltzmann 
weighted % 4.6 23.7 100 0 0 99.5 
ofZ 
This may be attributed to the fact that there is less steric bulle on that side, and the oxime 
OH also displays a 7f-H bond with electron rich phenyl rings in 4.11a-b as shown in Figure 
4.9. 
H-O 
~ ~ VJN~ 
~ 
4.11a U 
Figure 4.9: n-H bonding detected by modeling for 4.11a-c. 
In contrast, low energy conformers for 4.11c suggest a 100% Z configuration stabilized by 
a 7f-H bond between the oxime OH and the double bond. 
The experimental data for the major:minor isomers of 4.11-4.12a-c are summarized in 
Table 4.3, which show that 4.11a-b were obtained as single isomers (based on analysis of 
IH and l3C NMR spectrocopy), and were assigned as E-configuration based on modeling 
studies. 
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Table 4,3: Experimentally obtained major:millor ratio for 4.11a-c and 4.12a-c. 
Compound 4.11a 4.11b 4.11c 4.12a 4.12b 4.12c 
major 100 100 6 100 100 4 
minor a a 5 a a 
This is fUl1her supp0l1ed by the crude 1 H NMR data for intennediate hydroxamoyl chloride 
4.10b which was isolated, characterized and reacted with iV-allyl benzyl amine separately to 
give a single isomer of 4.11 b as shown in Scheme 4.11. 
DMF, r1 
" Allyl benzyl amine 
(E) - 4.10b 
HO'N 
Ph~N~ 
(E).4.11bU 
Scheme. 4.11: Synthesis of thermodynamically more favourable (E)- amidoxime. 
Johnson and co-workers 16 have also reported that O-alkyl hydroxamoyl chlorides isomerise 
to the thennodynamically and sterically more stable E isomers, and react stereospecifically 
to give predominantly (E)-amidoximes. 17 
(EIZ)-4.11c (4: 1) was prepared from a mixture of the hydroxamoyl chloride (EIZ)-4.10c 
(6:5). Modeling studies suggested low energy confonners for 4.11c to be in Z configuration, 
thus the major isomer was assigned as Z configured. 
The structures of global minima for (E)-4,l1a and (Z)-4.11c are represented in Figure 4.10. 
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(a) (b) 
Figure 4.10: Structure of global minima of 4.11a (a) and 4.11c (b). 
The O-pentafluorobenzoates 4.12a-b were obtained as single isomers (determined by IH 
NMR) and were assigned E-configuration based on modeling, which revealed that the low 
energy conformers have an E-configuration. This might be due to less steric bulk on that 
side and possible 1t-1t stacking between phenyl and pentafluorophenyl rings as indicated by 
the dotted lines in Figure 4.11 . 
F«F F 
:::::-...: I 
F 0 
·r 0 
" 'N ~ ii d-N~ 
U 
F 
Figure 4.11: 11: - l[ slacking between the phenyl rings in E - 4.lla-b and E - 4.1k 
Modeling suggested 4.12c predominantly to have Z configuration. However, the 
experimental data shows two isomers in a 4:1 ratio (established by IH NMR). The major 
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isomer was assigned as Z to represent the modeling results, as the low energy conformers 
of 4.12c show the x-x interaction between the pentafluorophenyl and the phenyl ring of the 
N-benzyl group. Figure 4.12 represent structures of the global minima of £-4.12a and Z-
4.12c. 
Figure 4.12 (a) 4.12a (b) 4.12c 
4.5.2 Stereochemistry of Amino Acid-based Amidoximes and O-pentafluorobenzoyl-
amidoximes 
Table 4.4 summanzes the Boltzmann weighted energy (representing the relative 
thermodynamic stability) of each isomer for the amino acid-based amidoximes 4.20a-c and 
the pentafluorobenzoylamidoximes 4.21a-c obtained from modeling. 
Table 4.4: Boltzmann weighted energy of E:Z ratio for 4.20a-c and 4.21a-c. 
Compound 4.20a 4.20b 4.20c 4.21a 4.21b 4.21c 
Boltzmann 
weighted % 5.9 20.5 16.8 98.7 98.2 99.6 
of E 
Boltzmann 
weighted % 94.1 79.5 83.2 1.3 1.8 0.4 
of Z 
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In contrast to the aliphatic amidoximes, the relative thermodynamic stability for 4.20a-c, 
decreases from 94.1 for 4.20a to 83.2 for 4.20c and further diminishes to 79.5 for 4.20b as 
the side chain group becomes progressively smaller from 4.20a.....;. c.....;. b. This may be 
attributed to the fact that there is less steI1C bulle on that side and the oxime OR also display 
a 7r-R bond with the electron rich double bond as shown in Figure 4.13. 
4.20a 4.20c 4.20b 
Figure 4.l3: rc-H bonding detected by modeling for 4.20a-c. 
The experimental results for 4.20a-c and 4.21a-c are summarized in Table 4.5, which show 
the ratio of major:minor isomers for 4.20a-c and 4.21a-c. 
Table 4.5: Experimentally obtained major:minor ratio for 4.20a-c and 4.21a-c. 
Compound 4.20a 4.20b 4.20c 4.21a 4.21b 4.21c 
major 5 8 5 100 100 100 
minor 2 3 o o o 
Thus, the major Isomers were assigned Z stereochemistry based on modeling results 
discussed earlier. The assignment of Z stereochemistry to the major isomer is further 
supported by an article published by Sauve et al.,21 who have reported the formation of Z-
isomers as the major isomer in their synthesis of amino acid-based amidoximes. 
Chapter 4 93 
Compared to the aliphatic hydroxamoyl chlorides 4.10a-b, the substituent pliorities for N-
Boc protected O!-amino hydroxamoyl chlorides are different, as the oxime OH group would 
prefer a trans stereochemistry to the bulky sidechain group and Boc group (Figure 4.14). 
(EZ) - 4.19a-c 
Figure 4.14: Stereochemically more favourable (Z)- hydroxamyl chlorides 
The pentafluorobenzoylamidoximes 4.2h-c were formed as single isomers [from (E/Z)-
mixture of the substrates] as shown in Table 4.4, whereas modeling suggested that >98% of 
the thermodynamically stable, low energy conformers have E configuration. This may be 
attributed to H-bonding observed between the NH and F of the pentafluorophenyl ring in 
4.21b-c, and 7f'-7f'stacking between the phenyl and petafluorophenyl rings in 4.21a (Figure 
4.15). Thus, these were assigned E configuration tentatively. 
4.15: FOlmation of hydrogen bond between F and NH in E 4.21h-c and 11 - 11 stacking 
between the two lings in E - 4.21a 
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The structure of the global minima for (E}4.20b and (Z)-4.21b are depicted in Figure 4.16 
Figure 4.16 (a) 4.20b (b) 4.21b 
4.6 Conclusion and Future Work 
In summary, a new synthesis of imidazoles from aliphatic and amino acid-based aldehydes 
has been developed.22 The sequence utilized metal-catalyzed Amino-Heck reaction to form 
the cyclic compounds. The imidazolyl mimetics were characterized using IH, I3C NMR and 
mass spectrometry. The reaction works well and both aliphatic and optically active C-
terminal imidazole mimetics are formed in good yields. The C-terminal imidazole mimetics 
have the potential for use as cis amide bond replacement using A-H methodology. In 
addition, attempts were made to prepare 2-substituted imidazoles other than benzyl 
substituents; and the presence of an N-substituent has been found to be crucial for A-H 
cyclization (to avoid the competing Beckmann rearrangement). 
Future work could involve extension of the A-H reaction to the synthesis of C-terminal di-
and tripeptide imidazole derivatives. Synthesis leading to the incorporation of a second 
amino acid residue at N(l) of the imidazole could also be achieved by using an amine 
bearing a protected carboxyl group in the coupling reaction of an oxime and amine, which 
in tum could be coupled to the N-terminus of an other amino acid. 
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CHAPTER FIVE 
SYNTHESIS OF 
2-ARYL 5-FUNCTIONALIZED PYRROLES VIA 
AMINO-HECK REACTION FOLLOWED BY OTHER 
DOMINO PROCESSES 
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Pynoles I are abundant as constituents of natural products and have found broad synthetic 
utility in both medicine and material science. The unique properties of pyrrole-containing 
compounds and their ubiquity in nature has thus inspired a significant interest in the 
synthesis of such compounds. The generality of the amino-Heck cyclization, coupled with 
other domino processes, has been extended to the synthesis of 2,5-disubstituted pyrroles 
from propargylic derivatives of N,O-pentafluorobenzoyl oximes. What follows is a brief 
introduction about the applications of pyrrole-containing compounds and methods of their 
synthesis. 
The PYlTole ring has found great use in the design and development of pharmaceuticals. 
Pynole-containing compounds display interesting biological properties including 
antipsychotic (e.g. 5.1, Figure 5.1),2 anti-inflammatory (e.g. 5.2, Figure 5.1),3 
radioprotective,4 and spasmolytic activity.s Other drugs that possess the PYlTole moiety as 
an essential component include the non-steroidal anti-inflammatory agents6 (e.g. and 
5.4), and cholesterol lowering agent7 5.5. 
R Alkyl or alyl 
5.1 
o 
5.2 5.3 
N 
F 
5.5 ) OH' HO~C02H 
Figure 5.1: Representative PYlTole-containing drugs. 
5.4 
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The pyrrole is a basic substructure of various natural products (see Figure 5.2). Novel 
applications of pyrrole containing natural products include bacterial metabolites (e.g. 
chromoxymicin found in S. rubropurpureus),8 fungal metabolites (e.g. lycogarubin A 
5.7 secreted by lycogala epidendrum, exhibiting some anti-HSV-l viral activity),9 
metabolites of marine origin (e.g. agelasine G 5.8 exhibiting antileukemic activity obtained 
from Okinawan Agelas spongelO and manzacidin C 5.9 obtained from hymeniacidon 
sponge), 11 and bilirubin 5.10 found in bile and gallstones. 
HO 
o o 
Me2N NMe2 
5.6 
o ~ 
H J-Ylo S.S 
Br 
o 
HO~ V~T] N 
H 
5.10 
Figure 5.2: PYHole-containing natural products. 
C02Me 
OH 
5.7 
5.9 
o 
Due to their widespread applications in nature and science, considerable efforts have been 
devoted to the development of straightforward reactions to build up pyrroles. The simple 
UNIVERSITY OF GANTERBUFlV 
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methods widely used in this context involve the cyclization reactions, e.g. the Paal-KnolT12 
synthesis, the KnOlT13 synthesis and the Hantsch14 synthesis. The Paal-KnolT synthesis 
involves the reaction of a 1,4-dicarbonyl compound with NH3, primary amines, 
hydroxylamines or hydrazines. The cyclization is thought to occur by the nucleophilic 
attack on the carbonyl group probably through the intermediate 5.11. 
Rl_(~~n-Rl 
o 0 + -- 1~1 R N R 
12 
R 
5.11 
Scheme 5.1: The Paal-KnolT synthesis ofPyrroles. 
The KnOlT synthesis, an aldol-type cyclization, involving the attack by a nucleophilic 
carbon on the carbonyl group, provides route to a variety of pyrroles. The reaction uses two 
moles of the starting l3-ketoester, one being nitro sated and reduced in situ to give an 
aminoketone 5.13 (via the intermediate oximinoketone 5.12), which then reacts with the 
second mole to give the pyrrole via the intermediate 5.14 (Scheme 5.2). 
0y 
HON~OR 
5.12 0 
j Z", M,C02II 
0\ OR 
H2N 
+ 
o 
5.13 5.14 
Scheme 5.2: The KnOlT synthesis ofPynoles. 
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The Hantsch synthesis involves the reaction of an a-haloketone with a IJ-ketoester and 
ammonia or a primary amine as depicted in Scheme 5.3 . 
.. 
Scheme 5.3: The Hantsch synthesis ofPynoles. 
Other methods involve metal-catalyzed cyclizations involving precursors that possess the 
requisite nitrogen nuc1eophile and an alkene in the same molecule. For example Baeckvall 
and co-workers 15 have synthesized a pyrrole 5.16 by a Pd-catalyzed cyclization of the 
amine 5.15. 
~NHBn AcO 
Cu(BF4h, THF, 60% 
5.15 
Scheme 5.4: Synthesis of P yrro Ie 5.16. 
ri 
N 
Bn 
5.16 
Baeckvall and co-workers16 have found that ptimary amines react with the dienes via a 1f'-
allyl Pd intermediate 5.17 to give the pyrroles 5.18 in variable yields. 
HOAc, 70·100% 
Rl R2 R3 4 , , ,R H,Me 5.17 
R5 = Et, Bn 
R5NH2' Ph3P, THF 
» 
AgBF 4, Cu(BF 4)2 
-30°C - rt, 13-54% 
5.18 
Scheme 5.5: Synthesis ofPynoles 5.18 via rc -allyl Pd Intelmediate 5.17. 
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Fiirstner et al.17 have synthesized a pyrrole ring 5.19 VIa a Pd(O)-mediated reaction 
(Scheme 5.6) in the first total synthesis of roseophilin. 
70% PhO~ 
° ° 
BnNH2' Pd(O) cat. 
Scheme 5.6: Synthesis ofPYlTole 5.19 in the total synthesis ofroseophilin. 
Alkynes also serve as the recipients of cycloamination protocols. For example Knolker et 
al. 18 have carried out a Ag(l) promoted cycloamination of homopropargyl amine 5.21 
(formed by the addition of an alkynyl Grignard reagent 5.20 to a Schiff base) to give 1,2-
disubstituted pyrrole 5.22 as depicted in Scheme 5.7. 
+ ii 
5.20 5.21 
Reagents and conditions: i) a) BFT Et20, THF, _23 0 C, 30 min; b) Et20, _23 0 C, ISh. 
ii) l.l eq. AgOAc, DCM, rt, I4h. 
Scheme 5.7: Synthesis of PYlToles 5.22 from 5.21. 
2J:1 R N 
II 
R 
5.22 
Gabriele et al. 19 reported a related cycloisomerization of (Z)-2-en-4-ynyl amines 5.23 to 
substituted pytToles 5.24 in the presence of a Pd(II) catalyst and KCl in N,N-
dimethylacetamide as shown in Scheme 5.8. Ring-closure occurs at rt if R3 is equal to H, 
otherwise heating is required for the cycloisomerization. 
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R2 R3 
~ Rl R4 
5.23 
Pdcat., DMA 
KCl, 25-100° C 
5.24 
Scheme 5.8: Synthesis ofPyrroles 5.24 from 5.23. 
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Grigg et ai. 20 carried out a palladium-catalyzed intramolecular cyclization of an enamine 
5.27 containing a vinyl bromide (formed from an amine 5.25 and alkyne 5.26 or an allene) 
as illustrated in Scheme 5.9. 
DMF,rt, 84% 
5.25 5.26 5.27 
Scheme 5.9: Pd-catlyzed cyclization of 5.27. 
Various substituted pyrroles have been synthesized by Narasaka et a/. 2l via A-H 
cyclizations of olefinic oximes, as discussed earlier in chapter 2 (section Table 2.1). 
Various applications of A-H reactions have been reported for the synthesis of different N-
heterocyeles from olefinic oximes. Here, I report the first A-H cyclization of alkynyl 
derivatives of O-pentafluorobenzoyl oximes followed by other domino processes, applied 
to the synthesis of 2,5-functionalized pyrroles. What follows is a discussion about the 
synthetie plan involved in the synthesis of pyrroles. 
5.2. Synthetic Synthesis of Pyrroles 
The synthetic strategy involved in the synthesis of pynoles was based on the A-H reaction 
of propargylic O-pentafluorobenzoyl derivatives of oximes as outlined in Scheme 5.10. 
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Oxidative addition of Pd(O) to the N-O bond of oxime would occur to gIVe the 
alkylideneaminopalladium(II) complex 5.28 which would add to the triple bond to give a 
living alkenylpalladium(II) complex 5.29. The termination of is vital for the 
regeneration of the Pd catalyst to the catalytic cycle. This could bc accomplished in a 
number of ways. For example, termination by dehydropalladation (under A-H reaction 
conditions) would give the pyrrole 5.30, whereas tennination by transmetallation with 
organometallic compounds, intermolecular Heck reaction or CO insertion followed by a 
nucleophile, would give rise to a variety of 2-substituted 5-functionalized pyrroles as 
depicted in Scheme 5.10. 
(II) 
RO~N 
Pd [ R'X::] ~RI 
5.28 
1 
OR 
[ 
I ] 11 
,J RI I Transmetallation R2_M 1:::-'" R R2 
:0 [:~ I Heck reaction ~ 1:::-'" rR2 R 1:::-'" R 
5.30 5.29 0 
Carbonylation R
2;J 
CO, R20H HN ~ 
1:::-'" 
R 
Scheme 5.10: Synthetic plan for the synthesis of functionalized pyrroles. 
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substrates for the Preparation of Pyrroles 
The synthesis of alkynyl ketones is outlined in Scheme 5.11. The aryl ketone containing 
tenninal allcyne moiety was synthesized by alkylation of the N,N-dimethylhydrazone 3.13b 
(derived from acetophenone) with 4-bromo-l-butyne 5.31 and successive hydrolysis.22 The 
clUde alkynyl ketone derivative was purified by flash column chromatography to 
in 91 % as depicted in Scheme 5.11. 
+ 
i, ii ° {\ Ph~ ___ ii_i_ ... p~~ 
3.13 b 5.31 5.32 5.33 
iv 
{\ 
v 0,/0 ~ //C02Me PIf'''-/~ 
5.35 5.34 
Reagents and conditions: i) LDA, THF, lh; then propargyJ bromide 5.31, -78oC-Lt, 16h, ii) NaOAc, AcOH, 
THF, water, rt, 3h. iii) ethylene glycol, C6H6,p-TsOH, reflux, 3h, iv) _78°C, n-BuLi, 1 h, then CIC02Me, 4h, v) 
INHC1, THF, reflux. 
Seheme 5.11:Synthesis of prop argyl ketones 5.32 and 5.35. 
The internal alkyne derivative was prepared subsequently from 5.32 in two steps by 
first protecting its carbonyl group as a keta123 (5.33), and then reacting the ketal (5.33) with 
methylchlorofonnate to The ketal functionality of 5.34 was subsequently 
hydrolyzed hy refluxing it with IN Hel (aq.) in THF to give the internal alkyne derivative 
in 88% yield. 
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The tenninal and internal alkyne-based aryl ketones (5.32 and 5.35) were then treated with 
pyridine and NI-hOH.HCI in EtOH at rt, stirred for 1-3 hand transfonned to the 
corresponding oximes EZ-5.36 (95%, 5:2) and E-5.37 (70%, single isomer by NMR) 
respectively. The major isomer of 5.36 and the single isomer of were tentatively 
assigned the thennodynamically more stable E configuration. The E-isomers of 5.36 was 
observed to be comparatively less polar than the corresponding Z-oximes. The minor 
Isomer was isolated after column chromatography and analysed by IH and l3C 
NMR spectroscopy, which revealed a slow isomerisation at rt to the more stable E-isomers. 
The substTates for A-H reaction were prepared by reacting the oximes [(E)-5.36 and 5.37] 
with and C6F5COCI at 0 DC, and stirred for 1-2 h to give N,O-pentafluorobenzoyl 
oximes [(E)-5.38, E-5.39] as depicted in Scheme 5.12. Purification by flash column 
chromatography gave (E)-5.38 (88%), (E)-5.39 (75%). No isomerisation was observed for 
these oximes in the pentafluorobenzoylation step and subsequent column chromatography. 
° Ph~R 
R H,5.32 
R C02Me 5.35 
,.r0H 
N 
---..... Ph~R 
(E:Z}-5.36, R = H 
(E}-5.37, R = C02Me 
(E}-5.38, R H 
(E}-5.39, R C~Me 
Reagents and conditions: i) Pyridine, NHzOH. HCl, EtOH, rt,l-3 h. ii) C6F5COCl, TEA, DCM, rt,OOC, l-2h. 
Scheme 5.12: Synthesis of oximes and O-pentafluorobenzoyl oximes 5.36-5.39 . 
....... 11-.01>11 via A-H reaction-TransmetaUation, 
Carbonylation-Termination Processes24 
;VCllZ~ltI(]~n of the Terminal Alkyne Derivative 
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The initial study was can'ied out using the telminal alkyne derivative (E)-5.38, which was 
subjected to the A-H reaction conditions first, using 10 mol% Pd(PPh3)4, 5 equivalents of 
TEA in DMF at 80° C as shown in scheme 5.l3. 
(E)-5.38 
lO mol% Pd(PPh3)4, TEA 
DMF, 80-900 C, 5h :6 Ph . 
5.40,35% 
Scheme 5.13: Attempted synthesis ofpyrrole 5.40 via A-H reaction of 5.38. 
The A-H reaction of (E)-5.38 gave a complex mixture in 1h, which contained 35% of the 
pyrrole 5.40. No further attempts were made to optimize the reaction conditions of A-H 
reaction of (E)-5.38. 
Next the O-pentafluobenzoyl OXIme of the tenninal alkyne derivative (E)-5.38 was 
subjected to the A-H reaction conditions followed by transmetallation with different 
organometallics as summarized in Table 5.1. Attempts directed towards the tennination of 
the living alkenylpalladium(II) complex (5.29, Scheme 5.10) by cross-coupling with 
PhSnBu3 resulted in a complex mixture (entry 1), which contained only 7% of the pyrrole 
fonned from the isomerisation of 5.29. The reaction was not even successful by changing 
the reaction medium from DMF to THF (entry 2). The A-H reaction followed by 
transmetallation with PhZnBr was also attempted at rt in THF as depicted in Table 5.1. 
When PhZnBr was added in 20 minutes, no product of transmetallation was observed, but 
the dihydropyrrole 5.41 was obtained in 28% as well as 11% of the stmiing material and 
16% of the corresponding ketone were fonned (entry 3). The slow addition (in 2h) of 
PhZnBr did not allow the transmetallation to happen either (entry 4), and again the 
premature products was obtained as a mixture of the pyrrole 5.40 (9%) and the 
dihydropyrrole 5.41 (5%). 
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Table 5.1: The A-H reaction followed by transmetallation with different organometallic reagents. 
-r'0COC6Fs P p~ ° N 10 mol% Pd(PPhJ)4 Ph~ " + +Ph~ RM, TEAa,b Ph 
(E)-5.38 5.40 5.41 5.32 
Entry RM solvent temp/oC time/ h 
Yield % 
5.32 5.38 5.40 5.41 
PhSnBuJ DMF 70 11 7 
2 PhSnBuJ THF 70 11 12 
3 PhZnBra THF rt 3 16 11 28 
4 PhZnBrb THF rt 3 5 9 5 
a) PhZnBr added over 20 min. The reaction was canied out in the absence of TEA. 
b) PhZnBr added over 2 h. The reaction was carried out in the absence of TEA. 
The failure of transmetallation reaction and the isolation of the intermediate pyrrole and 
dihydropyrrole indicate that the intermediate alkenylpalladium(II) complex (5.29, Scheme 
5.10) does not react further under the reactions tried during this work. 
Attempts were next diverted to check the possibility of an intermolecular olefin insertion 
via Heck reaction into the alkenylpalladium(II) intermediate (5.29, Scheme 5.10). The A-H 
reaction of (E)-5.38 followed by double bond insertion of methyl acrylate, was analysed 
using different Pd catalysts including Pd(PPhJ)4, Pd(dba)2.P(o-tolyl)J and Pd(dbah.P(t-
Butyl)J. However, the alkenylpalladium (II) intermediate (5.29, Scheme 5.10) did not seem 
to react further, as very low yields of the pyrrole 5.40 were obtained as illustrated in 
Scheme 5.14. 
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.,.OCOC6FS 10 mol% Pd cat., TEA 
,j N Ph)~ DMF, methyl acrylate Ph 
(E)-5.38 5.40 
Pd Cat. Temp DC Time/h % yield 
Pd(PPh3)4 80 5 trace 
Pd(dbah· P(t-BU)3 90 6 7 
Pd(dbah. P(o-tolY)3 90 4 7 
Scheme 5.14: Attempted synthesis of functionalized pynoles via 
A-H reaction followed by sequential olefin insertion. 
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The results were not so promising using the transmetallation and intermolecular Heck 
reaction for termination of the living Pd complex. In each case, the premature product, i.e. 
pyrrole was formed in very low yield and subsequent transmetallation and Heck reactions 
did not occur. 
Finally, the insertion of CO into the alkenylpalladium(II) intermediate (5.29, Scheme 5.l0), 
and termination by the addition of an alcohol, were undertaken as shown in Scheme 5.15. 
This domino process is thought to occur by the transformation of the alkenylpalladium(II) 
intermediate (5.29a) into an acylpalladium(II) complex (5.29b) by the reversible insertion 
of CO, followed by termination with ethanol. The domino A-H-carbonylation-termination 
by alcohol sequence of (E)-5.38 resulted in the formation of the esterifed product 5.42 in 
26% yield, as well as the pYlTole 5.40 (6%) obtained by the dehydropalladation of 5.29a 
(Scheme 5.15). The formation of the by product pyrrole 5.40 suggests that termination by 
intetmediate 5.29a by dehydropalladation competes with the acyl palladium intetmediate 
5.29b, and sequential termination by C2HsOH. The formation of the pYlTole 5.40 could 
probably be suppressed by calTying out the reaction under a high pressure of CO, however, 
no such attempts were made dming the course of this study. 
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10 mol% Pd(PPh3)4' CO(1 atm) 
DMF, TEA, C2HsOH 
70 °c, 3 h 
p,J 
5.40,6% 
1 
R-Pd 
PI,r) 
5.29a 
+ 
co 
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,sC02C2HS HN~ 
:::-.... 
Ph 
5.42,26% 
5.29b 
Scheme 5.15: A-H reaction of 5.38 followed by sequential insertion of CO and C2HsOH. 
The reason for the success of the carbonylation reaction could be the fast inseliion of CO 
into the alkylideneamino Pd complex, compared to transmetallation and Heck reaction. 
5.4.2 Cyclization of the Internal Alkyne Derivative24 
Next, the A-H reaction of the internal alkyne based O-pentafluorobenzoyl oxime (E}5.39 
was carned out using 10 mol% Pd(PPh3)4, 5 eq. of TEA in DMF at 800 C in 2h to give a 
37% of the cyc1ised pyrrole 5.43 as depicted in Scheme 5.16. 
DMF, 80-900 C, 2-5h 
,sC02Me HN~ 
:::-.... 
Ph 
(E)-5.39 5.43,37% 
Scheme 5.16: Synthesis of functionalized PYlToles via A-H reaction. 
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The domino A-H-carbonylation-telmination (via alcohol) of (E)-5.39 resulted in 52% of a 
mixture of the esteri±led product 5.45 formed from the acylpalladium complex and 
the premature product 5.43 fOlmed fi.-om dehydropalladation of the alkenylpalladium(II) 
complex (Scheme 5.17). 
N J OR 
Ph~ 
C02CH3 
(EJ-5.39 
R OCOC6Fs 
to mol% Pd(PPh3)4, co (1 atm) 
TEA, C2HsOH, DMF, 
90°C, 2 h 
5.43 5.45 
52%(5:2) 
1 1 
'----l p:lCO,CH,] co ~ [ :ZCO,CH,] 
5.44a 5.44b 
Scheme 5.17: Synthesis offunctionalized pyrroles via A-H reaction followed by carbonylation 
and tandem insertion of alcohol. 
The formation of a mixture of the esterified product 5.45 and the pyrrole 5.43 reflect again 
(as for the terminal allcyne derivative 5.38) the competition between the complex and 
the acylpalladium complex 5.44h. 
In summary, various efforts were made for termination of the living alkenylpalladium 
complexes via different approaches including transmetallation, intermolecular Heck 
reaction, and carbonylation followed by telmination with alcohols. The results fi'om 
transmetallation and intelmolecular Heck reaction were disappointing, however, 
comparatively better results were obtained by using carbonylation-termination via alcohols 
Chapter 5 112 
sequence, which indicate that an anay of 2,5-disubstituted pyrroles could be synthesized 
using this methodology. 
5.5 Conclusion and Work 
The A-H reaction of propargyl derivatives of O-pentafluorobenzoyl oximes has been 
investigated. The A-H reaction ofboth telminal and internal alkyne derivatives results in the 
synthesis of the cOlTesponding pYlTole in moderate yield. Of the various domino processes 
coupled with A-H reaction, for the termination of the living Pd complexes, the 
carbonylation-termination by alcohols has been comparatively successful, and provide a 
convenient and new approach for the synthesis of 2-aryl pyrrole 5-methyl esters. However, 
this methodology needs fUl1her development. 
Future work could include conducting the carbonylation reaction under high pressure of 
CO to minimize the premature termination of the alkenyl palladium complexes, and to 
improve the efficiency of the acylpalladium complexes to give the respective pyrrolo-5-
substituted methyl esters. Optimization of the reaction condition could also be 
accomplished to give better yields of the simple cyclised products via A-H cyclization. 
Attempts could also be made for the investigation of the yne-ene type cyclization using 
H reaction. Acceleration of the pyrrole synthesis using microwave irradiation could also be 
attempted. 
Further work could also involve termination of the alkenyl palladium complexes using 
other domino processes including termination by 
hydrogenolysis and C or 0 enolates.z4 
0, other heteroatom nucleophiles, 
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CHAPTER SIX 
RING CLOSING METATHESIS AS A GENERAL 
METHOD FOR THE SYNTHESIS OF AZA-
HETEROCYCLES 
Chapter 6 116 
6.1 Introduction 
The olefin metathesis reaction has gathered a widespread interest as a powerful tool in 
synthetic organic chemistry (see Chapter 1). Ring closing metathesis, a type of olefin 
metathesis has been used extensively to form functionalized heterocyclic rings present in 
natural products and other biologically active compounds. 1,2 It has also found elegant 
applications in total syntheses. Here, a detailed discussion about the catalysts, mechanism 
and applications of ring closing metathesis methodology involved in the synthesis of 
heterocycles is presented. 
Olefin metathesis is a powerful carbon-carbon bond forming reaction that redistributes 
unsaturated functionalities between substrates, was first reported3 in 1955; its origin can be 
traced to the development of Zeigler polymerization reactions. The reaction involves 
bringing together two olefins to form a new double bond (Figure 6.1), in the presence of a 
transition metal catalyst. The generality of this reaction has been largely underpinned by the 
development of well-defined transition metal alkylidene complexes, as well as the 
convenient operation of the reaction at rt or near rt, in a variety of media (aqueous or 
organic). The main types of olefin metathesis are summarized in Figure 6.1. 
Ring closing metathesis, a subtype of olefin metathesis, has the ability to transform an 
acyclic diene into an olefinic ring. Although, RCM has been widely used in industry for the 
production of linear olefins and polymers,4 it has only relatively recently been used 
extensively by organic chemists in the synthesis of numerous carbocycles and heterocycles. 
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o 
Diene or Diyne / 
RCM / ~OM 
A / \ 
CM R'~ + R"~ ----~ 
RC ene-yneM 
r1':-... .R" R,r ~ 
Figure 6.1: General types of Olefin metathesis reactions 
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The use of ring-closing metathesis to form nitrogen heterocycles was first reported by 
Grubbs 5 and Fu in 1992, who explored the cyclization of N-substituted dienes to 
dihydropyrroles in the presence of molybdenum carbene catalyst 6.1 developed by 
Schrock6 and co-workers (Scheme 6.1). 
R 
I 
N j~ 6.1 DCM, rt 
R = COCF3, Boc, Bn. HC\' 
R 
I (:; 
Scheme 6.1: Synthesis of dihydropyrroles by RCM. 
The mechanism of ling closing metathesis is depicted in Figure 1.6 (chapter 1). What 
follows is a discussion about the catalysts development and functionality tolerance of these 
catalysts involved in ling closing metathesis. 
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6.2 Catalysts development and functional group tolerance 
The generalization of RCM is directly correlated to the breakthrough in the development of 
metal-carbene catalysts, especially by Schrock6and Grubbs.7 The studies by these two 
groups have led to the functional group tolerant ruthenium and molybdenum catalysts that 
can affect the cyclization of a diverse range of substrates under milder reaction conditions 
leading to the synthesis of a variety of heterocyclic and carbocyclic rings. These include 
molybdenum-based complex 6.1, developed by Schrock and co-workers,6 and the 
ruthenium-based complexes 6.2 and 6.3 developed by Grubbs and co-workers7 (Figure 6.2). 
The ruthenium-based catalyst 6.2 is less air and moisture-sensitive compared to the 
molybdenum-based catalyst 6.1, easy in handling, and thus most commonly used. Catalysts 
6.1-6.3 have the capability of catalyzing the formation of simple 5-7 membered mono and 
bicyclic rings. Although the catalyst 6.1 is more air and moisture sensitive compared to 6.2 
and 6.3, it is more active than 6.2-3, that it can catalyze the formation of tri- and tetra-
substituted alkenes, which is otherwise very slow or impossible with catalysts 6.2 or 6.3. 8 
However, catalyst 6.3 with extended carbene tether is known to catalyze the RCM of more 
hindered substrates by exhibiting an increased coordination during the formation of 
intermediate metallocyclobutanes.9,10 After the introduction of Schrock's catalyst 6.1, and 
Grubbs' first generation catalysts 6.2 and 6.3, numerous other catalysts have been 
developed with improved reactivity and selectivity. Some of the commonly used catalysts 
in RCM are summarized in Figure 6.2. 
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Figure 6.2: Catalysts used for olefin metathesis 
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Subsequent exchange of a PCY3 group of 6.2 with N-heterocyclic carbene led to the 
'second-generation' metathesis catalysts with improved reactivity, selectivity and 
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stability.II-13 The reactivity of catalysts 6.4, and its analogues is thousand times superior 
compared to first generation catalyst 6.2, and efficiently catalyze ring closing metathesis 
reactions of substrates that were previously inactive to 6.2. Hoveyda and co-workers have 
developed robust ruthenium-based carbenes containing internal oxygen chelates, 6.5 14 and 
6.6,15 which are stable to silica gel chromatography and can be recycled without any 
detectable loss of reactivity. Hoveyda catalyst 6.6 (Figure 6.2), offers better reactivity than 
6.4 towards electron-deficient olefins. Wakamatsu and co-workers further modified 
catalysts 6.6 by the replacement of isopropoxybenzylidenc ligand with biphenyl-based 
benzylidene16 (6.7, see Figure 6.2) or with BINOL17 resulting in an improved reactivity of 
6.7 than 6.6 and 6.4. The replacement of the isopropoxybenzylidene grnup of catalyst 6.6 
with nitrophenyl based benzylidene by Gerala et al., resulted in the formation of catalyst 
6.8; exhibiting the same stability, and better reactivity than 6.6. 18 This increase in reactivity 
could be attributed to the reduced electron density on the oxygen atom of 6.8, due to the 
introduction of an electron-withdrawing N02 group, thus enhancing its catalytic activity. In 
addition, the titanium-based carbenes (e.g, 6.9) have found only occasional use in ReM, 
and are widely used as olefination catalysts. 19 Grubbs and co-workers have also synthesized 
catalysts 6.10 and 6.11 that allow ring-closing metathesis in water and methano1.20 The 
enhanced solubility and reactivity of catalysts 6.10 and 6.11 could be attributed to the 
quaternary ammonium phosphine ligands. 
A significant advantage of these catalysts is their tolerance to a variety of functional groups. 
These catalysts have been used to cyclise compounds containing free alcohols, carbonyl 
groups and other potentially reactive functionalities. Such reactive functionalities are often 
not compatible with conventional methods of ring closure and usually require extensive 
protection. 
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6.3 Applications of to the Synthesis of 
Three major categOlies that can be identified based on the types of olefins directly involved 
in the ReM process are diene, enyne, and diyne metathesis. Among these subclasses, diene 
ReM has drawn significantly more attention from synthetic chemists due to its 
effectiveness in the formation of a range of cyclic structures, central to the synthesis of 
carbocycles, heterocycles, alkaloids and peptidomimetics, and has been well studied and 
reviewed. 1,2,10 What follows is a stepwise discussion of the applications of ReM to the 
synthesis of different N-containing heterocycles from diene, eneyne (ene-yne-ene), and 
diyne precursors. 
6.3.1 ReM from Diene Precursors 
After early reports by Grubbs and Fu5 using ReM for the synthesis of dihydropyrroles, 
Martin et at.. demonstrated its application in the presence of Schrock's catalyst 6.1 to the 
synthesis of fused aza-heterocycles (6.13) found in a number of alkaloids (Scheme 6.2).21 
6.1 
6.13 
Scheme 6.2: Synthesis of dihydropyrroles 6.13 by ReM. 
A number of other reports after Martin's work was published that lead to the synthesis of 
fused bicyclic lactams?2 Recently, Hanessian et al. have reported the synthesis of a range 
of bicyclic fused indolizidinones (6.14), which have found applications as constrained 
mimetics of peptide fJ-turns, by ReM in the presence of Grubbs' catalyst 6.2 in 72-86% 
yields (Scheme 6.3).23 
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m=O-l,n 1-3 6.14 72-86% 
Scheme 6.3: Synthesis of fused bicyclic lactams by RCM. 
In addition to fused bicyclic lactams, there are numerous applications of ReM for the 
synthesis of medium24 to large size lactam rings. Huwe et al. 25 reported the synthesis of 6 
membered lactam rings (6.15a-c) using extended chain catalyst 6.3. The key observation of 
Huwe's work was that increased steric crowding around the oxygen substituent led to an 
increase in yield of the cyclised lactam. (See Scheme 6.4) 
10mol% 6.3 
6.1Sa, Rl H, 40 DC, 32h, 52% 
6.1Sb, R! =Bn,li,31h, 75% 
6.1Sc, Rl = Tr, rt, 60h, 95% 
o~ 
H OR! 
6.1Sa-c 
Scheme 6.4: Synthesis of lac tams 6.1Sa-c by RCM. 
Rodriguez and co-workers26 rep011ed the successful ring closure of di- and tri-substituted 
olefins 6.16a-b, to give six-membered o-lactams 6.17a-b, in the presence of an additive 
Ti(OiPr)4 and the catalyst 6.2 (Scheme 6.5), which was previously rep011ed to be 
unsuccessful in the ReM of tri-substituted dienes (in the synthesis oflactones).27 However, 
the ring closure of the tetra-substituted diene derivative 6.16c (R\ R2 Me) could not be 
achieved with either catalyst 6.2 or 6.4 (which has been reported to catalyze the ReM of 
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even tetra-substituted 01efins),28 in the presence or absence of Ti(OiPr)4, confirming that an 
increased degree of substitution on C=C,26 and in its close proximitl9 leads to blockage of 
the catalytic cycle. 
o 1 
Bn, jI W N~ 
Ph~ R 4 mol%6.2 Ti(iPrOh, DCM, reflux 
6.16aR1 H, H 
6.16bR 1 H,R2 Me 
6.16c Me, R2 Me 
6.17a-b 90-92% 
Scheme 6.5: Synthesis of conjugated six-membered lactams 6.17a-b by RCM. 
Ring-closing metathesis has also been successfully used for the synthesis of macrocyclic 
lactams. Lemarchand et al. 3o have recently reported the synthesis of 16-20 membered para-
quinone macrolactams 6.18, related to antitumor agent geldanamyein, using RCM in the 
presence of 10 mol% of an ethylidene ligand catalyst 6.19 [(prepared by the replacement of 
benzylidene ligand of 6.2 by an ethylidene ligand), (Scheme 6.6)]. They found that the IS-
20 membered macrolactams were readily accessible using RCM, however, 16-17 
membered rings could not be synthesized. 
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OMe 
"':: 0 I»U~ 
OMe 
n ~ 
n = 3 66% 6.18a 
n = 4, 77% 6.18b 
n = 5, 87% 6.18c 
CII fCY3 OMe 
Ru~ Cl' I 
PCY3 
10 mol% 6.19 
DCM 
6.18a-c 
Scheme 6.6: Synthesis of macrolactams 6.18a-c by RCM. 
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Ring-closing metathesis has found applications in the synthesis of rigidified peptides. 
Initial results by Miller and co-workers31 involved the synthesis of 5-7-membered a-amino 
E-Iactams 6.21a-c from olefinic linkers 6.20a-c to constrain the peptide backbone in the 
presence of the extended chain catalyst 6.3 (see Scheme 6.7). Ring closure of diene linker 
6.20a could not be achieved, whereas, six and seven-membered rings were formed in 91 
and 52% yields respectively (Scheme 6.7). 
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o Boc o Boc 
MOO~\ ~3~ CM, MOOAO 
6.20a 6.21a 
Meo~~ 5 mol% 6.3 DCM, rt o Boc MOO'1) 
6.20b 6.21b,91% 
o 0 
MeO N 5 mol% 6.3 )l J\NHBOC 
( I DCM,rt • 
6.20c 6.21c,52% 
Scheme 6.7: Synthesis of constrained peptidomimetics using RCM. 
The same report3l also included the synthesis of {3-tum mimetic 6.22 using catalyst 6.2 in 
80% yield (Scheme 6.8). 
° CY--N e
OCbZ(Bl') 
~I 
N H ° 4 mol% 6.2 BOCHN~O ~\-<?o 
,>' I DCM, reflux 
II (' HNi I C02Me 
6.22 
Scheme 6.8: Synthesis of macro lac tam 6.22 using RCM. 
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The scope of ReM has also been extended to the synthesis of a-amino acid derived 
Freidinger lactams (See Scheme 6.9)?2 ReM of vinyl glycine-based linker 6.23a was 
achieved in refluxing DeE to give 6.24a in 53% yield after 48h in the presence of catalyst 
6.2. N-Allyl glycine derived diene linkers 6.23b-c cyclized smoothly to give the 
conesponding seven-membered lactams 6.24b-c in 68 and 42% yields respectively, in the 
presence of 10 mol% catalyst 6.2. The methyl-substituted diene linker 6.23d cyclized in the 
presence of the catalyst 6.4 to give the 89% of azepinone. 
o R 
Bo'm'~l~:~2Rl DeM, rt ~ 6.24a-h 
6.23a-h 
6.24 a b c d e f g h 
R H H Me H H Me H H 
Rl Et Et Me Et Et Me Et Et 
R2 H H H Me H H H H 
m 0 0 
n 2 2 3 4 
yield 53 68 42 89 70 60 86 8 
Reagents and conditions: 10 mol% 6.2 or 5 mol% 6.4, DeM, Ii. 
Scheme 6.9: Synthesis of 6-1 0 membered Freidinger lactams 6.24a-h by ReM. 
The synthesis of 8-membered rings by ReM (at a higher concentration) is a well-known 
challenge, and usually oligomelization of the starting diene occurs after sometime?3 The 
cyclization of the diene linker 6.23e was canied out at a lower concentration of 2 mM to 
avoid any oligomerization. Thus, the azocanone 6.24e was isolated in 70%, without the 
fonnation of any byproducts. The alanine-based diene 6.23f cyclised to give the azocanone 
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6.24f in moderate yield (60%). The reaction worked well for the synthesis of only cis 
isomer of 9-membered azacycle 6.24g (86%). The 10-membered azacycle 6.24h was 
synthesized using catalyst 6.4 in 8% isolated yield at a further lower concentration of 0.5 
mM. 
Creighton et al. have studied the synthesis of constrained eight-membered cyclic 
peptidomimetics using Grubbs' catalysts 6.2 and 6.4 (Scheme 6.10).33 They found that the 
diene linker 6.25 cyclised smoothly in the presence of catalyst 6.2 at a lower concentration 
of 3 mM to give 6.26 in excellent yield (80%). However, RCM at a higher concentration 
(12, 50, and 100mM) led to the formation of byproducts 6.27 and 6.28 from the 
oligomerization of 6.25 and 6.26. 
o DMBO BOCHNJ-N~( 
:: :: OMe lOIll 
- -
- -
) (6.25 
o DMBO BOCHNJ-N~( 
:: :: OMe 
- -
- -
- -
- -
- -
M 0 = = 
e ir,N-('NHBOC 
ODMB 0 
6.27 
+ 
o DMBo BOCHNJ-N~ 
:: :: OMe 
- -
- -
"'=/ + 
6.26 
o DMBO BOCHNJ-N~ 
= = OMe 
- -
- -
- -) ( 
- -
- -
- -
M 0 = = 
e ir,N-('NHBOC 
ODMB 0 
6.28 
Reagents and conditions: i) 6.25 (3 mM), 6.2, DCM, reflux, 48-72h, 80%. 
ii) 6.25 (12, 50 and 100 mM), 6.2 0I 6.4, DCM, reflux, 48-72h. 
Scheme 6.l0: Synthesis of6.26, 6.27 and 6.28 from acyclic diene 6.25. 
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Fmiher applications of ReM include the synthesis of P and S tethered analogues 6,3034 and 
6.3135 of cyclic ureast (e.g, 6.29), a class of compounds known to be potent inhibitors of 
HIV (Figure 6.3). 
6.29 x P, 6.30 
X = S, 6.31 
Figure 6.3: Cyclic urea 6.29 and its analogue 6.30 & 6.31. 
The ring closing metathesis of dienes 6.32a-d gave heterocyclic compounds 6.33a-d, which 
were subjected to dihydroxylation in the presence of OS04 and NMO to give HIV protease 
inhibitors (cyclic urea analogues) 6.34a-d (Scheme 6.11). 
RCM Dihydroxylation 
6.32a-d 6.33a-d 
° / ° I q, //0 Bn Meo'(h Bn, ~S~ ,Bn 'S ~""< ~~ 
HO OR RO OH 
6.34a 6.34b 6.34c 
Scheme 6.11: RCM of dienes 6.32a-d to 6.33a-d. 
" A more detailed discussion about cyclic ureas is presented in chapter 7. 
R' A 0, /;,0 
Ro,e (f( 
Hd OR 
6.34d 
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One major drawback of the synthesis of macrocyclic alkenes formed by RCM of diene 
precursors is the lack of control over the stereochemistry of the new double bond, with 
mixtures of (E)- and (Z)-isomers being formed. This is exemplified, by several approaches 
to epothilone A: although different research groups succeeded in the synthesis of 16-
membered ring of this promising chemotherapeutic agent by RCM,36 (E,Z)-mixtures of 
isomers are formed affecting the yield of the target molecule, as only the (Z)-alkene can be 
convelied into the target. The fact that the required (Z)-isomer was formed as the minor 
product in many cases attests to the relevance of this stereochemical issue. This issue is 
solved by the RCM of diyne precursors, which will be discussed in section 6.2.3. What 
follows is a discussion about the ring closing ene-yne metathesis and ring closing ene-yne-
ene metathesis. 
6.3.2 from ene-yne or ene-yne-ene Precursors 
Despite its enormous potential, ring closing ene-yne and ene-yne-ene metathesis is 
relatively underdeveloped compared to the diene RCM metathesis process.3? The RCEYM 
is a powerful atom-economical38 method to generate ring structures (e.g. bridged, multiply 
fused, and dumbbell-shaped ring systems) from molecules with tethered alkene and alkynes 
via a tandem ring closure. The significant potential of RCEYM in cyclic systems is 
somewhat compromised because of the exolendo-mode selectivity problems. This 
e1:olendo-mode selectivity also dictates the ring-size, such that the endo-mode ring closure 
have one more C than that derived from an exo-mode ring-closure.39 It is known that the 
ring closing ene-yne metathesis usually follows the e1:o-mode path in the synthesis of 
small-medium sized rings,40 whereas the macrocycles follow the endo-mode pathway.39 
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Figure 6.4: Mode selectivity in RCEYM. 
Ring closing ene-yne metathesis of 6.35 in the presence of the active catalyst 6.4 under 
ethylene atmosphere gave the triene 6.36 as the major product (usually RCEYM reactions 
are carried out under ethylene atmosphere).41 However, the same reaction in the presence of 
less active catalyst 6.2 under an inert atmosphere resulted in the synthesis of the tropane 
6.37 as the sole product (Scheme 6.12). 
6.36 
10mol% 6.4 
ethylene,DCM, 
reflux 
L .~oc ~ ~ 
6.35 
10 mol% 6.2 
DCM, reflux 
Scheme 6.12: Synthesis of Tropane 6.37 by RCEYM. 
Boc 
I 
~ 
6.37 
RCEYEM has also been used as a key step in natural product synthesis. For example, the 
RCEYEM of substrate 6.37 in the presence of the highly active catalyst 6.8 (see Figure 6.2), 
gives the key intermediate 6.38 in the total synthesis of securinine 6.39 (Scheme 6.13).42 
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Steps 
Seeurinine, 6.39 
Scheme 6.13: RCEYEM of 6.37 to the key intennediate 6.38 in the total synthesis of securinine 6.39. 
In addition, ring closing ene-yne and ring closing ene-yne-ene metathesis have also 
successfully been applied to the synthesis of chiral ynamides and allenamides.43 
6.3.3 ReM from diyne Precursors 
Unlike alkene metathesis, little attention has been paid to alkyne metathesis. Fiirstner and 
co-workers45 reported the first efficient synthesis of functionalized macrocycles [lactams 
(e.g. 6.41), lactones and silyl ethers)] by the ReM of diyne substrates in the presence of 
tungsten catalyst 6.40 developed by Schrock,46 in chlorobenzene or trichlorobenzene under 
high dilution conditions (Scheme 6.14). Fiirstner et al. have described the suitability of only 
terminally substituted alkynes for the ring closing reaction (as the terminal alkynes are 
found to be incompatible46 with catalyst 6.40). 
6.40 
[W(=CM33)(OCMe3)3J 
• 
HN ( 
HN 
o 
6.4],90% 
+ II 
I \ 
Scheme 6.14: Synthesis of macrocyle 6.41 by RCM of diyne substrates 
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The stereochemical issue (EIZ isomerisation) in the RCM of the diene precursors for the 
synthesis of macro cyclic lactams, was solved by the advent of alkyne metathesis/Lindlar's 
reduction sequence.47 This allowed the synthesis of a number of biologically active 
alkaloids, which were other wise difficult to synthesize by RCM of dienes (as this will give 
a mixture of E and Z isomers). For example, diyne metathesis-Lindlar's reduction sequence 
was successfully used by Flirstner group in the synthesis of aza-macrolides (6.44a-b) 
(Scheme 6.15).47 The diyne precursors to the aza-macrolides 6.42a-b were treated with 
Schrock's precatalyst 6.4045 to give the allcyne macro cycles 6.43a-b in good yields, which 
then undelwent reduction in the presence of Lindlar's catalyst to give the desired 6.44a-b. 
n = I, 6.42a 
n=2, 6.42b 
5 mol% 6.40 
o 
00 i) H2, Lindlar 
NR • 
n = I, 71%, 6.43a 
n = 2, 69%, 6.43b 
ii) TBAF.3H20 
o 
6.44a 
o 
6.44b 
Scheme 6.15: Synthesis of aza-macrolides 6.44a-b by RCAMILindlar's reduction. 
n 
o NR 
ifNH 
Flirstner et at. also used ring closing alkyne metathesis/Lindlar's protocol for the synthesis 
of biologically active marine alkaloid latrunculin B (6.47) (Scheme 6.16).48 The 
Molybdenum catalyst 6.45 was used to affect the cyclization of the diyne precursor to give 
the alkyne macrocycle (6.46), which gave the desired alkaloid 6.47. 
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HN )r-S 
° 6.47 
Reagents and conditions: i) 6.45 [Mo{N(t-Bu) (3,5-MezC6H3)hJ (5 mol%), toluene, DCM, SOoC, 
70% ii) Hz, Lindlar's catalyst, DCM, quant. iii) CAN, MeCN/HzO, 78%. 
CAN=ceric ammonium nitrate. 
Scheme 6.16: Synthesis of marine alkaloid 6.47 via diyne RCM, Lindler's reduction sequence. 
6.4 Miscellaneous Applications of ReM 
The scope of ReM metathesis has been extended to the synthesis of natural products, 
macro cyclic peptidomimetics and amino sugars in solution phase, as well as in solid phase 
and in nanotechnology. Here, a few recent examples in the development of ReM are 
descIibed. 
Blackwell and Grubbs49 have used ReM in the synthesis of covalently cross-linked short 
peptide sequences 6.48a-b to initiate helix formation (Scheme 6.17). 
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BocHN 
20 mol% 6.2 
.. CO n I 0 
6.48a = Boc-Val-Ser-Leu-Aib-Val-Ser-Leu-OMe, n 1,85% 
6048b = Boc-Val-HSe-Leu-Aib-Val-HSer-Leu-OMe, n 2,90% 
Scheme 6.17: Synthesis of helical peptide 6.48a-b by ReM. 
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ReM has also been used in the synthesis of macrocyclic aminoglycosides, in the 
synthesis of l,4-butanediol linked 15N-labelled aminoglycosides (6.50) from diene linker 
6.49, which can be used as probes for binding to RNA and other biomacromolecules 
(Scheme 6.18)50. 
l"NHXO~ 
:2:f:d ~o 
C( XH"i 
o MJO Me~15NHX ~ 
o oP!!' 
'o~ l"NHX 
Me O~ 0\4 
~O 15NHX 
Me~ __ 20~ __ __ 
~O DCM, rt, 7 days 
6.49 
x = Trifluoroacetyl 
6.5045% 
Scheme 6,18: S)11thesis of aminoglycoside 6.50 by RCM. 
The tetrasaccharide 6.50 is thought to have formed by the dimerization of the starting diene 
to give an intermediate linear tetra-saccharide, which then cyclizes to the cyclo-
aminoglycoside 6.50; and that the axial amido substituent prevents the direct intramolecular 
olefin metathesis reaction. In addition to the cyclotetrasaccharide 6.50, 5% of hexa-
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saccharide was also formed, which is thought to be formed by trimerization of the stmiing 
diene 6.49. 
Olefin metathesis has emerged as a versatile technology for combinatorial and parallel 
synthesis in solution as well as on solid-phase.51 Recently, Timmer et al. 52 reported an 
interesting strategy for the construction and use of fused mannitol-derived oxacycles as 
combinatorial library scaffolds based on a RCMlresin cleavage approach (Scheme 6.19). 
o 
R~NH 
d' )=0 
HN 
\ 
R] 6.51 
o 
Scheme 6.l9: 
NH 
6.4, DCM 
Reflux, 16h 
o )l Ij 
R2 L:(D 
- = 0 ~ H 
o )=0 
HN 
\ 
Rl 6.52 
RCM has found interesting applications in the field of dendrimer chemistry. Zimmermann 
et al. 53 have used Grubbs' catalyst 6.2 in the controlled synthesis of nanotubes (Scheme 
6.20) 
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More recently, RCM in the presence of microwave radiation has made progress, in 
accelerating the rate of RCM reactions. 54 For example the ring-closure of 6.51 to 6.52 in 
the absence of microwave radiation resulted in only 45% conversion of the starting diene to 
the cyclic product, whereas in the presence of microwave, 91 % conversion of the substrate 
to the product occurred (Scheme 6.21).55 
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Ts 
I 
~N~ 
6.51 
Thennal conversion % 
45% 
2-3 mol% 6.4 
DCM,2Min. 
Ts 
I 
6 
6.52 
Vs Microwave conversion % 
91% 
Scheme 6.21: Compalison of the % conversion of 6.51 to 6.52 in the presence/or 
absence of microwave radiation. 
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All these applications demonstrate that there is substantial potential for heterocyclic 
synthesis by ReM. Incremental improvements in catalyst effectiveness have rendered 
cyclic compounds that were once considered too complex for synthesis, readily accessible 
by ReM. Although alternate syntheses could be carried out, but the high versatility and 
functional group tolerance of the metathesis catalysts have made a concise and convenient 
rout possible to the compounds accessible by other complex and multistep route. Due to 
this versatility and convenience of this method, we focused our research work on the 
synthesis of seven and six-membered amino acid derived lactams using ReM methodology 
(Scheme 6.22), which will be discussed in detail in chapter 7. 
0 0 BOolINt N-'" Ph P~N)R' 
Rl (-R2 R3? R4 /; ~ 
~ il 
0 0 BOolIND-'" 1;(' N Ph Ph~N ~ 
Rl - R5 R4 
Scheme 6.22: Application ofRCM to the synthesis of 7 & 6-membered o-laetams 
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CHAPTER SEVEN 
SYNTHESIS OF LACTAM ANALOGUES OF 
UREAS BY RING CLOSING METATHESIS AND 
THEIR DERIV ATIZATION 
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7.1 Introduction 
There is significant interest in the synthesis of heterocyclic compounds for use as HIV 
protease inhibitors, for example cyclic ureas and analogues based on lactams. We present 
here a ring closing metathesis approach to the synthesis of such lactams and a subsequent 
Sharpless asymmetric dihydroxylation protocol for the synthesis of cis-diol analogues, 
which could prove potent HIV protease inhibitors. 
The human immunodeficiency vuus (HIV) has infected almost 38 million people 
worldwide,l and is the cause of the deadly disease AIDS.2 It is classified as a retrovirus3 
and its pathogenicity is due to the virus attacldng components of immune system such as T 
ceHs and macrophages.4 This affects the immune system of those infected resulting in an 
increased susceptibility, to secondary infections such as pneumocystis carinii pneumonia 
and taxoplamosis, which are often the cause of AIDS related deaths. 
During replication, HIV encodes an essential aspartic protease,s that cleaves the gag and 
gag-pol viral polyproteins into four replicative enzymes and four structural proteins?,3 This 
protease is essential for the assembly and maturation of infectious virions. Inactivation of 
HIV protease by a single mutation of the Asp25 residue in the active site results in 
noninfectious virions,6 and this led to targeting of HIV protease inhibition as an important 
strategy for the therapeutic treatment of AIDS.7a-b The HN protease is a member of a class 
of aspal1ic proteases. Other aspartic proteases that catalyze the hydrolysis of amide bond 
via aspartate residues in the active site, include renin and pepsin. An enOlmous effOl1 has 
gone into developing renin inhibitors as antihypertensive drugs, based on the mechanism of 
action of aspal1yl proteases. Many of the principles established in these efforts were 
subsequently applied to the design of HI V protease inhibitors. 
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The rational design of the HIV protease inhibitors has been aided significantly by the 
availability of the three dimensional X-ray crystal structures of HIV protease in its native 
form,8 and numerous inhibitor complexes.9 The inhibitor-free structure of the HIV-l 
protease (Figure 7.1) contains two identical amino acid chains, each with 99 residues. The 
two chains are interdigitated to form a p-sheet at the dimer interface. The molecule has an 
exact C2 symmetry and the catalytic site of the protease is located at the bottom of a large 
cavity in the middle of the protease as defined by both subunits. Two flexible flaps are 
formed by residues 45 to 56 in each monomer, and these open to allow the incoming 
polypeptide, over the top of the cavity. 
Figure 7.1: Structure of the HIV protease illustrating the two flexible flaps 
and the catalytic site of the enzyme 
The enzyme's C2 axis lies between, and perpendicular to, the catalytic aspartyl residues 
Asp25 and Asp25 '. One aspartyl residue acts as a base initiating nucleophilic attack on the 
scissile amide bond of the substrate using an active site water molecule. The other aspartate 
is thought to act as an acid stabilizing the carbonyl oxygen in tetrahedral intermediate 
(Scheme 7.1). mv protease cleaves its substrate at specific sites, of which at least eight 
have been identified in the polyproteins, with a variety of amino acids adjacent to the 
scissile bond. 7&,10 
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Studies II have shown that a potent HIV protease inhibitor requires a hydrophobic P liP 1 ' 
substituent (such as benzyl) to occupy the complementary HIV protease specificity pockets 
(SlIS! ')/ and a lipophilic heterocycle at P2/P2' position to occupy the secondary 
specificity pocket (S2/S2'), as well as groups capable of forming hydrogen bonds in the 
active site of the HIV protease. The resistance profile against mutant HIV strains is also 
improved by increasing the number of hydrogen bonds to Asp29, Asp30 and Gly48 in the 
HIV active site. I I 
t Using Schechter-Berger nomenclature I2 (see Figure 7.2 on the next page), where the 
residues on the amino-terminal side ofthe cleaved bond are denoted as PI-Pn, and those on 
the carboxy-terminus are denoted PI' -Pn' (with the corresponding sub sites on the enzyme 
denoted as Sn-Sn'). 
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Figure 7.2: Schechter-Berger nomenclature for labelling positions around the substrate cleavage site 
and specificity pockets of the enzyme. 
Based on the C2 symmetry, a number of HN protease inhibitors have been designed and 
synthesized. The most successful and impressive example13 uses a diol to act as a transition 
state mimic. The initial key linear inhibitors synthesized were 7.1-7.3. 13 7.1 and 7.2 were 
found to be active against HN with IC50 = 500 nM and IC50 = 220 nM respectively. Thus, 
numerous analogues of 7.2 with different substituent patterns were synthesized and 
screened, to identify 7.3 as a particularly potent compound with an IC50 = 0.24 nM (Figure 
7.3). UnfOliunately, these types of inhibitors are not particularly soluble in aqueous media, 
and thus have poor bioavailability. 
7.1 ICso = 500 nM 7.2 ICso = 220 nM 
7.3 ICso = 0.24 nM 
Figure 7.3: Dihydroxyethylene based transition state mimetics as HN protease inhibitors 
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Subsequent work revealed another linear potent HIV protease inhibitor 14,15 and its 
ray crystal structure bound to HIV protease was investigated by Wlodawer8 to reveal that 
the hydrophobic side chains bind to the C2 symmetric HIV protease in extended 
conformation with extensive hydrogen bonding interactions with the enzyme backbone 
amides (Figure 7.4). A key feature of all these potent HIV protease inhibitors is the 
hydrogen bonding from two central earbonyls to a water molecule which bridges the Ile50 
and Ile150 residues in the flaps of the enzyme. 
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Figure 7.4: Observed hydrogen bonding in crystal structure of7.4. 
The main problem with the aforementioned inhibitors is their high molecular weight, lack 
of selectivity, poor antiviral activity and poor oral availability. Consequently, a new search 
for low molecular weight, conformationally constrained inhibitors was initiated. 
The search for inhibitors with greater potency in vivo, and improved resistance profiles, led 
to the rational design of cyclic urea HIV protease inhibitors. 16 Cyclic urea inhibitors were 
designed to mimic the hydrogen bonding in the X-ray crystal structure of HIV protease 
inhibitors. The binding mode of the cyclic ureas to the HIV protease inhibitors involves the 
replacement of the active site water molecule with the urea oxygen, as well as interaction of 
the diol oxygens with the aspmiyl residues. 17 Schechter-Berger12 nomenclature (see Figure 
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7.2 earlier) describes the interactions of IIlV -protease with its cyclic urea inhibitors (Figure 
7.5). 
(a) (b) 
Figure 7.5: Schester-Berger nomenclature used to describe the interactions of 
HIV protease and its cyclic ureas inhibitors. 
The rigid cyclic scaffold of urea based inhibitor allows optimal binding interactions of the 
Pl/Pl' and P2/P2' residues with their corresponding Sl/Sl', S2/S2' pockets in the active 
sites (Figure 7.5). Table 7.1 summarizes structure-activity relationship studies of some of 
the lead symmetric cyclic ureas developed by Lam et al .. 17 
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Table 7.1: P2/P2' SARs of synunetIic cyclic ureas 7.4. 
° P4 Jl ,P2' 
N N 
~ )""Bn 
Bn M, 
HO ()H 
Cyclic Ureas 7.4 
P2/P2' K j IC90 
Allyl 5.2 4.7 
Cyclopropylmethyl 2.1 1.8 
p-hydroxymethylbenzyl (DMP323) 0.34 0.057 
m-aminobenzy1.2CH3S03H (DMP450) 0.28 0.13 
m-aldoximebenzyl 0.01 0.005 
m-acetoximebenzyl 0.01 0.002 
A number of HI V protease inhibitors have been approved by FDA for use in AIDS therapy, 
including cyclic urea based inhibitors, 7.5 (DMP 323) and 7.6 (mozanavir, DMP 450) as 
well as linear inhibitors like 7.7 (Saquinavir)18 and 7.8 (Amprenavir)19 (Figure7.6). 
A major problem with these inhibitors is the resistance by different variants of the HIV to 
these inhibitors.4,2o,21 One possible way of overcoming this problem is to use combination 
therapy, in which a number of drugs are used concurrently to treat a patient. Unfortunately, 
mutant strains resistant to (Saquinavir) and 7.8 (Amprenavir) have appeared, whereas 
7.5 (DMP 323) was rejected for further clinical trials based on poor solubility, and highly 
variable oral availability. Fortunately, mozenavir 7.6 (DMP 450) shows substantial oral 
bioavailability observed in all species examined, including man.22 Compound 7.6 has been 
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the subject of phase IIII dose escalating clinical studies and appears to have good antiviral 
activity and tolerability at all doses tested. However, the plasma level at trough with 
multiple dosing procedure fall short of the concentration required for all HIV mutants. 
7.5 DMP 323 Ki 0.34 nM 7.6 DMP 450 Ki = 0.28 nM 
COn~ 0 ~Ph H 10 ,-: ~J N - N N : H o - OH 
lr-NH2 0 
o 
7.7 Saquinavir Ki = 0.12 nM 7.8 Amprenavir Ki =0.60 nM 
Figure 7.6: FDA approved HIV protease drugs. 
FUliher cyclic ureas analogues have been developed by modification of functional groups at 
the PIIPI' and P2/P2' positions. However, due to the low solubility of the symmetric cyclic 
ureas, and consequently the low oral bioavailability, research has recently been diverted to 
the synthesis of non-symmetrical cyclic urea analogues with better bioavailability.23 
De Lucca et al. 23 synthesized the first non-symmetric cyclic urea protease inhibitors 
analogues (Figure 7.7), e.g. 7.9-10. However, the resistance profile of these inhibitors 
against different HIV mutants was again not sufficient for a sustained antiviral effect in 
man. 
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o 
o:~ NJlN I ~ HN-2 I ~ J )""'\ // ( )--<,~ Ph 
Ph HO (m 
3-NH2 = 7.9 Ki = 0.03 ICso = 11 bioavailability = 93% (F) 
4-NH2 = 7.10 Ki = 0.03 ICso = 11 bioavailability = 100% (F) 
Figure 7.7: Non-symmehic cyclic ureas 
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Subsequently, Rodgers et aZ,z4 reported the synthesis of DMP analogues DMP 850 (7.11) 
exhibiting Ki of 0.031 and DMP 851 (7.12) exhibiting Ki of 0.021 nM respectively, and 
these show modest potency in a whole cell antiviral assay with an IC90 of 62 and 56 nM, 
respectively (Figure 7.8). 
o 
R, JlN ~ N I 
r\-{/""\ // ~, Ph 
Ph HO (m NH2 
R = Benzyl DMP 850 7.11 Ki = 0.03 nM IC90 = 62 nM 
R=n-Butyl DMP 851 7.12 Ki= 0.02 nM IC90 = 51 nM 
Figure 7.8: Non-symmetric cyclic ureas DMP 850 and DMP 851 
Kaltenback et aZ. further modified the P liP l' groups25 of the nonsymmetrical 3-
aminoidazoles DMP 850 and DMP 851, to increase their lipophilicity, thus improving their 
antiviral potency against wild type HIV (see Table 7.2). Based on the resistance profile 
against HIV mutants, the P liP 1 ' substituted 3-methyl or 4-methyl analogues of DMP 850 
and DMP 851 are approximately equipotent. However, their poor oral bioavailability 
outweighed the improvements in the antiviral potency, eliminating these substituted 
analogues as potential development candidates. 
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Table 7.2: Structure activity relationship studies ofP lIP I' substituted cyclic ureas 
Compound 
DMP 850 
DMP 851 
H 
H 
4-CH3 
Bn 
Bn 
Bn 
n-Bu 
n-Bu 
n-Bu 
Ki (nM)a RF IC90 (nM) HXB2 IC90 (nM) 
0.031 
0.062 
0.047 
0.021 
0.045 
0.037 
62 
25 
12 
56 
31 
12 
92 
26 
17 
69 
54 
16 
a: Detennined by measuring the accumulation ofRF-wild type viral RNA transcript 
after infection of cells with HN-1 
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Subsequent research in this area has been focused on the synthesis of non-symmetric cyclic 
urea analogues and related N-heterocyclic analogues. For example, De Lucca reported the 
synthesis of a o-lactam26 7.15 as heterocyclic analogues of the urea-based HIV protease 
inhibitors. Synthesis of 7.15 utilized the hydroxyl ethylene isostere based linear inhibitor 
7.13, by first inverting the stereocentres and subsequent cyclization of the carboxyl 
terminus into the amino terminus to give the conesponding 7.14, which is finally 
benzylated and desilylated to give 7.15 (Scheme 7.2). However, this synthetic methodology 
does not permit the convenient introduction of a P l' substituent into the cyclic inhibitor. 
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Inversion 
======:> 
Cyc1ization 
Linear Peptidomimetc Inhibitor Cyclic non-peptide inhibitor 
i) HCl, ether 
Scheme 7.2: 7.13 
Ph#Ph 
OTBDMS 
7.14 
iii) NaH, DMF 
BnBr 
o 
Ph~*Ph 
----Ph ~ 
iv) TBAF 
PI' OH 
7.15 
The lactam generated in this way has only modest potency, which has been linked to 
the lack of the PI' group (Figure 7.9a). The imp0l1ance of a PI' substituent for optimum 
potency is evident by a comparison of the corresponding six-membered cyclic urea 
analogues that possess (for example, Figure 7.9b) or lack (for example, Figure 7.9c) the PI' 
substituent. The absence of a P2' substituent in the six-membered cyclic urea analogue, 
however, shows only a moderate loss of potency (Figure 7.9d) compared to one caused by 
the absence of a PI' substituent (Figure 7.9c). Consequently, this synthetic methodology 
limits the investigation of potential o-lactams inhibitors. 
0 0 0 0 Ph#Ph Pl~NJlN/'--..Ph Ph~NJlN/'--..Ph Ph~NJlN-H 
Ph Ph~""'~Ph Ph~ Ph~"'~ 
" Ph 
OH OH OH OR 
Ki= 9.4 f.lM Ki= 15nM Ki=25 11M Ki=66nM 
(a) (b) (c) (d) 
Figure 7.9: Comparison ofK i8 for lactam and pyrimidinones 
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Battistini et al. 27 have reported the synthesis of the six membered lactam 7.16 using a 
vinylogous version of Mannich type addition as the key reaction in their synthesis (Scheme 
7.3). This synthetic target 7.16, again lacks the PI' substituent and is fOlmed after a tedious 
multistep synthesis. 
qo i). TBSOTf, DCM "'" . 
- 80° C OSiMe/Bu 
't'JHBn 
q~ 
--\0 o--{ 
° 
° BOC'~yPh steps 
X:MrBS 
DMF 
v). Boc20, DMAP, MeCN 
ii). H2, PdlC, THF 
, 
iii). DBU, 80° C 
Scheme 7.3: Synthesis ofIactam 7.16 via vinylogous Mannich reaction 
7.16 
Research in our laboratories has focused on the synthesis of six-membered piperidinones 
using ring closing metathesis methodology as the key step (Scheme 1.6, chapter 1)28 
leading to the fOlmation of lactam 7.15 that also lacks a PI' substituent required for 
optimum potency. 
It is clear from the above discussion that there is still a need for convenient and general 
method of the synthesis of appropriately substituted, potent and selective protease 
inhibitors. The corresponding seven-membered lactams proposed in Figure 7.10 are less 
symmetrical, and may improve the unfavourable solubility and the resistance profile that is 
the general characteristic of many protease inhibitors. 
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P2''''N)lN,P2 
Pt"'S--{P I 
RO OR 
PI, 
7.17 7.]8 7.]9 
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o 
'2pyl I;J' R P2 
'IPYPI 
OR 
7.20 
Figure 7.10: Seven and six-membered lactam analogue 7.18, 7.]9, and 7.20 of cyclic urea 7.17 
The target seven-membered lactam inhibitors can be synthesized with a variety of 
substituents at Rand R' positions (discussed in detail in sections 7.4 & 7.5). The N-t-
butyloxycarbonyl group in analogues of 7.18 can be easily deprotected and the resulting 
free amine could be coupled to other amino acids to give potent HIV protease inhibitors. 
The six-membered o-lactams prepared previously in this laboratory do not contain PI' 
substituent.28 Research has therefore been focused on the synthesis of 5-, and 8-lactams 
analogues 7.19 containing the PI' substituents. 
The remainder of this chapter describes the research on the design and synthesis of seven-
membered peptidomimetics-derived lactams (Figure 7.10), as well as the attempted 
synthesis of six membered lactam analogues of cyclic urea HIV protease inhibitors. The 
main aim of the research work described here is to develop a general methodology for the 
synthesis of substituted lactam HIV protease inhibitors. The key feature of this synthetic 
approach is the ring-closing metathesis reaction, that is used to generate an olefinic lactam 
from a diene. The derivatization of the resulting lac tarn is investigated to assess the 
feasibility of using this method to synthesize specific lac tarn HIV protease inhibitors. 
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7.2 Synthetic for the Synthesis of Rings 
and 
Four experiments were designed to synthesize seven-membered lactam analogues of cyclic 
urea protease inhibitors with varying PI, P2, PI' and P2' substituents. Retrosynthetic 
analysis of the target molecule 7.18 (Scheme 7.4) suggests that the appropriately 
substituted acid and amine (corresponding to PI and PI 'positions of the respective urea 
analogues), could be used as starting molecules for the preparation of the key diene, the 
substrate forting closing metathesis. 
PI, P2, PI', P2'=Bn 
K j=3,4 hm 
0: P2 0 P2' 
BOCHN!lf:' ./ ---. h 
" N P 
RI : R2 
==:> BOCHN0N./'---.Ph 
Rl~R2 
HO! OH 
7.18 
H 0 
Boc" rL,)-lOH 
RVV 
Experiment I = R I, R2 = H 
PI 
Experiment 2 = Rl = H, R2 = Bn 
Experiment 3 = Rl = Ph, R2= H 
Experiment 3 = Rl = Ph, R2 = Bn 
Scheme 7.4: Retrosynthetic Analysis for the synthesis of target molecules 
PI' 
The olefinic lactam could be synthesized from the respective diene using ring closing 
metathesis (Scheme 7.4). The olefinic lactam can then be functionalized to the cis-diol 7.18, 
using Sharpless dihydroxylation procedure. This sequenee provides a convenient and 
general protocol for the synthesis of the target lactam-based HN protease inhibitors. What 
follows is a brief introduetion of the Sharpless asymmetric dihydroxylation. 
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7.3 Sharpless Asymmetric dihydroxylation reaction 
The diastereospecific cis-dihydroxylation of alkenes using osmium tetroxide as developed 
by Sharpless and co-workers29 is a valuable synthetic procedure for the introduction of a 
vicinal diol moiety into a molecule. The reaction utilizes catalytic quantities of osmium 
tetraoxide [(or K20s02(OH)2 as a non-volatile source of osmium that generates OS04 in 
situ)] and a chiral amine ligand in conjunction with potassium ferricyanide and potassium 
carbonate [K3Fe(CN)6-K2C03] as stoichiometric reoxidants in a biphasic solvent medium 
(t-BuOH/H20). The most commonly used ligands in this regard are cinchona alkaloid based 
ligands 7.21 and 7.22,30 DABCO based ligand 7.23,31 chiral diamine ligands 7.24,32 7.25,33 
7.2634 and 7.2735 as depicted in Figure 7.11. 
MeO OMe 
(DHQD)z-PHAL 7.21 
OR 
DAB CO analogue 7.23 7.24 
N'P-<:=c:g 
7.26 
MeO ;:/ 
~ 
N 
(DHQ)z-PHAL 7.22 
7.25 
N~=}~N~' 
Ar Ar 
7.27 
Figure 7.11: Ligands used in the asymmetric dihydroxylation reaction. 
Et 
H 
OMe 
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The catalytic cycle for this reaction is illustrated in Figure 7.12. Coordination of the chiral 
amine ligand to the osmium results in the formation of a chiral monoglycolate osmate 
complex. This complex can distinguish between the prochiral faces of a substrate alkene, 
resulting in cis-diol fonnation on one face in preference to the other. This selectivity is 
controlled by a few factors including the structure of chiral amine ligand and the structure 
of the alleene substrate. Opposite enantiomers of the chiral tertiary amine afford opposite 
enantiomcrs of a cis-dioL Thc complex then hydrolyzes releasing the diol and the ligand 
into the organic phase while the resulting Os(IV) species finds its way in to the aqueous 
phase.36 
Solvent 
t-BuOH:H20 
1:1 
-J:'H o I 1'0 
" O/Os~ H I 0 
NR3 
Figure 7.12: Catalytic cycle for Sharpless asymmetric dihydroxylation. 
Sharpless has categorized the alkene substrates in this reaction into SIX general types 
varying in the degree and position of substituents Crable 7.3). Moderate to good levels of 
enantioselectivity can be achieved for most of these types of alkenes using the above 
mentioned phthalazine based ligand systems. 
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Table 7.3: Shatpless structure classification ofalkenes 
Class II III IV V VI 
Structure ~ 
The alkene precursors to the diols (see Scheme 7.4) fall into class III, i.e. cis-disubstituted 
olefins, in this classification. What follows is a discussion about the synthesis of seven 
membered ring lactams and their derivatization. 
7.4 Experiment 1: Synthesis of Seven-membered Lactam mimetic from 
racemic Allyl Glycine having Pl/Pl' = H, P2 = NHBoc, P2' = Bn: 
The introduction ofP2, P2' substituents into the target seven-membered lactam (see 7.18 in 
scheme 7.4) was achieved by coupling of (±) allyl glycine with N-allyl benzyl amine 7.28 
under standard peptide coupling conditions to give a rotameric mixture (5:2, detennined by 
analysis of IH NMR spectrum) of the diene 7.29 in 88% yield (Scheme 7.5). 
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(±) Allyl Glycine 7.28 
° BOCHNQl) 
° 7.31 
° BOCHN6l) 
:;, 
HO ()H 
(±) - 7.32 
111 
+ 
7.30 j iv 
BOCHNDl) 
H() em 
(±) - 7.33 
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Reagents and conditions: i) EDCI, HOBT, DIPEA, DCM, rt, 16h, 88%. ii) Grubb's catalyst 6.2, DCM, 
reflux, 24h. 67-76% iii) Oxone, acetone, water, 1't,62%. iv) (DHQD)zPHAL or (DHQhPHAL, 
K20s02(OH)b K2C03, K3Fe(CN)6' MeS02NHZ. OOC-rt, 48h, 71-75%. 
Scheme 7.5: Synthesis of Lactam 7.30 and its derivatives 7.31,7.32 and 7.33. 
The structure of the diene 7.29 was confirmed by 'H, Be NMR and mass spectrometry. 
The 'H NMR spectrum of the diene revealed the presence of two rotamers at rt (see Figure 
7.13). The allylic protons attached to N are observed as multiplets at 5 1-2.54 ppm. The 
allylic protons attached to also show two multiplets in the range 3.89-4.08 ppm 
confilTIling the presence of two isomers. The benzylic protons for the major isomer appear 
as doublets at 5 4.48 and 4.71 ppm with a large coupling constant 14.5 Hz, whereas the 
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same protons for minor isomer resonated as a singlet at (5 4.61 ppm. The Ha, for the major 
isomer gave a multiplet at (5 4.64-4.68 ppm; and for minor isomer Ha appear as a multiplet 
at (5 4.72-4.7S. In addition, the olefinic protons gave multiplets at (5 S-6 ppm. 
5.5 5.0 4.5 4.0 3.5 3.0 2.5 ppm 
Figure 7.13: Portion of the IHNMR spectrum (SOO MHz) of7.29. 
Further confirmation of 7.29 was made through high resolution mass spectrometry which 
revealed the observed [MHt of C2oH29N203 was in agreement with the calculated one 
which is equal to 34S.2178. 
Ring closing metathesis of the diene 7.29 with Grubb's catalyst (6.2) in dry degassed DCM, 
then resulted in the formation of the desired seven-membered cyclic mimetic 7.30 in 67-
76% yield (Scheme 7.S). The key IH, l3C NMR chemical shifts and the 2D COSY 
correlations, confirming the structural assignment of 7.30 are shown in Figure 7.14. 
Correlations observed between the NH and H-3 protons established the assignment of the 
exocyclic resonances. 2D correlations among H-3, H-4 methylene protons and H-S olefinic 
protons confirmed connectivity of C-3, C-4 and C-S, while correlations between H-S and 
H-6 olefinic protons assigned connection of CS to C6. Similarly, 2D correlations between 
H-6 olefinic proton and H-7 methylene protons show the connection of C-6 and C-7. In 
addition, the 2DHSQC/DEPT experiment allowed the assignment of protonated carbons, 
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thus showing a prominent peak for t-Bn protons at 28.3 ppm, with C-4 at 33.3 ppm and C-7 
resonating lower field at 45.1 ppm due to the proximity of N atom. Similarly, the olefinic 
carbons resonated at 124 ppm and l30 ppm as assigned by 2D HSQC/DEPT expel1ment, 
thus assigning the lactam as compound 7.30. 
1.38 (28.3) 
(79~4.89 (49.9) 
(154.9) O~ j 0 V 72.4) 
5.82 HNZJ4.53/4.63 (51.4) N/'-...Ph 
2.20/2.60 (33.3) _ 3.27/4.21 (45.1) 
5.53 (124.1) 5.64 (130.0) 
Figure 7.14: a) Key IH and 13C NMR (in brackets) chemical shifts and b) 
connectivity data obtained from 2D COSY expeIiment for 7.30 
After the synthesis and characterization of the olefinic lactam 730, the next step was 
functionalization of the ring bound olefin via epoxidation and cis-dihydroxylation. So, the 
olefinic lactam 7.30 was first subjected to epoxidation (as depicted in Scheme 7.5, step iii) 
using Oxone® and acetone/water mixture37 to generate the dimethyldioxirane in situ, to 
give a diasteroisomeric mixture [(~1:1), determined from IH NMR spectrum by the 
integration of t-Bu protons] of epoxides 7.3la and 731b (stereochemistry not assigned) in 
63% yield (Figure 7.15). Fmiher separation of the epoxides could not be achieved. 
o BOORNQu 
o 
7.31a 
o BOOHNDu 
\5' 
7.31b 
Figure 7.15: Two possible epoxides 7.31a and 7.31b from epoxidation oflactam 7.30. 
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The key IH NMR chemical shifts for the mixture of epoxides (7,31a and 7.31b) are listed 
in Table 7.4. Analysis of the lH NMR resonances showed that , H-5, H-6 and 
resonated at higher field ~O.12-0.17 ppm for the one of the isomer as compared to the 
second isomer. The NH protons also show the same trend resonating ~0.13 ppm higher 
field for one isomer compared the other one (see Table 7.4). 
Table 7 A: Characteristic 1 H NMR Chemical shifts of a mixture of epoxides 7.31a and 7.31b. 
0 
BO'HN~;V 
4 7 I ~ 
5 6 
0 
Isomer H-4 H-7 CHu H-5 H-6 NH 
7.31a/or b 1.91/2.03 3.65/3.92 4.57 3.18 3.04 5.86 
7.31a/or b 2.5212.65 3.62 4.42 3.01 2.90 5.73 
Efforts were then directed towards the derivatization of the double bond of the lactam 7.30 
via catalytic Sharpless cis-asymmetric dihydroxylation using the lmown methodology for 
the AD of a cis double bond3o (see Scheme 7.5, step d). The reaction was carried out using 
both bis cinchona alkaloid based ligands dihydroquinidine phthalazine [(DHQD)2-PHAL] 
7.21 or dihydroquinine phthalazine [(DHQ)2-PHAL] In principle, the reaction with 
ligand 7.21 (AD-mix-t3) should produce a diol obtained from top (13)-attack whereas with 
7.22 (AD-mix-a)t should result in the formation of the diol from the opposite face30 
(Scheme 7.6). 
t. The commercial names for the AD reagent containing ligand 7.21 with K3Fe(CN)6, 
K2C03, and K20s02(OH)4 are AD-mix-13 and AD-mix-acontaining ligand 7.22. 
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HO Off 
DC 
HO OH 
Scheme 7.6: Predicted dihydroxylation in the presence of AD-mix-a and AD_mix_~30 
However, the reaction with either ligand (7.21 or 7.22) gave a diastereomeric mixture [(9: 1), 
determined by analysis of IH NMR spectrum by the integration of t-Bu protons] of cis diols 
7.32 and 7.33. The major isomer was separated as a white solid by fractional crystallization 
using PE/CHCh. The remaining filtrate contained a mixture of both isomers which could 
not be separated by column chromatography or further crystallization. 
The configuration of the major diol (±)-7.32 was assigned on the basis of a 2D NOE 
experiment as depicted in Figure 7.16, showing a cis correlation between H-3, H-5 and H-6, 
thus suggesting that the N-t-Boc group at C-3, and OH protons attached C-5 and C-6 are all 
cis to each other. Figure 7.16 illustrates the key IH NMR chemical shifts, 2D NOE 
correlations and 3D computer model of 7.32. In addition, the connectivity of C-6 to C-7 
was further confirmed by correlations among the respective H-6 methine and H-7 
methylene protons. 
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1.23 
~ 
O~ 0 
1 4(j3.7115.16 
5.72 HN",; N"""'--""'Ph 
a 1.53/1.67 3.1413.25 
3.54.;; ·;J.65 
HO bH 
and 
~ 
O~ 0 
HN'Q~~ 
HO OH 
3.04 2.94 
b c 
Figure 7.16 a) Key IH NMR chemical shifts, b) Key 2D correlations and c) 3D 
computer model of (±) -7.32. 
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The structural assignment of the major diol 7.32 suggests that the attack of osmium occurs 
syn to N-t-Boc group irrespective of the facial selectivity of chiral ligands. This syn-
stereoselectivity is proposed38 as a result of the enhanced hydrogen bonding of the osmate 
ester intermediate with the nitrogen of the N-t-Boc group. Thus, the N-t-Boc group acts as a 
director in the osmium catalyzed dihydroxylation reaction of olefinic lactam 7.30 and the 
syn diol 7.32 is formed in excess (90010) compared to the minor isomer 7.33 (1 (010). 
Donohoe et al. 38 have reported analogous syn-stereoselectivity during their research on the 
osmium catalyzed cis dihydroxylation of six-membered cyclic olefins (see Scheme 7.7). 
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NRC OR Qf 
RO OR 
syn anti 
Scheme 7.7: (>20:1) 
Other literature reports also reveal that substituents containing hetero atoms (S 39,N, 0) in 
allylic and homoallylic positions direct the course of osmium-catalyzed 
dihydroxylation.29a,38,4o 
7.5 Experiment 2: Stereoselective synthesis of substituted Lactam 
analogoue having Pl' = Ph, Pl = H. 
Attempts were next directed to the introduce the PI', P2' and P2 substituents into the 
seven-membered lactam ring (Scheme 7.8). The synthesis41 of unnatural amino acids 7.37a 
and its enantiomer 7.37b gives rise to the possibility of the introduction of P2' and PI' 
substituents into the lactam ring in a stereo defined manner (see Scheme 7.8). Synthesis of 
acids began with Boc protection of the NH2 group of (±)-glycine using BOC-ON reagent 
[(2-ter-butoxycarbonyloxyimino )-2-phenyl acetonitrile]. (± )-N -t-Boc glycine was then 
coupled to cinnamoyl alcohol in the presence of DCC and DMAP in DCM to gIVe 
cinnamoyl N-t-boc glycinate 7.34 in 92% yield. The Claisen rearrangement of 7.34 in the 
presence of chiral ligand quinine gave the acid 7.37a in 50% yield, whereas the same 
reaction in the presence quinidine (enantiomer of quinine) gave the enantiomer (7,37b) of 
acid 7,37a. The Claisen rearrangement of 7.34 is thought to occur through a chelate 
complex 7,35 which rearranges to 7.36 and subsequently give the acids 7.37a or 7,37b 
depending on the chiralligand (Scheme 7.8). 
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Glycine 
H 0 
I II /N~ Boc OH 
BOCHN,,"),O 
--- Ph~ 
ii 
iii or iv 
, 
7.34 
7.35 
H 0 H 0 
BOc/
N0 oH OTBOC~"'~OH 
Pli"'V PhN 
7.37a 7.37b 
P2' ", 0 ,P2 
BOCHNu'" l »~ N Ph Ph,#' R2 PI' " 
HO OH 
/~CO Boc OH 
pli'" ~ 
7.37a 
quinine 1 iii
AI-O 
[ 
OiPr ] 
BOC~X:: 
7.36 
HN/'...Ph 
7.281 
iV/ 
/ quinidine 
Reagents and eonditions: i) BOC-ON, DCM, Dioxane: H20 (l: 1). ii) Cinnamyl alcohol, DCC, DMAP, DCM 
iii) Quinine, LHDMS, Al(OiPr)3, THF, -78°C to rt. iv) Quinidine, LHDMS, AI(OiPrh, THF, -78°C tort. 
Seheme 7.8: Synthesis of acids 7.37a and 7.37b. 
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(S)-Alanine benzyl ester hydrochloride was coupled separately with both enantiomers of 
the acid (7.37a and 7.37b) under standard peptide coupling conditions using EDCI, HOBT 
and NMP (Scheme 7,9), to check if any epimerization had occurred in the Claisen 
rearrangement of 7.34 (Scheme 7.8, steps iii and iv). Compound 7.38a, formed from 
coupling of 7.37a was obtained as a diastereoisomeric mixture (10:1, based on IH NMR, 
>90% de) in 58% yield. In contrast, the amide 7.38b was obtained as a mixture (6:2, based 
on analysis of the IH NMR spectrum) showing poor diastereoselectivity compared to 7.38a. 
Therefore, due to the observed high de of the acid it was chosen for further studies. 
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BOCHN~O l!~O'-/Ph 
I
r ----------~------~,' 0 
Ph" 
__ I 7.38a (10:1) 
/~CO Boc OH 
, ./ 7.37a 
Ph" // 
Ph i 
H 0 H 0 BOC/~'I,)lOH N 7.37b 
Ph 
I 7.38b (6:2) 
Reagents and conditions: i) EDCI, HOBT, NMP, DCM, 16h, rt. 
Scheme 7.9: Synthesis of amides 7.38a and 7.38b. 
The introduction of a P2 substituent (in the form of N-benzyl group of the amine 7.28, see 
Scheme 7.8) into the seven-membered lactam was allowed by coupling of the acid 7.37a 
with N-allyl benzyl amine 7.28 under peptide coupling conditions using EDCI, HOBT and 
NEM to give the precursor for ring-closing metathesis, 7.39 in 44% yield as illustrated in 
Scheme 7.10. 
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Reagents and conditions: i) EDCI, HOBT, NEM, DCM, rt, 72 h. 44% ii) Grubb's catalyst 6.2, DCM, reflux, 
24 h, 85% iii) Oxone, acetone, water, O°C-rt. 87%. iv) (DHQDhPHAL or (DHQ)zPHAL, K20s02(OH)2, K2C03) 
K3Fe(CN)6) MeS02NHb OOC-n, 48 h, 51 %. 
Scheme 7.10: Synthesis of 7.40 and its derivatives 7.41 & 7.42. 
The diene 7.39 was characterized by IH and l3e NMR and was found to be a mixture of 
two rotamers [(2:1), based on analysis of the IH NMR spectrum] as depicted in Figure 7.17. 
The chemical shift for methine proton attached to phenyl group, and N-allylic protons 
appear as multiplets at (j 3.64-4.20 ppm. The benzylic protons for both isomers appear as 
doublets between (j 4.27 and 4.68 ppm, The Ha resonated as triplets at (j 4,87 ppm for major 
isomer, and (j 4.98 ppm for minor isomer respectively. The olefinic protons resonated as 
complex multiplets at (j 5,01-6.09 ppm. 
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• ! ! l~jJL;~GL 
6.2 6.0 5.8 5.6 5.4 5.2 5.0 4.3 4.6 4.4 4.2 4.0 ppm 
Figure 17: Portion of IH NMR spectrum of 7.39. 
The diene 7.39 was then subjected to ring closing metathesis using Grubb's catalyst (6.2) in 
refluxing DCM under argon atmosphere to give 85% of the lactam 7.40 as a dark brown oil 
(see Scheme 7.10). After purification of the crude residue by flash column chromatography, 
the lactam was subjected to IH, l3C, 2D COSY, HSQC/DEPT and mass spectrometry, 
confirming the compound as 7.40. 
The characteristic lH and l3C NMR chemical shifts and the key 2D COSY connectivity 
data of 7.40 are illustrated in Figure 7.18. The absence of complex peaks of the olefinic 
protons of the diene, and the appearance of new peaks for H-5 and H-6 olefinic protons at 
o 5.65 and 5.73 respectively, confirmed the formation of the new double bond and ring 
closure. The key 2D COSY eOlTelations between NH and H-3 protons established the 
assignment of the exocyclic resonances, and COlT elation of H-4 to H-3 and confirmed 
connectivity of C-3, C-4 and C-5. The cOlTelation of H-7 methylene protons with 
established further connection of the seven-membered lactam ring. The structure of the 
lactam was further confirmed by 2D HSQC/DEPT and high resolution mass spectrometry 
data which revealed that the observed [MHt for C24H29N203 (393.2204) was in agreement 
with the calculated one (393.2178). 
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1.10 (27.8) 
(79i;< 5.16 (53.7) 
. 0 j 4.62 (51.4) 
(154.6) O~ O(l72~ 
5.41 HN5/'-.. 3.36 (49.4) ----... N Ph 
Ph"" _ 3.42/4.45 (44.6) 
5.73 (134.5) 5.65 (124.4) 
Figure 7.18: a) Key IH and I3C l\'MR (in brackets) chemical shifts and b) 
connectivity data obtained from 2D COSY expeliment for 7.40. 
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The next step was the derivatization of the double bond of olefinic lactam 7.40, as for 7.30. 
The lactam 7.40 was epoxidized37 using Oxone® and acetone/water (see Scheme 7.10). 
The epoxide 7.41 was obtained as a (~5:4) mixture of two diastereoisomers (detennined by 
analysis of the IH NMR spectrum) in 87%, which could not be separated by crystallization 
or column chromatography (Figure 7.19). Therefore, the configuration of the 
diastereoisomers could not be assigned. 
Table 
that 
BO'HN0lj"~ 
Ph""V V 
o 
7.41a 
BOCHN6l~ 
PH'" N V 
'\5' 
7.41b 
Figure 7.19: Two possible epoxides from the epoxidation oflactam 7.40. 
summarizes the key IH NMR chemical shifts for 7.41a and 7.41b, which shows 
and appear as multiplets for both isomers in the same regions. The 
proton of 7.41a/or b resonated ~0.17 ppm higher field for major isomer compared to 
the minor isomer. However, the chemical shift for H-4 proton for major isomer resonated 
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lower field at 5 
isomer (5 3.94). 
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compared to the chemical shift for the same proton for minor 
Table 7.5: Characteristic IH NMR Chemical shifts ofa mixture ofepoxides 7.41. 
0 
2 N I ~ BOOH O;U 
Ph",1 7 ~ 
5 6 
0 
lsomer H-4 H-7 Ha H-5 H-6 NH 
major 3.21-3.28 3.69-3.76 4.89-4.90 3.21-3.28 3.12-3.18 5.41 
minor 3.94 3.69-3.76 4.89-4.90 3.21-3.28 3.00-3.11 5.24 
After synthesis of the epoxide derivatives, the lactam 7.40 was subjected to Sharpless AD 
conditions (see Scheme 7.10, step iv). The AD oflactam 7.40 could give rise to two syn-
diols 7.42 or 7.43, formed from the top or bottom attack ofOs04 (Scheme 7.11). 
-\ -\ -\ 
0 0 0 oy 0 oy 0 oy 0 lIND,,", Ph AD HNQ""'Pb and/or 11N6""'Pb 
Ph"" _ Ph"" Ph"":;: -:., 
HO OH HO OH 
7.40 7.42 7.43 
Scheme 7.11: Two possible Diastereoisomers 7.42 or 7.43 formed from AD of 7.40. 
The reaction of 7.40 with either ligand 7.21 or 7.22 gave a single diastereoisomer 
(determined by analysis of IH NMR spectrum), which was assigned structure 7.42 based on 
a 2D NOE experiment (Figure 7.20), in 51 % yield along with 36% of the recovered starting 
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material 7.40. The key IH NMR chemical shifts, 2D NOE correlations and a 3D computer 
model of 7.40 are illustrated in Figure 7.20. The key 2D NOE correlation of H-4 (Figure 
7.20b) with NH and OH protons at C-5, C-6, establish their cis-relationship to each other. 
Similarly, the 2D correlation between H-3, H-5 methine and H-7 methylene assigns a syn 
configuration of the N-t-Boc group to the H-5 hydroxyl, and confirms their proximity to H-
7 (Figure 7.20c). Further ~yn relationship of the H-5 and H-6 methine protons and OH 
protons was confirmed by 2D NOE correlations between these protons. 
1.21 
--\( 
o 
O~ 0 
5.43 HN 4.7 
4.07 
1.9/2.74 L70 
a b 
Figure 7.20 a) Key IH NMR chemical shifts, b) Key 2D NOE correlations and c) 3D computer model of 7.42. 
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The syn configuration of the N-t-Boc group to the 5- & 6-0H protons suggests that the syn-
attack of osmium to N-t-Boc group occurs as before (for AD of lactam 7.30), due to 
enhanced hydrogen bonding38 of the NH to the intermediate osmate ester, irrespective of 
the facial selectivity of the chiralligands 7.21 or 7.22. The syn-stereoselectivity of osmium 
to the N-t-Boc group is further reinforced by the (R)-stereochemistry of the phenyl group at 
4-position which is evident by the generation of a single diastereoisomer 7.42 from lactam 
7.40, compared to the synthesis of a (9: 1) mixture of diastereoisomers 7.32 & 7.33 from the 
AD of lactam 7.30 (see section 7.4) that lacks an allylic substituent. Thus, dihydroxylation 
occurs anti to phenyl group which is the sterically favored face. 
7.6 3: Stereoselective synthesis of sUbstituted Lactam 
analogoue = , =H. 
There is a considerable scope for the introduction of natural amino acid-based PI and P2 
substituents into the seven-membered lactam ring (Scheme 7.12). The preparation of the 
amine bearing PI and P2 substituents is achieved by the manipUlation of an a-amino acid, 
as depicted in Scheme 7.12. The transformation28 of (S)-N-t-Boc phenyl alanine into amine 
7.46 allows the introduction of a benzyl PI substituent that mimics the polypeptide 
substrate of the HIV protease. DIBAL(H) reduction of (S)-N-t-Boc phenyl alanine methyl 
ester in dry toluene at _78° e gave the corresponding aldehyde, which was used in next step 
of Wittig olefination without further purification to give the olefinic amine 7.44 in 45% 
yield (see Scheme 7.12). Treatment of the 7.44 with NaH and BnBr at ooe gave the 
benzylated amine in 68% yield, along with 20% of recovered starting amine 7.44, 
which was treated with TF A in DeM at oOe to give the desired amine 7.46. The versatility 
of this method lies in the fact that a variety of amino acid based PI substituents (R1, 
Scheme 7.12) could be introduced into the seven-membered lactam ring as depicted in 
Scheme 7.12. In addition, a choice ofP2 groups could be introduced by the introduction of 
different N-protecting groups [(R2), step iv, Scheme 7.12]. 
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Bn, 
HN-Boc HN-Boc NBoc HN-Bn 
Me02c~Ph i, ii ~Ph iii ~Ph IV • ~Ph 
7.44 7.45 7.46 
0 P2'· 0 P2 
BOOHN"( BO'HN;'~ HN-R2 , OH ' Ph HN-Bn 
~ .,.., Ph ~Ph ~Rl 
I PI' -'HO OH "" PI 7.46 
Reagents and conditions: i) DIBAL, Toluene, _780 C. ii) CH3+PPh3Br',THF, LiHDMS, _780 CoLt. iii) 00 
C, NaH, BnBr, DMF. iv) TFA, DCM, _780 C. 
Scheme 7.12: Synthesis of amine 7.46 
Coupling of the amme 7.46 with (S)-allyl glycine under standard peptide coupling 
conditions using EDCl, HOBT and DlPEA could not be achieved probably due to steric 
crowding of the amine. However, coupling of 7.46 with (S)-allyl glycine was accomplished 
in the presence of BOP coupling reagent and DlPEA by stirring the reaction mixture at rt 
for 48 h in dry DCM to give the diene 7.47 in 67% yield (Scheme 7.13). The progress of 
the coupling reaction was monitored by TLC, and the turnover of the reaction was 
increased by the addition of another four equivalents of BOP in portions to the reaction 
mixture.42 Scheme 7.13 depicts the synthetic steps involved in the synthesis of 7.47,7.48, 
7.49, and 7.50. 
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o 
BOCHN',C ' OH 
/./ 
BOCHN"(O /"--... 
, N Ph 
~Ph ~ \ 
(5) - N-t-Boc allyl Glycine 7.46 
o 
BOCHN",~l~"""""""Ph 
\rPh 
o 
7.49 
n 
MesNyNMes 
_1.",Cl 
Ru"'--, 
C/ I Ph 
PCY3 
6.4 
iii 
7.47 
.. 1 6.4 11. 
o 
BOCHN"'~N~Ph 
~Ph 
7.48 
o 
BOCHN"'~N-------'. GPh 
," "0 Ph 
HO OH 
7.50 
Reagents and conditions: i) BOP, DIPEA, DCM, Ii, 72h. 67%. ii) Grubb's catalyst 6.4, DCM, 
reflux, 36h. 92% iii) Ox one, acetone, water, rt. 84%. iv) (DHQDhPHAL or (DHQ)2PHAL, K20s02(OHh, 
K2C03, K3Fe(CN)6' MeS02NH2' ODC-rt, 48h, .52-65 % 
Scheme 7.13: Synthesis of 7.48 and its derivatives 7.49 & 7.50. 
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The complex IH NMR spectrum (Figure 7.21) of 7.47 showed the presence of a rotameric 
mixture (3:2, determined by analysis of the IH NMR spectrum) at rt. The allylic protons 
next to Ha , and benzylic protons attached to methine proton appear as multiplets at 15 2.84-
3.01 ppm. The methine H adjacent to benzylic methylene protons, and N-CH2 protons 
resonate between 04.26 and 4.83 ppm for both isomers. 
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Figure 7.21: Portion of the IHNMR spectrum of 7.47. 
The for both isomers resonated as multiplets at (j 4.85-4.87 ppm. Fmther complex 
pattern of olefinic protons at (j 4.95-6.01 confirmed the presence of two rotamers at rt. The 
presence of the two isomers was further established by the 13C NMR spectrum which 
showed double characteristic resonances for all carbons. Further confirmation of 7.47 was 
made by the observed [MHt C27H3SN203 (435.2635), which was found to be in agreement 
with the calculated mass (435.2648). 
Ring closing metathesis of the diene 7.47 was achieved using Grubb's catalyst (6.4) in 
refluxing DCM to give 92% of the olefinic lactam 7.48 (Scheme 7.13, step ii). The key IH 
NMR and 2D COSY connectivity data for 7.48 are illustrated in Figure 7.22. The 
characteristic chemical shifts for H-5 and H-6 olefinic protons are observed at (j 5.77 and 
5.46 ppm respectively, confirming the forn1ation of a new double bond. The key 2D 
correlations among methylene and H-5 olefinic pTotons established 
connectivity of C-5 to C4 and C-3 and exocyclic N-t-Boc group in 7.48. Similarly, 2D 
correlations between 
structure of 
and and and the benzylic protons further confilm the 
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1.48 (28.4) 
(79-J<5) 4.85 (52.4) 
. 0 3.56/5.07 (52.3) 
(155.1) O~ O/lny 
6.03HN, /'.... 
I" N ~ 3.07/ (42.4) 
2.30 (32.5) " Ph 
3.92(61.4) 
5.77(126.9) 5.46 (128.2) 
Figure 7.22: a) Key IH and 13C NMR (in brackets) chemical shifts and b) 
connectivity data obtained from 2D COSY experiment for 7.47. 
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Further confirmation of the structure of 7.48 was done by high resolution mass data; which 
revealed the value for [MHt to be 429.2157, whereas the calculated value for [MHt is 
equal to 429.2154. 
Functionalization of the double bond of lactam 7.48 via epoxidation (as before for 7.30 and 
7.40) was carried out using Oxone® and acetone/water (see Scheme 7.13, step iii) to give 
the epoxide 7.49 as a mixture (~1:1, detelmined by analysis of the IH NMR spectmm) of 
two diastereoisomers in 84% (Figure 7.23), which could not be separated by column 
chromatography or crystallization. 
o 
BOcfINII,)lN~I l)-:h 
" ::: Ph 
H 
7.49a 
o 
BOCHNII~ I N Ph 
Ph 
o 
7.49b 
Figure 7.23: Two diasteroisomers formed from the epoxidation oflactam 7.48. 
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Table 7.6 summarizes the characteristic IH NMR chemical shifts for 7.49a/b. An analysis 
of the chemical shifts for the two isomers reveal that the protons for one isomer resonated 
higher field compared to the other isomer. 
Table 7.6: CharacteIistic IH NMR Chemical shifts of a mixture of epoxides 7.49a-b. 
0 
BO'HN"~ , Nt Ph 
4 7 
5 6 Ph 
0 
Isomer Ba B-4 H-5 H-6 B-7 NH 
7.49al or b 4.55 2.01/2.55 3.11 2.98 3.92 5.79 
7.49al or b 4.62 2.0912.69 3.17 3.27 4.11 5.97 
Further functionalization of the olefinic lactam 7.48 was then carried out via Sharpless AD 
using either ligand dihydroquinidine phthalazine [(DHQD)rPHAL] or dihydroquinine 
phthalazine [(DHQh-PHAL] 7.22 (Scheme 7.14). The AD reaction could occur from 
bottom or top face to give diastereoisomer 7.50 and lor 7.51 (Scheme 7.14). A single 
diastereoisomer (determined by analysis of the IH NMR spectrum), was obtained in ~52-
60%. The configuration of the diol was assigned based on a 2DNOE experiment, 
confirming 7.50 as the structure of the dioL 
AD 
and/or 
7.21,7.22 
7.48 7.50, major 7.51, minor 
Scheme 7.14: Two possible Diastereoisomers 7.50 or 7.51 from AD of7.48. 
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The key IH NMR chemical shifts, connectivity data obtained from 2D NOESY studies, and 
3D computer model of 7.50 are depicted in Figure 7.24. 
1.30 
--\:' 4.17 
o 3.9614.69 
o~ O(I72Y 
5.82 HN", /"'-.,. 
, N ~ 2.4912.86 
1.64-1.74 
Ph 
3.65 
a b 
c 
Figure 7 .24: a) Key IH chemical shifts, b) connectivity data obtained from 2D NOESY and c) computer model of 7.50. 
The 3-N-t-Boc group has the same relative configuration, but opposite absolute 
configuration as the 7-benzyl group in 7.50. The absolute configuration at 3 and 7 positions 
came over from the starting substrates and was confirmed from the 2D NOE data. The cis 
relationship of the 5 and 6-0H protons with the N-t-Boc group was established by the 2D 
NOE correlations among H-3, H-5 and H-6 methine protons. The correlation between H-7 
and the neighbouring H-6 methine proton confirms their connectivity. The correlation of 
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benzylic CH2 (attached to C-7) with H-5 and H-3 methine, and N-benzyl protons suggest 
their proximity in space (Figure 7.24 c). The structural assignments of the diol 7.50, 
therefore, suggest that the attack of osmium has occurred syn to N-Boc group (as before for 
7.30 and 7.40) and anti to the (S)-benzyl group of lac tam 7.48. Thus, the 7-benzyl group 
enhances the syn-stereoselectivity of the N-t-Boc group in the AD of 7.48, by generating a 
single diastereoisomer 7.50, compared to the synthesis of a mixture (9: 1) of diols (7.32 and 
7.33) from lactam 7.30, that lacks a substituent at 4 or 7 position. 
Cis-dihydroxylation of 7.48 in the absence of ligands was also carried out to check the role 
of (S)-benzyl group and ligands; and was anticipated to proceed on the sterically less 
hindered face, anti to benzyl group (Scheme 7.14). Experimentally, the cis-diol 7.50 was 
obtained as a single isomer (based on lH NMR). The generation of a single diastereoisomer 
7.50 (determined by lH NMR) in the presence or absence ofligands, strongly suggests that 
it is the carbamate group of 7.48 which directs the course of dihydroxylation; and that the 
7 -(S)-configured benzyl group further enhances the syn-directing effect of the carbamate 
group. 
In the light of results obtained from experiments 1-3, it is concluded that the attack of 
osmium is always preferred syn to the carbamate group (in the dihydroxylation of 7.30, 
7.40 and 7.48), and the stereochemistry of (R)-4-phenyl group (7.40) and (S)-7-benzyl 
group (7.48) further reinforce the syn-selectivity of the carbamate group in the AD reaction. 
7.7 Experiment 4: Stereoselective synthesis of substituted Lactam 
analogoue having Pl = Bn, Pl' = Ph, 
De Lucca et al. 26 reported the presence of all PI, P2, PI' and P2' substituent (see Figure 
7.9) as a requirement for optimum potency of a lactam-based HIV protease inhibitor. 
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Efforts were made to introduce the PI, P2, PI' and P2' substituents into the seven-
membered lactam ring, by coupling of the acid 7.373 with the amine 
o 
BOCHN0oH 
Ph',J~ -
Figure 7.25: 7.37a 
(see Figure 7.25). 
HN~Ph 
~Ph 
7.46 
Attempts to couple the acid 7.373 with amine 7.46 using conventional peptide coupling 
reagents e.g. EDCl, DCC or BOP failed, probably because of the steric crowding of both 
acid 7.373 and amine 7.46. Coupling was however, achieved by first transforming the acid 
7.373 to the corresponding acid fluoride 7.52 by reacting it with pyridine and cyanuric 
fluoride. 43 The crude acid fluoride 7.52 was coupled with the amine 7.46 in the presence of 
DrPEA to give the diene 7.53 in 12% yield (Scheme 7.15). 
0 
BOeHNe OR 
Ph"" ~ 
7.37a 
6.2 
0 
BOOHND • Ph"" ; 
7.52 
6.3 
HN/'....Ph 
+ ~Ph 
7.46 
n 
MesNyNMes 
_ L",CI 
Ru~ CI~ I Ph 
PCY3 
6.4 
iii)t( 
o 
BOCHN0N /'.... Ph 
Ph\'\\~Ph 
7.54 
Reagents and conditions: i) pyridine, Cyanuric fluoride, DCM. ii) DIPEA, DCM. 
iii) 6.21 6.31 and 6.4. 
Scheme 7.15: Attempted synthesis of the lactam 7.54. 
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The crude residue was purified by column chromatography. The complexity of 'H NMR of 
7,53 revealed that the diene was a mixture ofrotamers. Ring closing metathesis of was 
attempted using Grubb's catalyst 6.2, 6.4 and extended chain catalyst 6,3. However, the 
ring closure could not be achieved using any of the above mentioned catalysts, and stalting 
material 7.53 was recovered in each case. This could be due to the blockage of the catalytic 
cycle of ReM by the presence of steric bulk near the olefinic chains. The blockage of the 
catalytic cycle of ReM by increased substitution in the proximity of the double bonds has 
also been repOlted in the literature.44 
Unfortunately, the synthesis of the ideal target HIV protease inhibitor containing all PI, P2, 
PI' and P2' substituents (Figure 7.25) was unsuccessful using this methodology. Recent 
advancement in ring closing metathesis by using microwave radiation45 has made possible 
the ring closing reaction of substrates that were not possible, or very slow without 
microwave radiation. Research will be focused on the ring closing metathesis of 7.53 using 
microwave radiation as well as other more powerful ReM catalysts in the near future, to 
get the desired tetra substituted seven-membered HIV protease inhibitors. What follows is a 
brief introduction of the six-membered lactams and their attempted synthesis during the 
course of this research work. 
7.8 Extension of the N-Terminus of the Seven-Membered Cyclic Lactam 
7.30 
Studies" have shown that one of the requirement for a potent HIV protease inhibitor is the 
introduction of groups capable of forming hydrogen bonds in the active site of the HIV 
protease. Extension of the NH2 telminus of the lactam by removing Boe group and 
coupling of the resulting free amine to another amino acid would lead to the possibility of 
introducing amino acid residues into the lactam inhibitor to increase the hydrogen bonding 
interactions of the inhibitor in the active site of the enzyme. The removal of Boc group 
Chapter 7 184 
from olefinic lactam 7,30 was thus achieved by stirring the lactam with IN HCI (aq) in 
ethyl acatate for 4h at rt to give the free amine 7.55 in 100% as depicted in Scheme 7.16. 
The crude amine was then coupled with N-Cbz-(S)-Valine in the presence ofEDCI, 
HOBT and DIPEA to give a diastereomeric mixture (~ 1:1, determined by IH NMR) of the 
resulting amide 7.56 in 68% yield. 
o 
BOCHN0N~ U Ph 
7.30 
H'N'(rPh __ i_i_ .. 
7.55 
Reagents and conditions: i) 1N Hel (ag.), EA, rt, 4h, 100%. ii) N-Cbz- (S)-Valine, EDCI, 
HOBT, DIPEA, rt, 16h, 68%. 
Scheme 7.16: Synthesis of the amide 7.56. 
Fmiher derivatization of the double bond of the lactam 7.56 VIa epoxidation and 
dihydroxylation could not be carried out due to lack of time. However, research work in 
future will be focused on functionalization of the double bonds of extended chain inhibitors 
7.56). 
rntJtleSIS of Six-membered h-Iactams using Ring-Closing Metathesis 7.9 
Methodology 
Various26, 27, 28 synthetic procedures have been applied to the synthesis of six-membered 
lac tam inhibitors as discussed earlier in section 7.1. Previous research in our laboratories,28 
has also led to the synthesis of six-membered lactam analogue lacking a PI' substituent 
(Scheme 1.6, Chapter 1). The lack of a PI' substituent (as depicted in Figure 7.9) has been 
reported to be the probable cause of the loss in antiviral potency, of the six-membered 
lactams and related six-membered cyclic urea-based HIV protease inhibitors.26 Research 
was thus focused on the synthesis of six membered ring lactams containing the missing PI' 
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substituent as depicted in Scheme 7.17. What follows is a discussion about the attempted 
synthesis of six membered ring lactams. 
The introduction of a PI' substituent into the target six-membered lactam was achieved by 
the synthesis46 of 3-phenyl but-3-enoic acid 7.57 using literature method (Scheme 7.17). 
Iodo-3-butenoic acid was synthesized by treating 3-butynoic acid with HI at 70 DC. 
Coupling of the iodo-3-butenoic acid with phenyl zinc bromide (generated by the addition 
of zinc bromide to phenyl magnesium bromide in dry ether) in the presence of 5% 
PdCh(MeCN)2 in dry DMF gave the respective acid 7.57 in 68% yield (Scheme 7.17). 
)lOR 
~ 
RMgBr, PdCII) 
Rl=R 7.28 
R2=Bn 7.46 
Scheme 7.17: Synthesis of 3-substituted butenoic acid 7.57. 
R 
I 
Zn 
" Zn ~C( '~r I '0/ 'Br 
7.57 = R = Ph 68% 
The synthetic plan involved was to couple the acid first with simple N-allyl benzyl amine, 
and carry out the RCM. The next step would involve coupling of the acid to the amino acid 
derived amine 7.46 to introduce both PI and P2 substituents into the six-membered lactam 
ring (Scheme 7.17). 
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The introduction of a P2 substituent into the six-membered lactam was managed by 
coupling of the acid 7.57 with N-allyl benzyl amine 7.28 in the presence of EDCI, HOBT 
and DIPEA to give the diene 7.58, along with the by-product 7.59 fonned from 
isomerisation of the tenninal double bond. RCM of the diene 7.58 was attempted using a 
number of reaction conditions (including carrying out the reaction in the presence of 
Grubb's catalysts 6.2, or 6.4, at rt as well as at reflux, in dry degassed DCM, benzene or 
toluene) as shown in Scheme 7.18. But the reaction was unsuccessful under all these 
conditions. 
0 0 0 tOH HN~Ph i~>"'Ph »i<:~ {y"'Ph + V 
Ph ~ Ph Ph ~ 
7.57 7.28 7.58 7.60 
+ 
0 IN"Ph 
Ph ~ 
7.59 
Conditions: i) EDCI, HOBT, NMP, DMF, rt. ii) Grubb's catalys 6.2, 6.4, DCM (Benzene, or toluene), rt or reflux. 
Scheme 7.18: Attempted synthesis of six-membered ring lactam 
Due to failure of the ReM of the tenninally substituted diene 7.58, fUliher work was 
stopped at this stage. However, future work could involve extension of this work as 
discussed in the next section. 
Conclusion and Future Work 
In summary, a versatile and general method for the synthesis of seven-membered ring 
lactams using transition metal catalysts has been developed. These lactams have been 
derivatized to cis-diols using Sharpless asymmetric dihydroxylation, and to epoxides. The 
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syn-stereoselectivity of the tert-butyloxy carbonyl group and its enhancement by allylic 
substituents with suitable stereochemistry, in osmium catalyzed dihydroxylation reaction 
has been determined. This has further been confirmed by the generation of a single 
diastereoisomer (7.50) from the Sharpless AD of the 7-benzyl substituted lactam (7.48) in 
the absence of ligands (7.21 and 7.22). The synthesized cis-diols will be sent for testing 
their biological activity against HIV. Extension of the amino terminus of the seven-
membered lactam (7.30) has also been successfully achieved, which determine the 
considerable scope of the introduction of amino acid residues capable of increasing the H-
bonding interaction in the active site of the HIV protease, required for enhancement in 
potency of such inhibitors. 
Future work in this area could involve optimizing the conditions for the synthesis of the six 
and seven-membered lactam analogues of HIV protease inhibitors using ring-closing 
metathesis methodology. Optimization could involve microwave-assisted ReM for the 
synthesis of tetra-substituted six and seven-membered lactam-based HIV protease 
inhibitors. Further research could also include ring closing metathesis in the presence of 
new and improved catalysts to synthesize the desired tetrasubstituted six- and 7-membered 
lactam inhibitors and their derivatives, which could prove potent and selective HIV 
protease inhibitors. Future work could also involve, extension of the seven-membered cis-
diol mimetics and coupling with other amino acids. 
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8.1 General Methods 
Nuclear Magnetic Resonance! 
IH-NMR spectra were recorded on a Varian Inova spectrometer (500 MHz) or a Varain 
Unity 300 (300 MHz), and 13C-NMR spectra on a Varian Unity 300 (75 MHz) at 23°C. 
Chemical shifts are reported in parts per million (ppm) on the 8 scale. All spectra were 
recorded in CDCh using TMS (for IH: 8 = 0) and CDCh (for l3C: 8 = 77.0) as internal 
standard unless otherwise specified. 2D-NMR experiments including COSY, HSQC, 
NOESY, HMBC were recorded on Varian Inova spectrometer (500 MHz) with a delay (D I) 
of Is. 
Mass Spectrometry! 
Electron Impact (EI) mass specta were detected on a Kratos MS 80 RF A mass spectrometer 
operating at 4000 V (accelerating potential), 70 eV (ionization energy) and 200-250 dc. 
Electrospray ionization (ESI) mass spectra were detected on a micromass LCT TOF mass 
spectrometer, having a probe voltage of 3200 V, temperature of 150°C and a source 
temperature of 80°C. Direct ionization used 10 ilL of a 10 IlgmL-I solution using a can'ier 
solvent of 50% acetonitrile/H20 at a flow rate of 20 ilL min-I, Ionization was aided by the 
addition of 0,5% formic acid. 
M ' 1'1 lcroana YSIS 
Microanalysis was performed at the University of Otago Microanalytical Laboratory. All 
reported values are within the range of ±0.4% of the calculated value. 
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Infrared Spectroscopy! 
IR spectra were recorded on a Shimadzu 8201PC series FTIR interfaced with an Intel 486 
PC operating Shimadzu' s Hyper IR software. Spectra were obtained neat on either a KEr 
disc, in solid KEr or in solution in CHCh. 
Optical Rotations 
Optical Rotations were measured on a Perkin Elmer Polarimeter Model 341, with a 10 mm 
path length. The [afo D values are reported in units deg cm2 g-!, with concentrations given 
. 10-! -3 III g cm . 
Reagents and Solvents 
All reactions were perfonned in oven-, or flame-dried glass equipment under an 
atmosphere of argon, unless otherwise mentioned. All reagents and starting materials were 
obtained from commercial sources, or otherwise prepared in the laboratory. Analytical thin 
layer chromatography was perfonned on glass- or aluminium-backed Merck Kieselgel 
KG60F2S4 silica plates, and visualized using short-wave UV light, KMn04 or 
phosphomolybdate dip (and dried with a flame). Flash column chromatography was 
perfonned on silica gel (Merck Silica gel 60, and Kanto Chemical Co., Inc) following the 
procedure given by Still and co-workers? EA and petroleum-ether (hexanes) were distilled 
from CaH2 prior to use in chromatography. N,N-Dimethylfonnamide (DMF) was distilled 
under reduced pressure from P20 S initially and then from CaH2, and stored over molecular 
sieves 4A under an argon atmosphere. THF, EhO and PhH were distilled from sodium 
benzophenone ketyl immediately prior to use. TEA, DCM and toluene were distilled from 
CaH2 immediately before use, and/or stored over molecular sieves 4A. Pd(PPh3)4 was 
prepared by the literature procedure3 and all other Pd catalysts and phosphine reagents were 
obtained from commercial sources. Metathesis catalyst were obtained from Strem 
Chapter 8 195 
Chemicals. Pentafluorobenzoyl chloride, was used without purification. LDA was prepared 
from n-BuLi and N,N-diisopropylamine (distilled from CaH2). Grignard's reagents were 
prepared in the laboratory. All other reagents used in the work described in this thesis were 
purified according to literature procedures.4 
8.2 General Procedures 
General Procedure A: Preparation of the Di- and trienyl Ketones 
The ketone N,N-dimethyl hydrazone (1.5 equiv) was treated with freshly prepared LDA 
(1.5 equiv) [from n-BuLi and N,N-diisopropylamine in THF (25 mL)] at 0 °C and stirred 
for 1 h under argon atmosphere. The reaction mixture was then cooled to -78 °C and the 
dienyl bromides 3.14a (1 equiv) in THF was added slowly. The reaction was stirred 
continuously, warmed to rt ovemight and quenched by adding aqueous sat. N&CI solution. 
The reaction mixture was then extracted with diethyl ether (x3). The combined organic 
fractions were washed with water, brine, dried over anhydrous MgS04 and evaporated in 
vacuo to give crude the alkylated hydrazone which was used in the next step without 
further purification. 
To a mixture of acetic acid (5 equiv), sodium acetate (1 equiv), water (2 equiv), and THF (2 
equiv) was added the crude alkylated hydrazone,6 and the mixture was stirred at rt for three 
hours. The reaction was quenched by adding aqueous NaOH solution at 0 °C and the 
mixture was extracted with ether (x3). The combined organic extracts were washed with 
water, brine, dried over anhydrous MgS04 and evaporated in vacuo. The crude product was 
purified by flash column chromatography [H/EA = 95/5-90110] to give the pure dienyl 
ketone. 
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General Procedure B: Preparation of Oxime Derivatives 
The dienyl ketone (1 equiv), hydroxylamine hydrochloride (1.3 equiv) and pyridine (1.5 
equiv) were stilTed in EtOH (30 mL) at rt for 1 h. The reaction mixture was quenched by 
adding H20, brine and then 2 M HCI (aq.) and extracted with ethyl acetate. The combined 
organic fractions were washed successively with 2 M HCI, sat. NaHC03 (aq), brine and 
dried over anhydrous Na2S04, and concentrated in vacuo to give a (E/Z) mixture of the 
oximes. The residue was purified by flash column chromatography to give the 
cOlTesponding oxime. 
General Procedure C: Preparation of O-pentafluorobenzoyl Oxime Derivatives 
To a solution of the dienyl ketone oxime (1 equiv) and TEA (1.9 equiv) in DCM (20 ml) at 
o °C was added C6FsCOCI (1.3 equiv) in DCM (5 ml) and stirred for 30 min to 1 h at that 
temperature. The reaction was quenched by adding H20 at 0 °C and extracted with ether 
(X3). The combined organic extracts were washed with water, brine, dried over anhydrous 
MgS04 and evaporated in vacuo. The crude product was purified by flash column 
chromatography (H/EA = 95/5) to give the pure dienyl oxime pentafluorobenzoate. 
General Procedure D: Preparation of Spiro cyclic Imines by Domino A-H Reaction7 
Pd(PPh3)4 (0.01 equiv) was added to a mixture of the O-pentafluorobenzoyl OXIme (1 
equiv), TEA (5 equiv) and molecular sieves 4A (150 mg) in dry DMF (0.05 M) under 
argon atmosphere at rt. The reaction mixture was warmed to 110°C and stirred for 30 min. 
The progress of the reaction was monitored by TLC. The reaction mixture was cooled to rt, 
quenched by adding water and extracted with Et20 (x3). The combined extracts were 
washed with water, then brine (x2), dried over anhydrous MgS04, and evaporated in vacuo. 
The residue was purified by flash column chromatography to give the desired spiroimine. 
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General Procedure E: Preparation of Arnidoxirnes 
To a solution of the oxime (1.0 equiv) in dry DMF (25 mL), was added N-
chlorosuccinimde (1.01 equiv) in portions. The reaction mixture was heated to 50-70°C 
and stirred for 2 h. The reaction mixture was then cooled to rt, and a solution of N-allyl 
benzyl amine8 (1.2 equiv) in DMF (5 mL) was added to the reaction mixture and stirring 
was continued for 2-4 h (monitored by TLC) at 70°C. The mixture was cooled to rt, water 
was added, and extracted with ethyl acetate (x3). The combined organic extracts were 
washed successively with water, NaHC03 soln (aq.), brine, and dried over anhydrous 
MgS04. The solvent was evaporated in vacuo, and the crude residue purified by flash 
column chromatography. 
General Procedure F: Preparation of O-pentafluorobenzoyl Arnidoximes 
To a solution of the amidoxime (1 equiv) and TEA (1.2 equiv) in dry CH2Ch (20 mL) at 0 
DC, was added C6FsCOCl (1.2 equiv) in CH2Ch (5 mL) and the mixture was stirred for 2 h 
at the same temperature. Water was added and the mixture extracted with CH2Ch (x3). The 
combined organic extracts were washed with water, NaHC03 soln (aq.), brine, dried over 
anhydrous MgS04, evaporated in vacuo, and the crude residue purified by flash column 
chromatography. 
General Procedure G: Arnino-Heck9 Preparation of Imidazoles 
Pd(PPh3)4 (0.01 equiv) was added to a solution of the O-pentafluorobenzoyl amidoxime (1 
equiv) and TEA (5 equiv) in dry DMF (0.05 M) under argon atmosphere at rt. The reaction 
mixture was warmed to 80°C and stilTing was continued for 30 min to 1 h (the progress of 
the reaction being monitored by TLC). The reaction mixture was cooled to rt, quenched by 
adding water and extracted with Et20 (x3). The combined extracts were washed with water, 
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brine (x2), dried over anhydrous MgS04, evaporated in vacuo, and the residue pmified by 
flash column chromatography. 
General Procedure Preparation of aryl alkynyl Ketones 
The ketone N,N-dimethyl hydrazone (1.5 equiv) was treated with freshly prepared LDA 
(1.5 equiv) [fi-om n-BuLi and N,N-diisopropylamine in THF (25 mL)] at 0 °C and stirred 
for 1 h under argon atmosphere. The reaction mixture was then cooled to °C and a 
solution of 4-bromo-l-butyne 5.31 (1 equiv) in THF was added slowly. The reaction was 
stirred continuously, warmed to rt overnight and quenched by adding aqueous sat. NH4Cl 
solution. The reaction mixture was then extracted with diethyl ether (x3). The combined 
organic fractions were washed with water, brine, dried over anhydrous MgS04 and 
evaporated in vacuo to give crude alkylated hydrazone which was used in the next step 
without further purification. 
To a mixture of acetic acid (5 equiv), sodium acetate (1 equiv), water (2 equiv), and THF (2 
equiv) was added the crude alkylated hydrazone/ and the mixture was stirred at rt for three 
hours. The reaction was quenched by adding aqueous NaOH solution at 0 °C and the 
mixture was extracted with ether (x3). The combined organic extracts were washed with 
water, brine, dried over anhydrous MgS04 and evaporated in vacuo. The crude product was 
purified by flash column chromatography to give the pure alkynyl ketone. 
General Procedure I: Preparation of Pyrroles by Amino-Heck Reaction 
Pd(PPh3)4 (0.01 equiv) was added to a mixture of (or 1 equiv), TEA (5 equiv) in 
dry DMF (0.05 M) under argon atmosphere at 11. The reaction mixture was warmed to 80-
90°C and stirred for the time specified in the experimental section. The progress of the 
reaction was monitored by TLC. The reaction mixture was cooled to rt, diluted by adding 
water and extracted with EhO (x3). The combined extracts were washed with water, then 
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brine (x2), dried over anhydrous MgS04, and evaporated in vacuo. The residue was 
purified by preparative thin layer chromatography to give the desired pyrrole. 
General Procedure J: Preparation of Pyrroles by Amino-Heck Reaction Followed by 
TransmetaHation I 0 
The organometallic reagent (1.2-2 equiv) was added slowly to the reaction mixture 
containing 5.38 (or 5.39, 1 equiv), TEA (5 equiv) in dry solvent (DMF or THF, 0.05 M) 
under argon atmosphere at rt, over a period of time specified in the experimental section. 
The mixture was stirred at rt or at 80-90 °C for the time specified in the experimental 
section. The progress of the reaction was monitored by TLC. The reaction mixture was 
cooled to It, filtered tluough a celite pad, quenched by adding water and extracted with 
EtzO (x3). The combined extracts were washed with water, then brine (x2), dlied over 
anhydrous MgS04, and evaporated in vacuo. The residue was purified by flash column 
chromatography to give the desired pyrrole. 
General Procedure Preparation of Pyrroles by Amino-Heck Reaction Followed 
Intermolecular Heck reaction 
Pd (0) catalyst (0.01 equiv) was added to a mixture of 5.38 (or 5.39, 1 equiv), TEA (5 equiv) 
and methyl acrylate (2 equiv) in dry DMF (0.05 M) under argon atmosphere at rt. The 
reaction mixture was stirred at 80-90 °C for the time specified in the experimental section. 
The progress of the reaction was monitored by TLC. The reaction mixture was cooled to It, 
diluted by adding water and extracted with Et20 (x3). The combined extracts were washed 
with water, then brine (x2), dried over anhydrous MgS04, and evaporated in VaCl.lO. The 
residue was purified by flash column chromatography to give the desired pyrrole. 
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General Procedure L: Preparation of Pyrroles by Amino-Heck Reaction Followed by 
Carbonylation-Termination via Alcohol SequencelO 
Pd(PPh3)4 (0.01 equiv) was added to a mixture of 5.38 (or 5.39, 1 equiv), TEA (5 equiv) 
and alcohol (5 equiv) in dry DMF (0.05 M) under argon atmosphere at rt. CO was then 
bubbled through the solution for 10 min. The reaction mixture was stirred at 25-70 °C for 
the time specified in the experimental section under a balloon of CO. The progress of 
reaction was monitored by TLC. The reaction mixture was cooled to rt, quenched by 
adding water and extracted with Et20 (x3). The combined extracts were washed with water, 
then brine (x2), dried over anhydrous MgS04, and evaporated in vacuo. The residue was 
purified by flash column chromatography to give the desired pyrrole. 
General Procedure M: Couplings Using 1,3-(Dimethylaminopropyl)-3-ethylcarbo-
diimide hydrochloride/l-hydroxybenzotriazole Hydratell 
EDCI (1 equiv), HOBT (2 equiv) and base (3.0 equiv) were added to a solution of the acid 
(1.0 equiv) and amine (1.0 equiv) in dry solvent (~0.1 M, DMF or DCM) under an argon 
atmosphere with stirring at rt. After stirring for 16 h, the solution was diluted with water 
and EA (10 mL). The organic phase was separated and the aqueous phase was extracted 
with EA (x3) and combined organic fractions were washed successively with H20, 
NaHC03 soln (aq.), brine, dried (MgS04) and evaporated under reduced pressure to give 
the clUde diene. This was purified by column chromatography. 
Modified General Procedure M 
The reaction was performed in the manner described in General Procedure M, except that 
DCC was used instead of EDCI. See individual experiments for details. 
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General Procedure N: Couplings using benzotriazole-l-yloxytris( dimethylamino)-
phosphonium hexafluorophosphate12 (BOP) 
201 
BOP (1 equiv) and DIPEA (3 equiv) were added to a solution of the acid (1 equiv) and 
amine (1 equiv) in DCM (20 mL) under argon according to the general procedure. The 
mixture was stirred at rt for the specified time (see experimental for details). Additional 
equivalents of BOP were added in portions to the reaction mixture to increase the rate of 
reaction in the forward direction. The solution was diluted with water and EA (10 mL), 
organic layer separated and aqueous layer back extracted with EA (x3). The combined 
organic fractions were washed successively with H20, NaHC03 soln (aq.), brine and dried 
(MgS04). Evaporation in vacuo gave the crude diene which were purified by column 
chromatography. 
General Procedure 0: Ring-Closing Metathesis 
The catalyst (either 6.2, 6.3, or 6.4, 0.08 equiv), dissolved in dry degassed DCM, was 
added to a solution of diene (1.0 equiv) dissolved in dry degassed DCM under argon. The 
solution was refluxed for the specified time (see experimental for details). Water was added 
to dilute the reaction mixture, organic layer separated and aqueous layer back extracted 
with DCM (x3), washed with brine and evaporated in vacuo to give the crude cyclic 
product. Purification by flash column chromatography gave the desired olefinic product. 
General Procedure P: Preparation of Epoxide13 Analogues 
To a solution of the olefinic lactam (1 equiv) in acetone (12 mL) and water (10 mL) was 
added sodium hydrogen carbonate (34 equiv). The mixture was stirred vigorously for 15 
min at rt and then cooled to 0 DC, and Oxone® (10 equiv) was added portion-wise over 5 
min. The resulting mixture was vigorously stirred at this temperature for 2 h and then at 
room temperature for 16 h. The acetone was removed under reduced pressure before ethyl 
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acetate (50 mL) and water were added (50 mL). The organic layer was separated, and the 
aqueous layer was back-extracted with ethyl acetate (x3). The combined organic fractions 
were dried (MgS04), filtered, and concentrated, and the resulting residue was purified by 
silica gel column chromatography. 
General Procedure Q: Preparation of cis-diol analogues using Sharpless14 AD. 
Potassium osmate (0.05 equiv) was added to a heterogeneous slurry of the olefinic lactam 
(1 equiv), t-butyl alcohol (3 mL), water (3 mL), potassium carbonate (3 equiv), potassium 
ferricyanide (3 equiv), ligand 7.21 or 7.22 (0.05 equiv) and methane sulphonamide (2 equiv) 
under argon at 0° C. The mixture was stirred for 48 h and warmed to rt. The mixture was 
cooled to 0° C, sodium sulphite was added and allowed to warm to rt and stirred for 1-2 h. 
EA was added to the reaction mixture: organic layer was separated and the aq. phase further 
extracted with EA. The combined organic layers were washed with 2 N KOB, dried 
(MgS04) and concentrated to give the diol and the ligand, which were purified by flash 
column chromatography. 
Modified General Procedure Q: Preparation of cis-diol analogues using Sharpless 
conditions in the absence of ligands. 
The reaction was performed in the manner described in General Procedure Q, except that 
the reaction was carried out in the absence of ligands 7.21 or 7.22. See individual 
experiments for details. 
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8.3 Experimental Work Described in Chapter Three 
Dienyl bromide 3.14a5 and trienyl chloride 3.14b5 were prepared by literature methods. 
6-methylene-l-phenyl-9-decen-3-one (3.15a) 
o 
~ 
4-Phenyl-2-butanone N,N-dimethyl hydrazone (1.75 g, 9.2 mmol) was treated with freshly 
prepared LDA [from n-BuLi (1.6 M in hexane, 3.9 mL) and N,N-diisopropylamine (9.2 
mL) in THF (25 mL)] at 0 °C and stirred for 1 h under argon atmosphere. 3.14a (1.07 g, 6.2 
mmol) in THF (4 mL) was added according to general procedure A. The crude alkylated 
hydrazone was then hydrolyzed by adding acetic acid (3.4 mL, 69 mmol), sodium acetate 
(1.89 g, 13.9 mmol), water (500 /-LL), and THF (2.2 mL) and the mixture was stirred at rt for 
3 h. The crude product was purified by flash column chromatography [H/EA = 95/5 then 
9011 0] to give 540 mg (55%) of 3.15a as a yellow oil. 
FTIR (KBr) 1716, 1643, 1604, 1496, 1454, 1365, 1282, 1187, 1091,910,748,700 cm-l. 
IH NMR (500 MHz) 82.08 (t, J= 7.5 Hz, 2H), 2.16-2.20 (m, 2H), 2.27 (t, J= 7.5 Hz, 2H), 
2.53 (t, J= 7.5 Hz, 2H), 2.74 (t, J= 7.6 Hz, 2H), 2.90 (t, J= 7.7 Hz, 2H), 4.67 (s, 1H), 4.74 
(s, 1H), 4.95 (dd, J= 10.2 Hz, 1.5 Hz, 1H), 4.95 (dd, J= 10.2 Hz, 1.6 Hz, 1H), 5.01 (dd, J 
= 17.1 Hz, 1.5 Hz, 1H), 5.75-5.83 (m, 1H), 7.16-7.20 (m, 3H), 7.25-7.28 (t, J= 7.4 Hz, 2H). 
13C NMR (125 MHz) 8 29.7, 29.8, 31.9, 35.6,41.2,44.3, 109.4, 114.6, 126.1, 128.3, 128.5, 
l38.2, 141.1, 147.7,209.3. 
Micro. Found: C, 83.96; H, 8.98%. Calcd. for C17H220: C, 84.25; H, 9.15%. 
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4-Methylene-l-phenyl-7-octen-l-one (3.15b) 
o 
Acetophenone N,N-dimethyl hydrazone (1.17 g, 7.20 mmo1) was treated with freshly 
prepared LDA [from n-BuLi (1.6 M in hexane, 3 mL) and N,N-diisopropyl amine (1.0 mL) 
in THF (25 mL)] at 0 °C and stirred for 1 h under argon atmosphere. Compound 3.14a (840 
mg) in THF (4 mL) was added according to general procedure A. The crude alkylated 
hydrazone was then hydrolyzed by adding acetic acid (3.1 mL, 54 mmol), sodium acetate 
(1.47 g, 10.8 mmo!), water (400 ilL), and THF (1.8 mL) and the mixture was stirred at rt for 
5 h. After work up was purified by flash column chromatography (H/EA 95/5) to 
give 600 mg (62%) of3.15b as a yellow oil. 
FTIR (KBr) 1689, 1643, 1596, 1581, 1448, 1355, 1278, 1205, 1180, 989, 906, 744, 690, 
507 em-I. 
IH NMR (500 MHz) 8 2.14-2.17 (m, 2H), 2.20-2.24 (m, 2H), 2.45 (t, J 7.7 2H),3.12 
(t, J= 7.7Hz, 2H), 4.77 (s, lII), 4.79 (s, IH), 4.96 (d, J= 10.5 Hz, IH), 5.02 (dd, J 17.0 
Hz, 1.6 Hz, IH), 5.81 (ddt, J 17.0 Hz, 10.5 Hz, 6.5 Hz, IH), 7.45 (dd, J 7.2 Hz, 8.5 Hz, 
2H), 7.55 (t, J= 7.2 Hz, 1H), 7.96 (dd, 8.5 Hz, 1.5 Hz, 2H). 
l3C NMR (125 MHz) 8 30.1, 32.0, 35.7, 36.9, 109.4, 114.7, 128.0, 128.6, 133.0, 136.9, 
138.2, 147.9, 199.7 
Micro. Found: C, 83.84; H, 8.52%, Calcd. for C15H1SO: C, 84.06; H, 8.46%. 
2-(2-Metbylene-5-hexenyl) cyclobexanone (3.15c) 
o 
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Cyclohexanone N,N-dimethyl hydrazone (1.34 g, 8.57 mmol) was treated with freshly 
prepared LDA [from n-BuLi (1.6 M in hexane, 5.7 mL) and N,N-diisopropylamine (1.2 mL, 
8.57 mmol) in THF (25 mL)] at 0 °c and stirred for 1 h under argon atmosphere. 
Compound 3,14a (1.0 g, 5.71 mmol) in THF (4 mL) was added according to general 
procedure A. The crude alkylated hydrazone was then hydrolyzed by adding acetic acid 
(2.5 mL, 42.85 mmol), sodium acetate (1.17 g, 8.57 mmol), water (300 ilL), and THF (1.4 
mL) and the mixture was stined at rt for 2.5 h. The crude product was purified by flash 
column chromatography (H!EA = 92/8) to give 800mg (63%) of 3.15c as a colorless oil. 
FTIR (KBr), 1712, 1641, 1448, 1338, 1313, 1224, 1128,998,908,811,636 cm-I 
IH NMR (500 MHz) 0 1.26-1.34 (m, 1H), 1.60-1.73 (m, 2H), 1.87 (dd, J 14.8 ,8.8 Hz, 
2H), 2.02-2.07 (m, 3H), 2.09-2.25 (m, 3 H), 2.29-2.35 (m, 1H), 2.39-2.49 (m, 2H), 2.61 (dd, 
J 14.8 Hz, 4.8 1H), 4.70 (s, 1H), 4.79 (s, 1H), 4.95 (d, J 7.1 Hz, 1H), 5.02 (dd, J 
17.1 Hz, 1.6 Hz, IH), 5.77-5.82 (m, 1H). 
BC NMR (125 MHz) 8 24.8, 28.0, 31.9, 33.4, 35.2, 35.7, 42.0, 48.5, 11 0.8, 114.6, 138.3, 
146.5,212.8. 
Micro. Found: C, 81.17; H, 10.29%. Calcd. for C13H200: C, 81.19; H, 10.48%. 
2-(2-Methylene-5-hexenyl)-3,4-dihydro-2H-naph thaI ene-I-on e (3,15d) 
o 
Tetralone N,N-dimethyl hydrazone6 (1.02 g, 6.92 mmol) was treated with freshly prepared 
LDA [from n-BuLi (1.6 M in hexane, 5.3 mL) and N,N-diisopropylamine (960 ilL, 6.92 
mmol) in THF (25 mL)] at 0 °c and stined for 1 h under argon atmosphere. Compound 
3,14a (810 mg, 4.61 mmol) in THF (4 mL) was added according to general procedure A 
The crude alkylated hydrazone was then hydrolyzed by adding acetic acid (2.0 mL, 34.6 
mmol), sodium acetate (941 mg, 6.92 mmol), water (400 ilL), and THF (1.6 mL) and the 
Chapter 8 206 
mixture was stirred at rt for 2.5 h. The crude product was purified by flash column 
chromatography (H/EA = 90/10) to give 650 mg (50%) of 3.15d as a colorless oil. 
FTIR (KBr), 1683, 1641, 1600, 1484, 1454, 1432, 1355, 1295, 1218, 1157, 1029,998, 902, 
773,742,669,628 em-I. 
IH NMR (500 MHz) <5 1.74-1.82 (m, 1H), 2.09 (dd, J= 14.5 Hz, 9.8 Hz, 1H), 2.13 (t, J= 
7.5 Hz, 2H), 2.18-2.29 (m, 3H), 2.63 (ddd, J = 15.1 Hz, 10.2 Hz, 4.3 Hz, 1H), 2.87 (dd, J= 
14.5,3.9 Hz, IH), 2.92-3.02 (m, 2H), 4.80 (s, IH), 4.87 (s, 1H), 4.97 (dd, J= 10.2 Hz, 1.2 
Hz, 1H), 5.04 (dd, J = 17.1 Hz, 1.6 Hz, 1H), 5.79-5.87 (m, 1H), 7.23 (d, J = 7.6 Hz, 1H), 
7.29 (t, J = 7.5 Hz, 1H), 7.45 (dt, J = 7.5 Hz, 1.2 Hz, 1H), 8.03 (d, J = 7.7 Hz, 1H). 
13C NMR (125 MHz) <5 27.7,28.3,31.8,34.8,36.1,45.4, 111.6, 114.6, 126.5, 127.4, 128.7 
132.4, 133.1, 138.2, 144.0, 146.4, 199.8. 
Micro. Found: C, 84.75; H, 8.33%, Cal cd. for C17H200: C, 84.95; H, 8.32%. 
4,7-Dimethylene-l-phenyl-10-undecen-l-one (3.15g) 
Acetophenone N,N-dimethyl hydrazone6 (696 mg, 4.29 mmol) was treated with freshly 
prepared LDA [from n-BuLi (1.6 M in hexane, 1.8 mL) and N,N-diisopropylamine (600 ilL, 
4.29 mmol) in THF (25 mL)] at 0 °C and stined for 1 h under argon atmosphere. The 
trienyl chloride 3.14b (530 mg, 2.86 mmol) in THF (4 mL) was added according to general 
procedure A. The crude alkylated hydrazone was then hydrolyzed by adding acetic acid 
(2.5 mL, 42.89 mmol), sodium acetate (1.17 g, 8.57 mmol), water (300 ilL), and THF (1.4 
mL and the mixture was stined at rt for 5 h. The crude product was purified by flash 
column chromatography (HIEA = 98/2) to give 620 mg (81 %) of 3.15g as a colorless oil. 
FTIR (KBr), 1687, 1643, 1596, 1581, 1448, 1357, 1321, 1203, 1180, 1000, 985, 908, 889, 
744,690,502 em-I. 
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IH NMR (500 MHz) 8 1.99 (t, J 7.5 Hz, 1H), 2.11-2.24 (m, 2H), 2.16-2.20 (m, 6H), 2.47 
(t, J = 7.5 Hz, 2H), 3.13 (t, J 7.8 Hz, 2H), 4.75 (s, 1H), 4.76 (s, 1H), 4.77 (s, 1H), 4.80 (s, 
1H), 4.96 (d, J 10.5 Ill), 5.03 (dd, J= 17.2 Hz, 1.5 Hz, IH), 5.78-5.86 (m, 1H), 7.46 
(t, J= 7.7 Hz, 2H), 7.56 (t, 7.4 Hz, 1H), 7.79 (d, J= 7.4 Hz, 2H). 
l3C NMR (125 MHz) 830.1,32.0,34.4,34.7,35.4,36.9, 109.2, 109.3, 114.5, 128.0, 128.6, 
133.0, 136.9, 138.4 148.3, 148.7, 199.7. 
Micro. Found: C, 85.05; H, 8.93%, Calcd. for C19H240: C, 85.02; H, 9.01%. 
(EZ)-6-Methylene-l-phenyl-9-decene-3-one oxime (3.16a) 
HO'1., 
N 
I 
The dienyl ketone 3.15a (1.37 g, 5.7 mmol), hydroxylamine hydrochloride (530 mg, 7.6 
mmol) and pyridine (700 ,uL, 8.5 mmol) were stirred in EtOH (30 mL) at rt for 1 h 
according to the general procedure B. The crude oxime (1: 1 mixture, based on analysis of 
IH NMR spectrum) was purified by flash column chromatography (HIEA 90/10) to give 
1.41 g (97%) of (EZ)-3.16a (1:1) as an inseparable mixture of oximes as a pale yellow oil. 
Data for (E/Z) - 3.16a 
FTIR(RJ3q 1643, 1604,1496,1454,1299,1166,1078,1031,997,962,910, 748,700,555 
~l 
cm . 
IH NMR (500 MHz) 8 2.01 (t, J = 7.4 Hz, 1H), 2.07-2.19 (m, 6H), 2.42-2.46 (m, 2H), 2.57 
(dd, J = 8.5 Hz, Hz, IH), 2.78 (dd, J = 16.5 Hz, 10.0 2H), 4.66 (s, 0.5 H), 4.68 (s, 
0.5 H), 4.70 (s, 0.5 H), 4.71 (s, 0.5 H), 4.88 (dd, J 10.1 1.6 Hz, IH), 4.96 (dd, J=17.1 
Hz, 1.8 Hz, IH), 5.69-5.78 (m, 1H), 7.07-7.20 (m, 3H), 7.21 (t, J= 7.6 Hz, 2H), 8.46 (bs, 
1H). 
Chapter 8 208 
l3C NMR (125 MHz) is 26.5, 30.0, 31.5, 31.6, 31.9, 31.9, 32.3, 32.5, 33.0, 35.3, 35.4, 36.0, 
109.7, 109.7, 114.6, 126.1, 126.1, 128.3, 128.4, 138.3, 141.3, 141.4, 147.9, 148.1, 160.7. 
Micro. Found: C, 79.04; H, 9.10; N, 5.34%. Calcd. for Cpl-bNO: C, 79.33; H, 9.00; N, 
5.44%. 
(EIZ/ S_ 4-Methylene-l-phenyl-7-octen-l-one oxime (3.16b) 
HO.., 
N 
I 
The dienyl ketone 3.16b (222 mg, 1.03 mmol) , hydroxylamine hydrochloride (153 mg, 
2.15 mmol) and pyridine (220 ilL, 2.58 mmol) were stilTed in EtOH (30 rnL) at rt for 2 h 
according to general procedure B. The crude (EZ)-3.16b (8:1.5, based on analysis of 'H 
NMR spectrum) was purified by column chromatography (H/EA 90110) to elute 166 mg 
(70%) of E-3.16b as a yellow oil first, and then 32.5 mg (14%) of Z-3.16b as a yellow oil, 
thus yielding the oxime in a combined yield of 84%. 
Data for E-3.16b 
FTIR (KBr) 1643, 1597, 1578, 1448, 1345, 1155, 1075,989,906,744,690 ern-I. 
IH NMR (500 MHz) is 2.14-2.20 (m, 4H), 2.27 (t, J= 8.1 Hz, 2H), 2.94 (t, J 8.2 Hz, 2H), 
4.78 (s, IH), 4.81 (s, IH), 4.95 (d, J= 10.2 Hz, IH), 5.01 (dd, J 17.5 Hz, 1.3 Hz, IH), 
5.76-5.84 (m, 1H), 7.37-7.39 (m, 3H), 7.58-7.60 (m, 2H), 8.49 (bs, IH). 
DC NMR (125 MHz) is 24.9, 31.9, 32.3, 35.3, 109.7, 114.6, 126.3, 128.7, 129.2, 135.6, 
138.4,148.2,159.5. 
Micro. Found: C, 78.28; H, 8.41; N, 6.17, Ca1cd. for C,sHI9NO: C, 78.56; 
6.11%. 
8.35; N, 
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Data for Z-3.16b 
lH NMR (500 MHz) 3 2.01-2.21 (m, 6H), 2.68 (t, J = 8.0 Hz, 2H), 4.73 (s, 1H), 4.76 (s, 
IH), 4.92-5.00 (m, 2H), 5.73-5.81 (m, IH)' 7.37-7.39 (m, 3H), 7.34-7.43 (m, 5H)' 8.69 (bs, 
IH). 
L3C NMR (125 MHz) 3 24.7,31.9,32.4,35.4, 109.7, 114.6, 126.3, 128.7, 129.2, 135.6, 
138.4, 148.2, 159.5. 
(EZ)-2-(2-Methylene-5-hexenyl) cyclohexanone oxime (3.16c) 
HO.., 
N 
I 
The dienyl ketone (280 mg, 1.47 mmol), hydroxylamine hydrochloride (154 mg, 2.21 
mm01) and pyridine (230 /-tL, 2.94 mmol) were stirred in EtOH (30 mL) at rt for 1 h 
according to general procedure B. The crude (EZ)-3.16c (4:2, based on analysis of LH NMR 
spectrum) was purified by flash column chromatography (IDEA = 90/10) to give 181 mg 
(60%) of E-3.16c as a colorless oil, as wel1 as 91 mg (30%) of Z-3.16c as a yellow oil. 
Data for E-3.16c 
FTIR (KBr) 1641, 1444, 1351, 1249, 1145,997,939,908,823,767,665 em-I. 
IH NMR (500 MHz) 31.36-1.40 (m, IH), 1.42-1.52 (m, IH), 1.54-1.62 (m, IH), 1.65-1.76 
(m,2H), 1.84 (ddd, J 4.3 8.1 Hz, 12.2 Hz, 1H), 2.05-2.09 (m, 3H), 2.15-2.22 (m, 2H), 
2.26 (ddd, J 4.5 Hz, 9.0 Hz, 14.0 1H)' 2.41 (ddd, J= 13.5 Hz, 8.5 Hz, 4.8 Hz, 1H), 
2.47 (dd, J= 13.8 5.4 Hz, IH), 2.75-2.81 (m, 1H), 4.74 (s, 1H), 4.80 (s, 1H), 4.95 (dd, 
J =10.2 Hz, 1.6 Hz, 1H), 5.02 (dd, J 17.2 Hz, 1.7 Hz, 1H), 5.77-5.85 (m, 1H), 8.73 (bs, 1 
H). 
L3C NMR (125 MHz) 323.3,23.6,26.1,31.8, 32.0, 34.8, 37.5, 39.6, 111.3, 114.5, 138.4, 
146.5, 162.7. 
Chapter 8 21 0 
Micro. Found: C, 75.14; H, 10.15; N, 6.72%, Calcd. for C\3H21NO: C, 15.31; 10.20; N, 
6.75%. 
Data for Z-3.16c 
IH NMR (500 MHz) 01.37-1.50 (m, 2H), 1.52-1.61 (m,2H), 1.72-1.75 (m, IH), 1.S6-1.90 
(m, IH), 2.14-2.31 (m, SH), 3.63-3.67 (m, IH), 4.79 (s, 2H), 4.93-5.05 (m, 2H), 5.78-5.S6 
(m, IH), 9.07 (bs, 1H). 
l3C NMR (125 MHz) 0 2004,26.8,28.1,28.7,30.1,31.8, 34.4, 36.7, 111.5, 114.4, 138.5, 
146.4, 163.0. 
(E)-2-(2-Methylene-S-hexenyl)-3, 4-dihydronaphthalene-l (2H)-one oxime (3.16d) 
HO.., 
N 
I 
The dienyl ketone 3.1Sd (165 mg, 0.69 mmol), hydroxylamine hydrochloride (120 mg, 
1.73 mmol) and pyridine (140 ilL, 1.73 mmol) were stirred in EtOH (30 mL) at rt for 1 h 
according to general procedure B. The crude oxime 3.16d (single isomer, based on analysis 
of IH NMR spectrum) was purified by flash column chromatography (HIEA 90/10) to 
give 141 mg (80%) of (E)-3.16d as a white solid. 
FTIR (KBr) 1644, 1598, 1488,1454,1353,1313,1124,1095,1054,1037,964,892,767, 
730,665 em-I. 
IH NMR (500 MHz) 0 1.78-1.92 (m, 2H), 2.13 (q, J 13.7 Hz, 11.1 Hz, 1H), 2.20 (t, J= 
5.8 Hz, 1H), 2.23-2.26 (m, 2H), 2.32 (m, IH), 2.50 (dd, J 4.2 Hz, 13.8 Hz, 1H), 2.65 (td, 
J = 16.7 Hz, 4.0 Hz, 1H), 2.95 (ddd, J 17.1 Hz, 11.9 Hz, 5.3 Hz, IH), 3.74-3.79 (m, 1H), 
4.80 (s, 1H), 4.85 (s, 1H), 4.97 (d, J 10.3 Hz, IH), 5.05 (dd, J= 17.3 Hz, 1.1 1H), 
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5.81-5.89 (m, 1H), 7.15 (d, 7.5 Hz, 1H), 7.19 (t, J= 7.4 Hz, 1H), 7.27 (dt, J= 7.6 Hz, 
1.0 Hz, 1H), 7.88 (d, Hz, 1H), 9.23 (bs, 1H). 
13C NMR (125 MHz) 8 23.9,24.7,29.5,31.9,34.4,35.0, 111.9, 114.5, 124.4, 126.3, 128.9, 
129.2, 129.9, 138.5, 138.7, 146.5, 158.2. 
Micro. Found: C, 79.68; H, 8.29; N, 5.42%. Calcd for C17H20NO: C, 79.96; H, 8.28, N, 
5.48%. 
(EZ)-4,7-Dimethylene-l-phenyl-1O-undecen-l-one oxime (3.16g) 
HO 
"'" N I 
The trienyl ketone 3.15g (540 mg, 2.01 mmol), hydroxylamine hydrochloride (329 mg, 4.7 
mmol) and pyridine (400 JlL, 5.03 mmol) were stirred in EtOH (30 mL) at rt for 3 h 
according to general procedure B. The crude (EZ)-3.16g (9: 1, based on analysis of lH NMR 
spectrum) mixture was purified by flash column chromatography (H/EA 93/7) to give 
480 mg (84%) of (E)-3.16g as a colorless oil as well as 63 mg (11 %) of (Z)-3.16g as a 
yellow oil. 
Data for (E)-3.16g 
FTlR (KBr) 1949, 1643, 1598, 1575, 1498, 1446, 1319, 1303, 1157, 1070,998,931,890, 
765,694 cm l. 
lH NMR (500 MHz) 82.10 (t, J Hz, 2H), 2.14-2.21 (m, 6H), 2.28 (t, J 8.2 Hz, 2H), 
2.96 (t, J = 8.1 Hz, 2H), 4.73 (s, 2H), 4.79 (s, IH), 4.80 (s, IH), 4.95 (dd, J 10.3 Hz, 1.2 
Hz, IH), 5.02 (dd, J 17.2 
7.60 (m, 2H) 9.20 (bs, IH). 
1.7 Hz, HI), 5.77-5.85 (m, IH), 7.37-7.40 (m, 3H), 7.58-
13 C NMR (125 MHz) 024.9,31.9,32.2,34.3,34.3,35.4,109.3, 109.5,114.5, 126.3,128.6, 
129.2, 135.5, 138.4, 148.5, 148.7, 159.4. 
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Micro. Found: C, 80.24; H, 8.75; N, 4.85%. Calcd for CI9H2SNO: C, 80.52; H, 8.75; N, 
4.94%. 
Data for (Z)-3.16g 
IH NMR (500 MHz) 0 2.06-2.11 (m, 4H), 2.16-2.22 (m, 4H), 2.64-2.72 (m, 2H), 4.71-4.76 
(m, 4H), 4.95 (dd,./ 10 Hz, 1 Hz, HI), 5.00-5.02 (m, IH), 5.76-5.85 (m, IH), 7.36-7.43 
(m, 5H), 8.68 (bs, IH). 
l3C NMR (125 MHz) 0 31.9, 32.7, 33.8, 34.2, 34.2, 35.4, 109.2, 109.5, 109.7, 114.5, 127.7, 
128.2, 128.5, 128.9, 133.2, 138.4, 147.9, 148.6, 158.3. 
(EZ)-6-::Wethylene-1-phenyl-9-decene-3-one O-pentafluorobenzoyloxime (3.17a) 
To a solution of (EZ)-3.16a [(1: 1), 1.41 g, 5.5 mmol] and TEA (1.6 mL, 10.9 mmol) in 
DCM (20 mL) at 0 °C was added C6FsCOCl (1.6 g, 7.1 mmol) in DCM (5 mL) and stirred 
for 30 min according to general procedure C. The crude (EZ)-3.17a (1:1, based on IH NMR) 
was purified by flash column chromatography (H/EA = 95:5) to give 2.29 g (95%) of an 
inseparable mixture of (EZ)-3.17a (1:1, based on analysis of IH NMR spectrum) as a pale 
yellow oil. 
Data for (EZ)-3.17a 
FTIR (KBr) 1760,1650,1523,1506,1454,1417,1326,1189,1091,1002, 906, 862, 750, 
700,509 em-I. 
NMR (500 MHz) 02.01 (t, 7.4 Hz, 1H), 2.07-2.19 (m, 6H), 2.42-2.46 (m, 2H), 2.57 (dd, 
8.5 5.5 Hz, 1H), 2.78 (dd,./= 16.5 Hz, 10.0 Hz, 2H), 4.66 (s, 0.5 H), 4.68 (s, 0.5 H), 
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4.70 (s, 0.5 H), 4.71 (s, 0.5 H), 4.88 (dd, J= 10.1 Hz, 1.6 Hz, 1H), 4.96 (dd, J=17.1 Hz, 1.8 
Hz, IH), 5.69-5.78 (m, IH), 7.07-7.20 (m, 3H), 7.21 (t, J= 7.6 Hz, 2H), 8.46 (bs, 1H)). 
13C NMR (125 MHz) 826.4,29.9, 31.5, 31.6, 31.9, 31.9, 32.3, 32.5, 33.0, 35.3, 35.4, 36.0, 
109.7, 109.7, 114.6, 126.1, 126.1, 128.3, 128.4, 138.3, 141.3, 141.4, 147.9, 148.1, 160.7. 
Micro. Found: C, 64.08; H, 5.04; N, 3.08%. Calcd for C24FsH22N02: C, 63.85; H, 4.91; N, 
3.10%. 
(E)-4-Methylene-l-phenyl-7-octen-l-one O-pentafluorobenzoyloxime (3.17b) 
To a solution of E-3.16b (146 mg, 0.63 mmol) and TEA (330 p,L, 2.4 mmol) in DCM (20 
mL) at 0 °C was added C6FsCOCl (235 mg, 1.02 mmol) in DCM (5 mL) and stirred for 1.5 
h according to general procedure C. The crude oxime was purified by silica 
chromatography (H/EA = 95/5) to give 233mg (87%) of (E)-3.17b as a white solid. 
Data for (E)-3.17b 
FTIR (KBr), 1766, 1648, 1523,1498,1444,1419,1326,1195,1095,1004,946,904,865, 
769,694 em-I. 
IHNMR (500 MHz) 8 2.11-2.14 (m, 4H), 2.27 (t, J= 8.3 Hz, 2H), 3.03 (t, J= 8.3 Hz, 2H), 
4.78 (s, 1H), 4.80 (s, IH), 4.91-4.97 (m, 2H), 5.70-5.79 (m, IH), 7.44 (t, J= 7.3 Hz, 2H), 
7.49 (t, J= 7.3 Hz, 1H), 7.74 (d, J= 7.5 Hz, 2H). 
13 C NMR (125 MHz) 8 27.5, 31.7, 32.7, 35.0, 107.0, 110.4, 114.6, 127.4, 127.6, 128.0, 
128.6, 128.8, 131.1, 132.9, 136.7-136.9 (overlapping m), 137.9, 138.7-138.9, 142.4-142.5, 
144.4-144.5, 146.4-146.5 (overlapping m), 146.9, 156.5, 168.4. 
Micro. Found: C, 62.29; H, 4.42; N, 3.38%, Calcd for C22FsHIsN02: C, 62.41; H, 4.28; N, 
3.31%. 
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(E)-2-(2-Methylene-5-hexenyl) cyclohexanone O-pentaflnorobenzoyloxime (3.17c) 
To a solution of the E-3.16c (111 mg, 0.57 mmol) and TEA (160 p,L, 1.14 mmol) in DCM 
(20 mL) at 0 °C was added C6FsCOCI (171 mg, 0.74 mmol) in DCM (5 mL) and stined for 
2 h according to general procedure C. The crude product was purified by flash column 
chromatography (H/EA 95:5) to give 176 mg (77%) of E-3.17c as a clear oil along with 
20% of recovered starting material. 
Data for E-3.17c 
FTIR(KBr), 1752, 1652,1523,1508,1448,1419,1326,1197,1141,1093,1002, 873, 759, 
698 em-I. 
'H NMR (500 MHz) S 1.54-1.62 (m, 2H), 1.68-1.78 (m, 3H), 1.87-1.93 (m, 1H), 2.11 (t, J 
7.5 Hz, 2H), 2.15-2.25 (m, 3H), 2.52 (ddd, J =13.6 Hz, 6.5 Hz, 6.5 Hz, 2H), 2.62-2.66 (m, 
1H), 2.67-2.74 (m, IH), 4.79 (s, 1H), 4.84 (s, IH), 4.96 (d, J =10.1 Hz, IH), 5.03 (dd, J = 
17.1 Hz, 1.45 Hz, 1H), 5.77-5.85 (m, IH). 
l3C NMR (125 MHz) S 22.6,25.9,26.4,31.6,31.8,34.7,37.2,39.9, 107.5 (complex), 11.8, 
114.6, 137.7 (d complex, J 254 Hz), 138.2, 143.2 (d complex, J 258 Hz), 145.3 (d 
complex, J= 250Hz), 145.8, 156.9, 173.1. 
Micro. Found: C, 60.06; H, 5.11; N, 3.55%. Calcd for C2oFsH2oN02: C, 59.84; H, 5.02, N, 
3.48%. 
Chapter 8 
(E)-2-(2-Methylene-5-hexenyl)-3,4-dihydronaphthalene-l(2H)-one O-pentafluoro-
benzoyloxime (3.17d) 
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To a solution of the E-3.16d (97 mg, 0.38 mmol) and TEA (115 ilL, 0.76 mmol) in DCM 
(15 mL) at 0 °C was added C6FsCOCI (114 mg, 0.49 mmol) in DCM(5 mL) and stirred for 
2 h according to general procedure C. The crude product was purified by flash column 
chromatography (H/EA 95:5) to give 142 mg (75%) of (E)-3.17d as a white solid. 
FTIR (KBr), 1762, 1652, 1523, 1452, 1417, 1326, 1251, 1193, 1091,1002,946,904,865, 
769, 730 em-I. 
IH NMR (500 MHz) a 1.87-1.95 (m, 2H), 2.02-2.13 (m, 4H), 2.20 (dd, J = 14.0 Hz, 10.5 
Hz, 1 H), 2.31 (dd, J 3.8 Hz, 1H), 2.71 (dt, J = 16.7 Hz, 4.0 IH), 2.97 (ddd, J 
17.3 Hz, 11.6 Hz, 6.0 HZ,1H), 3.65-3.70 (m, 1H), 4.77 (8, 1H), 4.84 (8, IH), 4.87(8, 2H), 
4.91 (dd, J = 8.2 Hz, 1.4 Hz, 2H), 5.65-5.73 (m, 1H), 7.17 (d, J= 7.7 Hz, IH), 7.23 (t, J = 
7.5 Hz, IH), 7.36 Cdt, J 7.5 Hz, 1.2 1H), 8.15 (d, J = 7.7 Hz, 1H). 
13C NMR (125 MHz) a 24.0, 24.2,31.7,31.9,34.1,35.7, 107.4, 112.8, 114.5,126.3, 126.5, 
126.6, 127.5, 129.1, l31.4,137.7 (d complex, 255 Hz), 137.80, 140.0, 143.4 (d complex, 
271 Hz), 145.1 , 145.2 (d complex, 257 Hz), 156.5, 166.5. 
Micro. Found: C, 63.87; H, 4.57; N, 3.16%. Calcd for C24F5H2oN02: C, 64.14; H, 4.48, N, 
3.11%. 
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(E)-4, 7-Dimethylene-l-phenyl-lO-undecen-l-one O-pentafuorobenzoyloxime (3.17g) 
To a solution of the trienyl ketone oxime E-3.16g (359 mg, 1.26 mmol) and TEA (350 ILL, 
2.53 mmol) in DCM (20 mL) at 0 °C was added C6FsCOCl (496 mg, 2.14 mmol) in DCM 
(5 mL) and stirred for 2 h at that temperature according to general procedure C. The crude 
product was purified by flash column chromatography (HIEA = 98:2) to give 486 mg (80%) 
of (E)-3.17g as a clear viscous oil. 
FTIR (KEr), 1760, 1650, 1604, 1521, 1506, 1455, 1417, 1324, 1197, 1091, 1002,948, 865, 
750,698 em-I. 
I H NMR (500 MHz) 8 2.04-2.10 (m, 4H), 2.12-2.18 (m, 4H), 2.28 (t, J= 7.9 Hz, 2H), 3.04 
(t, J = 8.2 Hz, 2H), 4.66 (s, IH), 4.70 (s, IH), 4.77 (s, IH), 4.80 (s, IH), 4.95 (d, J = 10.9 
Hz, IH), 5.01 (dd, J = 17.1 Hz, 1.5 Hz, IH), 5.75-5.83 (m, IH), 7.44 (t, J = 7.4 Hz, 2H), 
7.49 (t, J= 7.3 Hz, IH), 7.74 (d, J= 7.2 Hz, 2H). 
13C NMR (125 MHz) 8 27.5, 31.9, 32.8,34.0,34.1, 35.3, 107.0 (complex), 109.1, 110.2, 
114.5,127.4,128.8, 131.1, 133.0, 137.7 (d complex, J= 242 Hz), 138.2, 143.4 (d complex, 
J= 246 Hz), 145.4 (d complex, J= 260 Hz), 143.7, 148.4, 156.4, 168.3. 
Micro. Found: C, 65.70; H, 5.28; N, 2.94%. Calcd for C24FsH24N02: C, 65.40; H, 5.06, N, 
2.93%. 
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(EZ)-6-Methylene-l-phenyl-9-decene-3-one 0-2,4-dichlorobenzoyloxime (3.17h) 
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To a solution of the dienyl ketone oxime 3.16a (265 mg, 1.03 mmol) and TEA (300 /-tL, 
2.06 mmol) in DCM (15 mL) at 0 °C was added 0-2,4-dichlorobenzoyl chloride (0.2, 1.34 
mmol) in DCM (5 mL) and stirred for 30 min according to general procedure C. The clUde 
product (1:1, based on analysis of IH NMR spectmm) was purified by flash column 
chromatography (HIEA = 95:5) to give 400 mg (90%) of an inseparable mixture of (EIZ)-
3.17h (1: 1) as a cream solid. 
Data for (EIZ)-3.17h 
IH NMR (500 MHz) 82.10 (t, J= 7.4 Hz, 2H), 2.11-2.19 (m, 2H), 2.23 (t, J= 8 Hz, IH), 
2.30 (t, J= 8 Hz, 1H), 2.43 (t, J= 6.5 Hz, IH) 2.59 (t, J= 7.5 Hz, 1H), 2.70-2.76 (m, 2H), 
2.87 (t, J = 7.5 Hz, IH), 2.96 (t, J = 7.5 Hz, IH), 4.76 (s, 1 H), 4.79 (s, 0.5 H), 4.80 (s, 0.5 
H), 4.93-4.98 (m, IH), 5.00 (m, 0.5 H), 5.02 (m, 0.5H), 5.73-5.84 (m, IH), 7.17-7.32 (m, 
8H). 
l3C NMR (125 MHz) 8 28.7, 31.7, 31.8, 31.9, 32.0, 32.2, 32.3, 43.9, 35.2, 36.0, 110.2, 
110.5, 114.7, 126.4, 126.6, 128.1, 128.3, 128.5, 128.6, 136.1, 137.9, 138.0, 139.4, 139.8, 
140.3, 141.7, 143.6, 145.0, 146.7, 147.0, 147.1, 156.5, 170.9, 171.0. 
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7 -Meihylen e-2-ph eneihyl-l-aza-s piro [4.4] n on-l-ene (3.18a) 
Pd(PPh3)4 (26 mg, 0.020mmol) was added to a suspension of (EIZ)-3.17a (102 mg, 020 
mmol), (200 p.L, L 1 mmol) and molecular sieves 4A (150 mg) in dry DMF (0.05 M) 
under argon atmosphere at rt and stirred at 110°C for 30 min according to general 
procedure D. The residue was purified by flash column chromatography (H/EA = 9515-
90110) to 42 mg (77%) of3.17a as a yellow oiL 
FTIR (KBr) 1641, 1604, 1496, 1454, 1428, 1311, 1085, 1031,875, 750, 700 em-I. 
IH NMR (500 MHz), 0 1.62 (ddd, J = 12.5 Hz, 7.3 Hz, 5.5 Hz, 1H), 1.71-1.79 (m, 2H), 
1.93 (dd, J 8.5 Hz, 12.0 Hz, IH), 2.22 (d, J = 15.5 Hz, 1H), 2.34-2.40 (m, IH), 2.46-2.49 
(t, J= 7.7 Hz, 2H), 2.56 (dd, J= 17.5 Hz, 2.0 Hz, 2H), 2.63(t, J 7.8 2H), 2.90 (t, J= 
7.9 Hz, 2H), 4.87 (s, 2H), 7.17 (d, J = 72 Hz, 1H), 7.21 (d, 7.2 2H), 7.27 (t, J= 7.5 
Hz,2H). 
13C NMR (125 MHz) 0 31.3, 32.9, 34.4, 35.4, 37.3, 39.0, 46.3, 82.1, 106.1, 125.7, 128.3, 
128.3, 141.3, 150.9, 175.2. 
HRMS [FAB+] [MHt: Found: 240.1727; Calcdfor C17H22N :240.1727. 
7-Methylene-2-phenyl-l-aza-spiro[4.4 ]non-l-ene (3, 1Sb) 
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Pd(PPh3)4 (20 mg, 0.017mmol) was added to a suspension of E-3.17b (73.4 mg, 0.17 
mmol), TEA (120 ilL, 0.86 mmol) and molecular sieves 4A (150 mg) in dry DMF (0.05 M) 
under argon atmosphere at rt and stirred at 110°C for 30 min according to general 
procedure D. The residue was purified by preparative thin layer chromatography (H/EA = 
812) to give 29.5 mg (82%) of 3.18b as a yellow oil. 
FTIR (KBr), 1660, 1614, 1575, 1494, 1448, 1428, 1340, 1299, 1240, 1340, 1299, 1178, 
1074,1029,919,875,759,692,557 em-I. 
lH NMR (500 MHZ) 8 1.73 (ddd, J = 12.5 Hz, 7.5 Hz, 4.5 Hz, 1H), 1.91-1.96 (m, 2H), 
2.09 (ddd, J = 12.2 Hz, 8.6 Hz, 3.6Hz, 1H), 2.33 (d, J = 15.9 Hz, 1H), 2.39-2.46 (m, 1H), 
2.62-2.67 (m, 1H), 2.71 (dd, J= 15.8 Hz, 1.9 Hz, 1H), 2.99 (t, J= 7.5 Hz, 2H), 4.91 (s, 2H), 
7.37-7.40 (m, 3H), 7.82 (dd, J= 7.3 Hz, 1.8 Hz, 2H). 
l3C NMR (125 MHZ) (CDCh); 8 31.4, 34.4, 34.9, 39.2, 46.5, 82.8, 106.1, 127.7, 128.3, 
130.2 134.8, 151.0, 170.6. 
Micro. Found: C, 85.02; H, 8.17; N, 6.57, Calcd for CIsH17N: C, 85.26; H, 8.10; N, 6.62%. 
3',3 'a,4' ,5' ,6', 7'-hexahydro-3-methylene-spiro [cyclopentane-1,2 '-[2H]indole] (3.18c) 
Pd(PPh3)4 (13.5 mg, 0.012mmol) was added to a suspension of E-3.17c (47 mg, 0.12 
mmol), TEA (80 ilL, 0.58 mmol) and molecular sieves 4A (150 mg) in dry DMF (0.05 M) 
under argon atmosphere at rt and stirred at 110°C for 30 min according to general 
procedure D. The residue was purified by flash column chromatography (HiAcetone = 
85115) to give 14 mg (64%) of diastereomer mixture (1: 1, based on analysis of IH NMR 
spectrum) of 3.18c as a yellow oil. 
Chapter 8 220 
FTIR (KBr), 1654, 1648, 1430, 1348 1309, 1276, 1166,1083,1029,977,873,804 em-I. 
IH NMR (500 MHz) 8 1.08-1.18 (m, HI), 1.32-1.49 (m, 3H), 1.58-1.64 (m, 0.5 H), 1.67-
1.86 (m, 2H), 1.93-2.02 (m, IH), 2.03-2.27 (m, 4H), 2.27-2.42 (m, 2H), 2.49-2.78 (m, 3.5 
H), 4.83-4.94 (m, 2H). 
!3C NMR (125 MHz) 8 25.28, 25.30, 26.7, 26.8,31.26,31.30,31.9,34.9,35.0,38.8,40.6, 
41.7,41.9,46.2,47.9,48.0,48.2,80.5,80.6, 106.0, 106.1, 151.0, 177.1. 
HRMS FAB [MHt: Found: 190.1562; Calcd for C13H20N: 190.1596 
3,3 a,4,5-tetrahydro-3 '-methylene-spiro [2H-benz[g ]indole-2,1' -cyclopentane] (3.18d) 
Pd(PPh3)4 (20.8 mg, 0.018 mmol) was added to a suspension of E-3,17d (82 mg, 0.18 
mmol), TEA (130 ilL, 0.91 mmol) and molecular sieves 4A (150 mg) in dry DMF (0.05 M) 
under argon atmosphere at rt and stirred at 110°C for 30 min according to general 
procedure D. The residue was purified by preparative thin layer chromatography (HIEA = 
80120) to give 34.5 mg (80%) of diastereomer mixture (1:1, based on analysis of IH NMR 
spectrum) of 3.18d as a yellow oil. 
FTIR (KBr), 1658 1619, 1602, 1569, 1481, 1459,1430, 1355, 1342, 1274, 1247, 1153, 1074, 
1029,871, 767, 730, 663 em-I. 
IH NMR (500 MHz) 8 1.48 (dd, J 19.8 Hz, 8.8 Hz, IH), 1.63 (dd, J 12.9 4.6 Hz, 
IH), 1.55-1 (m, 1.5 H), 1 1.83 (m, 1H), 2.19-2.45 (m, 5H), 2.56-2.70 (m, 1H), 2.85-
3.06 (m, 3.5 H), 4.80-4.93 (m, 2H), 7.17 (d, J= 7.6 Hz, IH), 7.22 (t, J= 1H),7.31 
(t, J = 7.4 Hz, IH), 8.10 (d, 7.7 Hz, IH) . 
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l3C NMR (125 MHz) 0 29.9, 29.9, 29.9, 30.0, 31.4, 31.4, 37.1, 40.4, 42.2, 42.3, 44.5, 46.6, 
46.7,47.7,80.9,80.9, 105.9, 106.1, 126.1, 126.3, 128.7, l30.2, l30.3, l30.5, 140.8,151.0, 
151.1,171.5. 
Micro. Found: C, 85.74; H, 8.11; N, 6.09%. Calcd for C17H19N: C, 86.02; H, 8.06, N, 
5.90%. 
9-Methylene-2-phenyl-1-aza-dispiro[4.1.4.2]tridec-1-ene (3.18g and 19) 
3.18g 
Pd(PPh3)4 (23.6 mg, 0.02 mmol) was added to a suspension of E-3.17g (98 mg, 0.20 
mmol), TEA (140 pL, 1.0 mmol) and molecular sieves 4A (150 mg) in dry DMF (0.05 M) 
under argon atmosphere at rt and stirred at 110 °C for 30 min according to the general 
procedure D. The residue was purified by preparative thin layer chromatography (H/Et20 = 
80/20) to give 24 mg (44%) of the major isomer (18g or 19) as a yellow oil, and 18 mg 
(33%) of the minor isomer (18g or 19) as a low Rf fraction. Thus, 3.18g and 19 were 
isolated in a combined yield of 77%, and the configuration was not assigned. 
Data for major isomer 
FTIR (KBr),1658, 1614, 1575, 1494, 1448, 1428, l342, l305, 1176, 1014, 987, 917, 875, 
759, 692, 665, 559. 
lH NMR (500 MHz) 0 1.63-1.70 (m, 2H), 1.71-1.87 (m, 4H), 1.96-2.08 (m, 4H), 2.29 (s, 
2H), 2.35 (t, J = 8.2 Hz, 2H), 2.92-2.96 (m, 2H), 4.83-4.86 (m, 2H), 7.36-7.40 (m, 3H), 
7.81-7.83 (m, 2H). 
l3C NMR (125 MHz) 0 31.4, 34.9, 36.9, 37.7, 39.7, 40.1, 47.7, 50.0, 51.4, 83.3, 105.4, 
127.6,128.3, l30.1, l35.0, 152.8, 169.5. 
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Micro. Found: C, 85.74; H, 8.69; N, 5.14%. Calcd for C19H23N: C, 85.98; H, 8.73, N, 
5.27%. 
Data for minor isomer 
lH NMR (500 MHz) 8 1.60-1.81 (m, 6H), 1.84 (ddd, J = 12.8 Hz, 5.5 Hz, 7.6 Hz, IH), 
1.95-2.07 (m, 4H), 2.34-2.41 (m, 3H), 2.89-2.98 (m, 2H), 4.82 (s, IH), 4.86(s, IH), 7.36-
7.41 (m, 3H), 7.82 (dd, J= 7.7 Hz, 1.8 Hz, 2H). 
13C NMR (125 MHz) (CDCh) 8 = 31.5, 34.9, 36.9, 37.8, 39.6, 40.0, 47.8,50.0, 51.4, 109.3, 
114.5, 127.6, 128.0, 128.6, 133.0, 152.5, 169.0. 
8.4 Experimental Work Described in Chapter Four 
Oximes 4.9a,16 4.9bb,17 4.18a_cI8 and hydroxamoyl chloride 4.10C19 were prepared by the 
literature methods. 
(E)-l-N-allyl-N-benzyl-N -hydroxy-2-phenylefhanimidamide (4.1h) 
(EIZ)-4.9a (1: 1) (400 mg, 2.96 mmol), NCS (400 mg, 2.99 mmol) and N-allyl benzyl amine 
(849 mg, 3.55 mmol) in dry DMF (25 mL) were reacted according to general method E and 
the residue purified by flash column chromatography (PE/EA = 9/1 then 8/2) to give 525 
mg (63%) of (E)-4.11a as a yellow crystalline solid. 
lH NMR (500 MHz) 8 3.72 (d, J= 5.5Hz, 2H, NCH2CH), 3.98 (s, 2H, PhCH2CN), 4.32 (s, 
2H, NCH2Ph), 5.09 (dd, J= 22 Hz, 10 Hz, 2H, CHCH2), 5.67-5.75 (m, IH, CHCH2), 7.13 
(d, J= 8 Hz, 2H, Ar), 7.20-7.23(m, 2H, Ar), 7.26-7.34 (m, 6H, Ar). 
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l3C NMR (75 MHz) 8 30.4 (PhCH2CN), 49.9 (NCH2CH), 50.4 (NCH2Ph), 116.8 (CHCH2), 
126.4, 126.9, 127.1, 128.3, 128.5, 128.6 (Ar), 133.5 (CHCH2), 136.2, 138.3 (Ar), 159.1 
TOF MS ES+[MHt: Found. 281.2135; Calcd for C18H21N20: 281.1654. 
(E)-l-N-allyl-N-benzyl-N' -hydroxy-3-phenyl propanimidamide ( 4.11 b) 
(a) (EIZ)-4.10b (3:2) (235 mg, 1.57 mmol), NCS (211 mg, 1.59 mmol) and N-allyl benzyl 
amine (276 mg, 1.88 mmol) in dry DMF (25 mL) were reacted according to general method 
E and the residue purified by flash column chromatography (PE/EA 9/1 then 8/2) to give 
370 mg (61 %) of (E)-4.11b as a cream solid. 
IH NMR (500 MHz) 8 2.80-2.94 (m, 2H, CH2CH2), 3.73 (d, J = 5.5 2H, NCH2CH), 
4.31 (s, 2H, NCH2Ph), 5.08-5.16 (m, 2H, CHCH2N), 5.74-5.82 (m, IH, CHCH2), 7.20 (t, J 
7.5 Hz, 4H, Ar), 7.23-7.33 (m, 6H, Ar). 
I3 C NMR (75 MHz) 0 27.0 (PhCH2), 32.6 (PhCH2CH2), 49.9 (NCH2CH), 50.5 (PhCH2N), 
116.8 (CH2CH), 126.2, 127.0, 127.2, 128.4, 128.4, 128.5 (Ar), 133.8 (CH2CH), 138.4, 
141.4 (Ar), 160.8 (C=N). 
TOF MS ES+(MHt: Found: 295.1694; Calcd for C19H22N20: 295.1810. 
(b) (E)-3-phenylpropanoyl chloride oxime (4.10b) 
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(EIZ)-4.9b (3:2) (1.87 g, 12.61 mmol), and NCS (1.68 mg, 12.61 mmol) in dry DMF (25 
mL) were reacted according to the modified general method E. Work up as for 4.11b gave 
2.0 g (87%) of (E)-3b as a yellow oily solid. 
IH NMR mixture (300 MHz) 82.77-2.82 (m, 2H, PhCH2CH2), 2.94-2.99 (m, 2H, PhC 
H2CH2), 7.18-7.32 (m, 5H, Ar), 8.15 (bs, IH, OH). 
A solution of (E}-4.10b (50 mg, 0.27 mmol) and N-allyl benzyl amine (40 mg, 0.27 mmol) 
in dry DMF (20 mL) was stirred at 50-70° C for 2 h. Workup as described in general 
procedure E, followed by purification by flash column chromatography (PE/EA = 9/1 then 
8/2) gave 56 mg (66%) of (E}-4.11b as a cream solid. 
IH NMR & l3C NMR data as above. 
(EZ)-MethyI2-[aUyl(benzyl)amino](hydroxyimino)acetate (4.11c) 
A solution of (EIZ}-4.10c (6:5) (502 mg, 4.0 mmol) and N-allyl benzyl amine (586 mg, 4.0 
mmol) in dry DMF (20 mL) was stirred at 50-70° C for 2 h. Workup as described in 
general procedure E, followed by purification by flash column chromatography (PE/EA = 
80140) gave 748 mg (75%) of (EZ}-4.11c (6:5, based on analysis of lH NMR spectrum) as a 
yellow solid. 
IH NMR (300 MHz): 83.63 (d, J= 6 Hz, 2H, NCH2CH, major), 3.73 (s, 3H, CH3, minor), 
3.78 (d, J= 7 Hz, 2H, CH2CHCH2, minor), 3.89 (s, 3H, CH3, major), 4.26 (s, 2H, NCH2Ph, 
major), 4.44 (s, 2H, NCH2Ph, minor), 5.09-5.21 (m, 2H, CHCH2, minor & major), 5.69-
5.93 (m, IH, CHCH2, minor & major), 7.23-7.35 (m, 5H, Ar, minor & major), 7.49 (bs, IH, 
C=NOH, major), 9.16 (bs, IH, C=NOH, minor). 
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l3C NMR (75 MHz) 849.7 (NCH2CH, minor), 50.8 (NCH2Ph, minor), 52.4 (CH3, minor), 
major), 52.6 (NCH2CH, major), 53.5 (NCH2Ph, major), 117.9 (CHCH2, major), 
118.3 (CHCH2, minor), 127.2, 127.5, 127.8, 128.0, 128.4, 128.5, (Ar, major & minor), 
132.1, 134.4 (NCH2CHCH2, major & minor), 136.3 (Ar, minor), 137.9 (Ar, minor & 
major), 146. 4 (C=O, major), 154.4 (C=O, minor), 162.5 (C=N, major), 162.7 (C=N, 
minor). 
TOFMS [MHt: Found: 249.1142; Calcd for C19H22N20: 249.1239. 
(1-EZ)-N-allyl-N'-hydroxy-3-phenylpropanimidamide (4.14) 
.OH 
N 
Ph~N~ 
H 
(E/Z)-4.9b (3:2) (399 mg, 2.67 mmol), NCS (357 mg, 2.67 mmol) and allyl amine (276 mg, 
1.88 mmol) in dry DMF (25 mL) were reacted according to general method E and the 
residue purified by flash column chromatography (PE/EA = 10120) to give 441 (81 %) 
of (E)-4.14 as a colorless oil. 
lH NMR mixture (300 MHz) (5 2.38 (t, J= 13.5 Hz, 2H, PhCH2), 2.79 (t, 13.5 2H, 
CH2CH2), 3.62 (m, 2H, NHCH2), 4.99-5.16 (m, 2H, CHCH2), 5.35 (bs, IH, NH), 5.54-5.56 
(m, IH, CHCH2), 7.08-7.20 (m, 5H, Ar), 8.76 (bs, IH, C=NOH). 
l3C NMR (75 MHz) (j 30.3 (PhCH), 32.8 (PhCHCH), 44.2 (NHCH2), 115.5 (CHCH2), 
125.9,128.1,128.3 (Ar), 135.5 (CHCH2), 141.0 (Ar), 154.6 (C=N). 
TOF MS ES+[Elt: Found: 204.1262; Cal cd for C12HI6N20: 204.12626. 
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(E)-1-N-allyl-N-benzyl-2-phenyl-N' -[ (pentafluorobenzoyl)oxy] ethanimid amide (4.12a) 
A solution of (E)-4.11 a (461 mg, 1.64 mmol), TEA (300 ilL, 2.14 mmol), and C6FsCOCl 
(492 mg, 2.14 mmol) in dry DCM (30 mL) was reacted as descIibed in general procedure F, 
and the crude product puIified by flash column chromatography (PE/EA = 9812) to give 
650 mg (83%) of (E)-4.12a as a colorless oil. 
lH NMR (500 MHz) 83.87 (d, J= 5 Hz, 2H, NCH2CH), 3.98 (s, 2H, PhCH2CN), 4.50 (s, 
2H, NCH2Ph), 5.16 (dd, J= 24 Hz, 10 Hz, 2H, CHCH2), 5.73-5.81 (m, IH, CHCH2), 7.19 
(t, J= 8 Hz, 4H, Ar), 7.27 (t, J = 7 Hz, 2H, Ar), 7.32 (t, J= 7 Hz, 4H, Ar). 
13C NMR (75 MHz): (j = 32.2 (PhCH2CN), 50.0 (NCH2CH), 50.5 (NCH2Ph), 107.9 (m, C-
F), 117.6 (CHCH2), 126.9, 127.3, 127.4, 127.7, 128.6, 129.1, 132.5 (Ar) , 134.5 (CHCH2), 
135.7-139.5 (m, C-F), 140.9-144.9 (m, C-F), 143.2-147.1 (m, C-F), 156.9 (OCOC6FS), 
164.9 (C=N). 
Micro. Found: C = 63.44, H = 4.08, N = 5.68; Calcd for C24H17FsN202: C = 63.29, H = 
4.04, N = 5.90. 
(E)-1-N-allyl-N-benzyl-3-phenyl-N'- [(pentafluorobenzoyl)oxy] propanimid amide 
(4.12b) 
Chapter 8 
A solution of (hj-4.11b (273 mg, 0.93 mmol), TEA (150 I-lL, 0.99 mmol) and C6F5COCI 
(229 mg, 0.99 mmol) in dry DCM (30 mL) was reacted as described in general procedure F, 
and the crude product purified by flash column chromatography (PE/EA 9812) to give 
393 mg (87%) of (E)-4.12b as a white solid. 
lH NMR (500 MHz) 02.81-2.91 (m, 4H, CH2CH2), 3.83 (d, J = 5.5 Hz, 2H, NCH2CH), 
4.44 (s, 2H, NCH2Ph), 5.12-5.19 (m, 2H, CHCH2), 5.76-5.83 (m, IH, CHCH2), 7.11 (d, J 
7.5 2H, Ar), 7.18-7.29 (m, 6H, Ar), 7.34 (t, 2H, J= 7 Hz, Ar). 
l3C NMR (75 MHz) 0 28.4 (PhCH2), 32.8 (PhCH2CH2), 50.1 (NClhCH), 50.5 (PhCH2N), 
107 (m, C-F), 117.5 (CH2CH), 126.5, 127.3, 128.1, 128.5, 128.6 (Ar) , 132.6 (NCH2CH), 
139.5 (m, C-F), 140.9-144.9 (m, C-F), 143.2-147.1 (m, C-F), 137.1 (Ar), 139.8 (Ar), 
156.8 (OCOC6F5), 166.7 (C=N). 
Micro. Found: C 64.07, H = 4.49, N = 5.70; Ca1cd: C = 63.87, H 4.33, N 5.73. 
TOF MS ES+ [MHt: Found: 489.1610; Calcd for C25H19F5N202: 489.1601. 
(EZ)-Methyl-2-[ allyl(benzyl)amino] {[ (pentafluorobenzoyl) oxy] imino} acetate (4.12c) 
A solution of 4.11c (594 mg, 2.39 mmol), TEA (420 j...lL, 2.75 mmol) and C6FsCOCl (634 
mg, 2.75 mmol) in dry DCM (30 mL) was reacted as described in general procedure F, and 
the crude product purified by flash column chromatography (PE/EA 80120) to give 835 
(88%) of (EIZ)-4.12c (4:1 based on analysis of lH NMR spectrum) as a yellow solid. 
lH NMR (500 MHz) 0 3.85-3.99 (m, 5H, NCH2CH, minor& major), 4.42 (s, 2H, 
NCH2Ph, minor), 4.53 (s, 2H, NCH2Ph, major), 5.16-5.28 (m, 2H, CHCH2, minor & 
major), 5.75-5.88 (m, 1H, CHCH2, minor & major), 7.18-7.44 (m, 5H, minor & major). 
l3C NMR (75 MHz) 049.7, 50.8, 52.9, 53.6, 54.0, 54.3, 106.8 (m), 119.2 119.3, 126.7, 
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127.4, 127.9, 128.1, 128.5, 128.7, 131.1, 132.4, 135.5-147.3 (m), 135.1, 136.2 , 135.5-
147.3 (m), 151 159.4, 155.4, 156.1, 159.4, 160.1, 161.4 (C=N). 
TOF MS ES+ [M+2t: Found: 443.l023; Calcd for C20H14FSN204: 443.1030. 
(EZ)-1-N-allyl-3-phenyl-N' [(pentafluorobenzoyl)oxyJ propanimidamide (4.15) 
A solution of 
C6F50CO~N 
Ph~N~ 
H 
(76 mg, 0.41 mmol), TEA (75 ilL, 0.53 mmol) and C6F5COCI (124 mg, 
0.53 mmol) in dry DCM (10 mL) was reacted as described in general procedure F, and the 
crude product purified by flash column chromatography (PE/EA 80120) to give 110 mg 
(90%) of (EIZ)-4.15 (4: 1 based on analysis of lH NMR spectrum) as a yellow solid. 
Data for (EIZ)-4.15 
lHNMR (500 MHz) 0 2.63 (t, J = 8.5 Hz, 2H, PhCH2, major), 2.69 (t, J = 8.5 Hz, 2H, 
PhCH2, minor), 2.93 (t, J 8 Hz, 2H, CH2CH2, minor), 2.98 (t, J 8.5 Hz, 2H, CH2CH2, 
major), 3.76-3.78 (m, 2H, NHCH2, minor), 3.80-3.82 (m, 2H, NHCH2, major) 5.09-5.13 (m, 
2H, CHCH2, minor), 5.22-5.29 (m, 2H, CHCH2, major), 5.75-5.80 (m, 1H, CHCH2, minor), 
5.82-5.89 (m, 1H, CHCH2, major), 7.16-7.32 (m, 5H, Ar, major and minor). 
I3C NMR (75 MHz) 0 30.1 (PhCH2, major), 32.5 (PhCH2, minor), 32.5 (CH2CH2, minor), 
32.8 (CHCH2, major), 44.3 (NHCH, minor), 44.7 (NHCH, major), 116.7 (CHCH2, major), 
117.2 (CHCH2, minor), 126.5 (major, Ar), 126.6 (minor Ar), 128.2, 128.5 (major Ar), 
128.6 (minor, Ar), 133.3 (CHCH2, minor), 134.0 (CHCH2, major), 1 147.1 (m, C-F), 
139.7 minor), 140.2 (Ar, major), 156.2, 160.1 (C=N, major), 164.2 (C=N, minor). 
HRP EI+[M-lt: Found: 397.0975; Calcd for C19H14FsN202: 397.0975. 
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1,2-dibcnzyl-4-mcthyl-lH-imidazole (4.13a) 
A mixture of (E)-4.12a (169 mg, 0.36 mmol), TEA (300 ilL, 1.78 mmol), and Pd(PPh3)4 
(41 mg, 0.035 mmol) in dry DMF (7 mL) was treated as described in general procedure G 
with heating at 80°C for 30 min. The residue was purified by flash column chromatography 
{(PE/EA = 60/40 - 10/90 (gradually increasing the gradient)} to give 62 mg (65%) of 4.13a 
as a yellow oil. 
IH NMR (500 MHz) 15 2.22 (s, 3H, CH3 ), 4.02 (s, 2H, PhCH2), 4.80 (s, 2H, NCH2Ph), 6.52 
(s, 1H, CH3CCHN), 6.92 (dd, 6 Hz, 1Hz, 2H, Ar), 7.14 (d, 7.5 Hz, 2H, Ar), 7.19 (t, 
J= 7.5 Hz, 1H, Ar), 7.27 (m, 5H, Ar). 
I3C NMR (75 MHz) 15 13.6 (CH3), 33.7 (PhCH2C=N), 49.3 (NCH2Ph), 116.7 (CH3CCHN), 
126.5, 126.7, 127.7, 128.2, 128.6, 128.7, 136.3, 136.4 (Ar), 137.3 (CH3CCHN), 145.8 
(C=N). TOFMS ES+[MHt: Found: 263.1436; Calcd for C1sH19N2: 263.1548. 
I-Bcnzyl-4-methyl-2-(2-phenylethyl)-lH-imidazole (4.13b) 
A mixture of (E)-4.12b (151 mg, 0.31 mmol), TEA (230 ilL, 1.55 mmol), and Pd(PPh3)4 
(36 mg, 0.031 mmol) in dry DMF (6 mL) was treated as described in general procedure G 
with heating at 80°C for 30 min. The residue was purified by flash column chromatography 
(PE/EA = 60/40-10/90) to give 53 mg (62%) of 4.13b as a yellow oil. 
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IH NMR (500 MHz) 8 2.23 (s, 3H, ),2.85-3.01 (m, 4H, CH2CH2), 2.99 (t, J= 7.5 Hz, 
2H, PhCH2CH2C=N), 4.80 (s, 2H, NCH2Ph), 6.50 (s, tH, CH3CCHN), 7.00 (d, J = 7 Hz, 
2H, Ar), 7.11 (d, J= 7.5 Hz, 2H, 7.19 (t, J= 7.5 Hz, 1H, Ar), 7.26-7.33 (m, 5H, Ar); 
l3C NMR (75 MHz) 8 13.5 (CH3), 29.1 (PhCH2), 34.7 (PhCH2CH2), 49.1 (NCH2Ph), 116.1 
(CH3CCHN), 126.2, 126.7, 127.9, 128.4, 128.5, 128.9, 136.3, 137.3 (Ar) , 141.2, 
(CH3CCHN), 147.0 (C=N). 
TOF MS ES +[MHt: Found: 277.1605; Calcd for C19H21N2: 277.1705. 
Methyl 1-benzyl-4-methyl-1H-imidazole-2-carboxylate (4.13c) 
A mixture of (EIZ)-4.12c (4:1, 226 mg, 0.51 mmol) , TEA (400 /-lL, 2.55 mmol) and 
Pd(PPh3)4 (59mg, 0.051 mm01) in dry DMF (9 mL) was treated as described in general 
procedure G with heating at 80°C for 3 h. The residue was purified by flash column 
chromatography (PE/EA = 60140) to give (34 mg, 30%) of 6c as a yellow oiL 
lH NMR (500 MHz) 8 2.18 (s, 3H, ),3.84 (s, 3H, OCH3), 5.51 (s, 2H, NCH2Ph), 6.74 
(s, 1H, CH3CCHN), 7.11 (d, J= 7 Hz, 2H, Ar), 7.19-7.28 (m, 3H, Ar). 
l3C NMR (75 MHz) 8 13.7 (CH3), 51.3 (OCH3), 52.2 (NCH2Ph), 122.5 (CH3CCHN), 
127.4, 128.0, 128.8, 134.8 (Ar), 136.4, (CH3CCHN), 139.1 (CH30COC=N), 159.4 (C=N); 
TOF MS ES+[MHt: Found: 231.1181; Calcd for C13H1SN202: 231.1134. 
N-allyl-3-phenylpropanamide (4.16)20 
o 
Ph~lN~ 
H 
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A mixture of (EIZ)-4.15 (104 mg, 0.26 mmo]), TEA (180 IkL, 1.3 mmol) and Pd(PPh3)4 (30 
mg, 0.026 mmol) in dry DMF (6 mL) was treated as descdbed in general procedure G with 
heating at 80 °C for 3 h. The residue was purified by flash column chromatography (PE/EA 
80120-60/40) to give (46 mg, 94%) of 4.16 as a yellow oil. 
'H NMR (500 MHz) 0 2.82 (t, J = 7.5 Hz, 2H, PhCH2), 3.05 (t, J 8.0 Hz, 2H, CH2CH2), 
4.06-4.07 (m, 2H, NHCH2), 5.16-5.29 (m, 2H, CHCHz), 5.74-5.81 (m, lH, CHCHz), 7.20 
(d, 7.5 Hz, 2H, Ar), 7.26 (d, J= 7.5 Hz, lH, Ar), 7.33 (d, J'-" 7.5 Hz, 2H, Ar). 
I3C NMR (75 MHz) 026.7,30.9,44.0, 118.9, 126.9, 128.3, 128.8, 130.2, 139.1, 158.7. 
(E)-(S)- tert-Butyl (l-aHyl(benzyl)amino )-1-{ [(pentafluorobenzoyl)oxyJimino} propan-
2-yl-carbamate (4.21a) 
.OCOC6Fs N th JL I'N~ 
Boc-NH l 
Ph 
A mixture of (EIZ)-4.18a (2:1,400 mg, 1.52mmol), NCS (204 mg, 1.53 mmol) and N-allyl 
benzyl amine (268 mg, 1.82 mmol) in dry DMF (10 mL) were reacted according to general 
method E and the cl1lde residue (isomer ratio 3:1 detrmined by analysis of IH NMR 
spectl1lm) was then subjected to flash column chromatography (PE/EA = 9:1-17:3) to give 
300 mg of (EIZ)-4.20a as a yellow foam, which was not purified further (isomer ratio 5:2 
by'HNMR). 
Selected data for 
TOF MS ES+[MH( Found: 410.2122; Calcd for C24H32N303: 410.2444. 
A sample of (EIZ)-4.20a (285 mg), TEA (90 ilL, 0.60 mmol) and C6FsCOCI (138 mg, 0.60 
mmol) in dry DCM (15 mL) was reacted as described in general procedure F, and the cl1lde 
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product purified by flash column chromatography (PE/EA = 9713) to give 210 mg (61 %) of 
(E)-4.21a as a colorless oil. 
lH NMR (500 MHz) 8 1.41 (s, 9H, t-Bu), 3.07-3.15 (m, 2H, PhCH2CH), 3.70 (dd, J= 16.5 
Hz, 5 Hz, 1H, NCH2CH), 3.95 (dd, J= 16.5 Hz, 5 Hz, 1H, NCH2CH), 4.35 (d, J=16 Hz, 
1H, NCHAPh ),4.45 (d, J = 16 Hz, 1H, NCHBPh), 4.93 (dd, J = 17 Hz, 8 Hz, 1H, CH), 
5.10 (m, 2H, CHCH2), 5.49 (bd, J = 10 Hz, 1H, NH), 5.60-5.67 (m, 1H, NCH2CHCH2), 
7.03-7.07 (m, 4H, Ar), 7.21-7.26 (m, 6H, Ar). 
13C NMR (75 MHz) 828.2 (t-Bu), 39.10 (PhCH2CH), 51.2 (CHNH), 51.5 (NCH2CH), 
51.8 (NCH2Ph), 80.1 (C(CH3)3, 108.0 (m, C-F), 117.7 (CHCH2), 127.0, 127.2, 127.3, 
128.4, 128.6, 129.2 (Ar), 132.6 (CHCH2), 135.7-139.7 (m, C-F), 136.4, 136.7 (Ar), 141.2-
144.7, 142.9-146.4 (m, C-F), 155.1 (OCO), 158.0 (OCO) , 165.2 (C=N); [a]2oD -1.4 (c 1.3 
CHCh). 
TOF MS ES+[MHt: Found: 604.2239; Calcd for C31H31F5J'h04: 604.2235. 
(E)-(S)- tert-Butyl (l-allyl(benzyl)amino )-1-{ [(pentafluorobenzoyl)- oxy ]imino} 
propan-2-yl-carbamate ( 4.21 b) 
A mixture of (EIZ)-4.18b (3:1, 400 mg, 2.12 mmol), NCS (286 mg, 2.14 mmol) andN-allyl 
benzyl amine (312 mg, 2.12 mmol) in dry DMF (10 mL) were reacted according to general 
method E and the crude residue (isomer ratio 8:3 based on analysis of lH NMR spectrum) 
was subjected to flash column chromatography (PE/EA = 911-17/3) to give 4.20b as a 
single isomer (210, mg, 30%), which was not purified further. 
Selected data for 4.20b. 
TOF MS ES+[MHt; Calcd for ClsH2SN303: 334.2131, Found: 334.2021. 
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A sample of (EIZ)-4.20b (170 mg), TEA (80 flL, 0.54 mmol) and C6FsCOCl (123mg, 0.54 
mmol) in dry DCM (15 mL) was reacted as described in general procedure and the c11lde 
product purified by flash column chromatography (PE/EA 9713) to give 170 mg (63%) of 
(E)-4.21b as a viscous colorless oil. 
IH NMR (500 MHz) <31.41 (d, J= 7.5 Hz, 3H, CH3CH), 1.45 (s, t-Eu), 3.77 (dd, J 17Hz, 
5Hz, IH, NCH2CH), 4.33 (m, IH, NCH2CH), 4.38 (d, J 16.5 Hz, 1H, NCHAPh), 4.75-
4.81 (m, 2H, NCHBPh, CH3CHa), 5.18-5.22 (m, 2H, CHCH2), 5.36 (d, J 9 Hz, IH, NH), 
5.81-5.89 (m, 1H, CHCH2), 7.22-7.32 (m, 5H, Ar). 
BC NMR (75 MHz) <3 18.6 (CH3CH), 28.2 (t-Eu), 45.2 (CHu), 51.8 (NCH2CH), 52.2 
(NCH2Ph), 80.0 (C(CH3)3), 108.0 (m, C-F), 117.2 (CHCH2), 127.1, 127.2, 128.5 (Ar), 
132.9 (CHCH2), 135.7-139.4 (m, C-F), 137.0 (Ar), 141.0-144.7, 142.8-146.3, (m, C-F), 
155.2 (OCO), 157.2 (OCO), 166.8 (C=N); [afon +33.2 (c 1.0 CHCh). 
TOF MS ES+ [MHt: Found: 528.1944; Calcd for C2sHnFsN304 528.1922. 
(E)-(S)- tert-Eutyl(l-allyl(benzyl) amino )-1-{ [(pentatluorobenzoyl)- oxy]imino }-4-
metbyl pentan-2-yl-carbarnate (4.21c) 
A mixture of (EIZ)-4.18c (3:2, 600 mg, 2.79 mmol), NCS (372 mg, 2.79 mmol) and N-allyl 
benzyl amine (414 mg, 2.81 mmol) in dry DMF (10 mL) were reacted according to general 
method E and the c11lde residue (isomer ratio 11: 1 based on analysis of 1 H NMR spect11lm) 
was subjected to flash column chromatography (PEIEA 9/1-17/3) to give 180 mg (20%) 
of (EIZ)-4.20c as yellow gum (5: 1 determened by analysis of IH NMR spectrum), that was 
not purified further. 
Selected data for 4.20c. 
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A sample of (E/Z)-4.20c (150 mg), TEA (64 ilL, 0.46 mmol) and C6FsCOCI (106mg, 0.46 
mmol) in dry DCM (15 mL) was reacted as described in general procedure F, and the crude 
product purified by flash column chromatography (PE/EA 9713) to give 40% of 
recovered starting materia14.20c and 75 mg (31 %) of (E)-4.21c as a colorless oil. 
IH NMR (500 MHz) 0 0.72 (d, 6.5 Hz, 3H, CH3), 0.86 (d, J= 6.5 Hz, 3H, 0.93-
1.01 (m, IH, (CH3)2CH), 1.45 (s, t-Bn), 1.59-1.65 (m, 1H, CHCH2CH), 1.87-1.93 (m, 1H, 
CHCH2CH), 3.80 (dd, J 16.5Hz, 5Hz, IH, NCH2CH), 4.28 (dd, J 17 IH, 
NCH2CH), 4.41 (d, J 16.5 Hz, 1H, NCHAPh), 4.61-4.72 (m, 1H, CH), 4.75 (d, J 16.5 
Hz, IH, NCHBPh), 5.1 (m, 2H, CHCHz), 5.25 (d, J = 9.5 Hz, 1H, NH), 5.81-5.88 (m, 
IH, CHCHz), 7.20-7.32 (m, 5 H, Ar). 
l3C NMR (75 MHz) 0 21.2 (CH3CH), 23.2 (CH3CH), 25.1 «CH3)2CH), 28.2 (t-Bn), 41.3 
(CHCHa), 48.3 (CHu), 51.8 (NCH2CH), 52.1 (NCHzPh), 79.9 «CH3)3C), 117.5 (CHCHz), 
127.1, 127.2, 128.5 (Ar), 132.7 (NCH2CHCHz), l35.6-139.5 (m, C-F), 137.0 (Ar), 140.9-
144.9 (m, C-F), 142.5-146.4 (m, C-F) 155.5 (OCO), 157.2 (OCO), 166.8 (C=N); [a]zoD + 
59.8 (c 2.0 CHCh). 
TOF MS ES+[M+ Nat: Found: 592.1835; Calcd for C2sH32FsN3Na04 : 592.2211. 
(8)- tert-Butyl-l-(1-benzyl-4-methyl-1H-imidazol-2-yl)-2-phenylethyl carbamate (4.22a) 
A mixture of (E)-4.2la (100 mg, 0.17 mmol), TEA (120 ilL, 0.83 mmol) and Pd(PPh3)4 (19 
mg, 0.017 mmol) in dry DMF (4 mL) was treated as described in general procedure G with 
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heating at 80°C for 30 min. The residue was purified by flash column chromatography 
(PE/EA = 60140-20/80) to give 45 mg (70%) of 4.22a as a yellow solid. 
IH NMR (500 MHz) 8 1.36 (s, 9H, t-Bn), 2.20 (s, 3H, ),3.12-3.22 (m, 2H, PhCH2CH), 
4.67 (m, 2H, NCH2Ph), 4.95 (m, IH, CH), 5.44 (bd, J = 8.5 Hz, IH, NH), 6.35 (bs, IH, 
CHN), 6.88 (m, 2H, Ar), 7.02 (d, J 5.4 Hz, 2H, Ar), 7.19-7.23 (m, 6H, Ar). 
l3C NMR (75 MHz) 0 13.6 (CH3CCHN), 28.3 (3 t-Bn), 42.0 (PhCH2CH), 48.0 
(CH2CH), 48.9 (PhCH2N), 79.4 (C(CH3)3), 115.9 (CH3CCH), 126.5, 127.2, 127.8, 129.3, 
128.7, 129.5, 136.3, 136.7 (Ar), 137.4 (CH3CCH), 147.0 (OCO), 155.0 (C=N); [a]20D -8.3 
(c 1.0 CHCh). 
TOF MS ES+[MHt: Found: 392.2330; Ca1cd for C24H30N302: 392.2338. 
(S)- tert-Bntyl-l-(1-benzyl-4-methyl-1H-imidazol-2-yl)ethyl carbamate (4.22b) 
A mixture of (E)-4.21b (110 mg, 0.21 mmol), TEA (145 j..tL, 1.09 mmol) and Pd(PPh3)4 (24 
mg, 0.021 mmol) in dry DMF (6 mL) was treated as described in general procedure G with 
heating at 80°C for 1 h. The residue was purified by flash column chromatography (EAlPE 
70/30) to give 42 mg (68%) of 4.22b as a yellow solid. 
I H NMR (500 MHz) 0 1.39 (s, 9H, ), 1.43 (d, J= 7 3H, CH3CH), 2.19 (d, J= 1 
Hz, 3H, CH3), 4.88-4.94 (m, IH, CH3C1Lx), 5.08 (d, J 16 IH, NCRa.Ph), 5.16 (d, J = 
16 Hz, 1H, NCHBPh), 5.27 (bd, J 8.5 Hz, IH, CHNH) , 6.52 (s, 1H, CHN), 7.10 (d, J= 
7.5 Hz, 2H, 7.28 (d, J= 7 Hz, IH, 7.32 (t, 7.5, 2H, Ar). 
l3C NMR (75 MHz) 0 13.5 (CH3CCHN), 20.9 (CH3CH), 28.3 (3 CH3, t-Bn), 41.9 
(CH3CHNH), 49.1 (PhCH2N), 79.4 (C(CH3)3), 116.5 (CH3CCH), 126.8, 127.8, 128.8, 
136.4 (CH3CCH), 136.7 (Ar), 148.2 (OCO), 154.9 (C=N); [afoD -72.4 (c 1.0 CHCh). 
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(S)-tert-Butyl-l-(1-benzyl-4-methyl-1H-imidazol-2-yl)-3-methyl butyl carbamate 
(4.22c) 
A mixture of (E)-4.21c (51 mg, 0.09 mmol), triethylamine (62 p,L, 0.44 mmol) and 
Pd(PPh3)4 (10 mg, 0.009 mmol) in dry DMF (6 mL) was treated as described in general 
procedure G with heating at 80°C for 1 h. The residue was purified by flash column 
chromatography (PE/EA = 70/30-30/70) to give 18 mg (56%) of 4.22c as a thick oil. 
IH NMR (500 MHz) 0 0.78 (m, 6H, 2 CH3), 1.38 (s, 9H, t-Bu), 1.52-1.56 (m, 2H, CH2CH), 
1.81 (t, J = 14.5 Hz, IH, CH2CH), 2.19 (d, J = 1.5 Hz, 3H, CH3), 4.83-4.88 (m, IH, CH), 
5.04-5.25 (m, 3H, NH, NCH2Ph), 6.52 (s, IH, CH3CCHN), 7.13 (d, J = 10 Hz, 2H, Ar), 
7.27-7.35 (m, 3H, Ar). 
l3C NMR (75 MHz) 0 13.6 (CH3CCHN), 21.9 (CH3CH), 22.8 (CH3CH), 24.60 ((CH3)2CH), 
28.3 (t-Bu), 43.8 (CH2CHNH), 44.0 (CH2CHNH) 49.1 (PhCH2N), 79.3 (C(CH3)3), 116.3 
(CH3CCHN), 127.0, 127.8, 128.8 (Ar), 136.5 (CH3CCHN), 136.9 (Ar), 148.4 (OCO), 
155.2 (C=N); [afoD -54.3 (c 1.0 CHCh). 
TOF MS ES+[MHt: Found: 358.2596; Calcd for C21H32N302: 358.2495. 
(8)- tert-Butyl-N- [1-(1-benzyl-4-methyl-1H-imidazole-2-yl)-2(S)-phenylethyl] alaninate 
(4.24) 
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Compound 4.22a (20 mg, 0.05 mmol) was reacted with IN HCl (aq, 1 mL) in ethyl acetate 
(3 mL) at rt with stirring for 3 h. The progress of the reaction was monitored by TLC. EA 
was evaporated in vacuo, MeOH was added (x2) and the solvent was evaporated in vacuo. 
The crude free amine 4.23 was dried in vacuo and used without further purification. 
(S)-N,t-Boc alanine (9.7 mg, 0.05 mmol) was added to the crude free amine (15 mg, 0.05 
mmol), EDCI (10 mg, 0.05 mmol), HOBT (14 mg, 0.10 mmol) and DIPEA (180 ttL) in dry 
DMF (6 mL) and the mixture was stilTed at rt for 16 h. Water (2 mL) and EA (4 mL) werc 
added to the mixture, organic phase separated and the aq. phase extracted with EA (x3). 
The combined organic fractions were washed successively with H20 (x2), NaHC03, brine, 
dried (MgS04) and evaporated in vacuo, The residue (a single diastereoisomer determined 
by analysis of IH NMR spectrum) was purified by flash column chromatography (PE/EA 
50:50 then 70:30) to give 4.24 (12 mg, 52%) as a clear oil. 
IH NMR (500 MHz) 8 1.20 (d, J 7.5 Hz, IH, CH3CH), 1.41 (s, 9H, t-Bu), 2.19 
(s, 3H, CH3), 3.11-3.15 (m, IH, PhCHACHa), 3.20 (dd, J= 13.5 Hz, 7 Hz, IH, PhCHBCH), 
4.08 (bs, lH, CH3CH), 4.66-4.75 (m, 3H, NCH2Ph, NH), 4.89 (bm, 1 NH), 5.26 (dd, J= 
15.5 Hz, 8,5 Hz, IH, PhCH2CH), 6.37 (s, lH, CHN), 6,88 (t, 3.5 2H, Ar), 7.01 (m, 
3H, Ar), 7.19-7.27 (m, 2H, Ar). 
l3C NMR (75 MHz) 8 13.4 (CH3CCH), 18.3 (CH3CH), 28.2 (t-Bu), 41.2 (PhCH2CH), 46.4 
(CHa), 48.9 (NCH2Ph), 50.2 (CH3CHc;), 80.0 (C(CH3)3), 116.2 (CHN), 126.6, 127.0, 127.8, 
128.3, 128.8, 129.4, 136.2, 136.6 (Ar), 137.1 (CCRN), 146.3 (OCO), 155.1 (C=N), 171.7 
(NHCOCH); TOF MS ES+[MHt: Found: 463.2760; Calcd for C27H3SN403: 463.2709. 
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8.5 Experimental Work Described in Chapter Five 
1-Phenylpent-4-yn-1-one (5.32) 
Acetophenone N,N-dimethyl hydrazone6 (2.0 g, 12.32 mmol) was treated with freshly 
prepared LDA [from n-BuLi (1.6 M in hexane, 7.7 mL) and N,N-diisopropylamine (2.6 
mL) in THF (25 mL)] at 0 °C and stirred for 1 h under argon atmosphere. 4-Bromo-l-
butyne 5.31 (0.92 mL) in THF (4mL) was added according to general procedure H. The 
crude alkylated hydrazone was then hydrolyzed by adding acetic acid (5.9 mL, 104 mmol), 
sodium acetate (2.83 g, 20.85 mmol), water (0.7 mL), and THF (3.3 mL) were added and 
the mixture was stirred at rt for five hours. After work up, the crude product was purified 
by flash column chromatography (H/EA = 9317) to give 1.1 g (91 %) of 5.32 as a yellow oil. 
1H NMR (500 MHz) 0 1.99 (t, J = 2.5 Hz, IH, C=CH), 2.63 (dt, J = 8 Hz, 3 Hz, 2H, 
CH2C=CH), 3.24 (t, J= 7.5 Hz, ,CH2CH2C=CH), 7.45 (t, J= 8 Hz, 2H, Ar), 7.57-7.59 (m, 
IH, Ar), 7.96 (d, J= 8 Hz, 2H, Ar). 
l3C NMR (75 MHz) 0 13.1 (CH2C =CH), 37.4 (CH2CH2C =CH), 68.7 (C =CH), 83.3 
(C =CH), 127.9, 128.6, 133.2, 136.4 (Ar), 197.5 (C=O). 
Micro. Found: C, 83.32; H, 6.49%. Calcd for C l3H IOO: C, 83.51; H, 6.37% 
2-But-3-yn-1-yl-2-phenyl-1,3-dioxolane (5.33)21 
1\ 
o 0 ~ V 
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A solution of the ketone 5.32 (1.90 g, 12.04 mmol) in benzene, ethylene glycol (2.5 mL, 
45.17 mmol) and a catalytic amount of p-TsOH were refluxed for 3 h using a Dean-Stark 
apparatus for removal of water. The reaction was quenched by adding sat. NaHC03 so In 
(aq.), extracted with EA (x3), washed with brine, dried over MgS04 and evaporated in 
vacuo. The crude product was purified by recrystallization from n-hexane to give 2.3 g 
(95%) of 5.33 as a colorless solid. 
IH NMR (500 MHz) 8 1.89 (t, J = 2.5 Hz, 1H, C =CH), 2.14-2.17 (m, 2H, CH2CH2C =CH), 
2.27-2.30 (m, 2H, HC=CCH2), 3.77 (t, J= 7 Hz, 2H, CH20), 4.01 (t, J= 7 Hz, 2H, CH20), 
7.28-7.31 (m, 1H, Ar), 7.34 (t, J= 7.5 Hz, 2H, Ar), 7.43-7.45 (m, 2H, Ar). 
l3C NMR (75 MHz) 8 13.1 (CH2C=CH), 39.3 (CH2CH2C=CH), 64.6 (OCH2CH20), 67.8 
(C =CH), 84.1 (C =CH), 109.3 (PhCOO), 125.9, 128.01, 128.2, 141.9 (Ar). 
Micro. Found: C, 76.91; H, 7.05%. Calcd for Cl3HI402: C, 77.20; H, 6.97% 
Methyl 5-(2-phenyl-l,3-dioxolan-2-yl)pent-2-ynoate (5.34) 
n 
o 0 ~CO'M' 
n-Butyllithium (1.6 M in hexane, 2.2 mL) was added to a solution of 5.33 (684 mg, 3.38 
mmol) in THF (15 mL) at -78 °C and stirred for 1 h at the same temperature. Methyl 
chloroforrnate (0.05 mL, 4.06 mmol) in THF (5 mL) was added to the reaction mixture and 
stirred for 1 h. The reaction was stopped by adding NH4Cl (sat.), extracted with Et20 (x3), 
washed with H20 (x2), brine (x2), dried (MgS04) and evaporated in vacuo. The crude 
product was purified by flash column chromatography (HIEA = 90/10) to give 780 mg 
(88%) of 5.34 as a cream solid. 
I H NMR 8 2.18 (t, J= 7.5 Hz, 2H, CHCH2), 2.43 (t, J= 7.7 Hz, 2H, CCH2), 3.73 (s, 3H, 
CH3), 3.78 (ddd, J= 7.3 Hz, 6.0 Hz, 3.4 Hz, 2H, CH20), 4.01 (ddd, J= 7.4 Hz, 6.1 Hz, 3.6 
Hz, 2H, CH20), 7.28-7.36 (m, 3H, Ar), 7.42-7.44 (m, 2H, Ar). 
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NMR 0 13.4 (C =CCH2), 38.1 (C=CCH2CH2), 52.5 (C02CH3), 64.7 (OCH2CH20), 
72.6 (C =CC02CH3) 89.4 (C =CC02CH3), 109.0 (PhC02), 125.7, 128.2, 128.3, 141.6 (Ar), 
154.2 (C02CH3). 
6-oxo-6-phenylhex-2-ynoate (5.35) 
A solution of 5.34 (730 mg, 2.80 mmol) in THF (15 mL) and 1 N HCI (aq. 10 mL) was 
stirred at 40°C for 4.5 h. NaHC03 som. (sat) was added to the mixture, extracted with Et20 
(x3), washed with H20 (x2), brine (xl), dried (MgS04) and evaporated in vacuo. The crude 
product was purified by column chromatography (HIEA 90/10) to give 513 mg (84%) of 
as a white solid. 
IH NMR (500 MHz) 0 2.79 (t, J = 7.5 Hz, 2H, COCH2CH2), 3.31 (t, J = 7.5 Hz, 2H, 
COCH2CH2), 3.76 (s, 3H, CH3), 7.49 (t, J = 7.5, 2H, Ar), 7.59 (t, J = 7.4,lH, Ar), 7.96 (d, 
J 7.4 Ar). 
l3C NMR (75 MHz) 0 13.3 (C=CCH2), 36.5 (C=CCH2CH2), 52.6 (C02CH3), 73.1 
(C=CC02CH3), 88.3 (C=CC02CH3), 128.0, 128.7, 133.5, 136.1 (Ar) , 154.0 (C02CH3), 
196.7 (PhCO). 
Micro. Found: C, 72.13; H, 5.61 %. Calcd for C13H1203: C, 72.20; H, 5.59%. 
oxime (5.36) 
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The aryl alkynyl ketone 5.32 (1.09 g, 6.90 mmol), hydroxylamine hydrochloride (1.19 g, 
13.8 mmol) and pyridine (1.56 mL, 19.32 mmol) were stined in EtOH (30 mL) at rt for 2 h 
according to general procedure B. The crude oxime (5:2, based on analysis of lH NMR 
spectrum) mixture was purified by column chromatography using (HIEA 92/8) to elute 
997 mg (83%) of E-5.36 as a white solid first, and then 147 mg (12%) of Z-5.36 as a yellow 
solid, thus yielding the oxime in a combined yield of 95%. 
Data for (E)-5.36 
lH NMR (500 MHz) 0 1.98 (t, J = 3.0 Hz, 1H, C =CH), 2.53 (dt, J 7.5, 
=CH), 3.06 (t, J= 7.5 Hz, 2H, CH2CH2C=CH), 7.39-7.40 (m, 3H, Ar), 7.63-7.64 (m, 
Ar). 
BC NMR (75 MHz) 0 15.4 (CH2C=CH), 25.8 (CH2CH2C=CH), 69.1 (C 83.1 
(C 126.4, 128.6, 129.4, 135.1 (Ar), 157.9 (C=N). 
Micro. Found: C, 76.26; H, 6.39; N, 7.98%. Calcd for CI1HIlNO: C, 76.27; H, 6.4; N, 
8.08%. 
Data for (Z)-5.36 
IH NMR (300 MHz) 0 1.98 (t, J = 3.0 Hz, tH, C =CH), 2.37 (dt, J 7.5, 3 Hz, 
2H,CH2C =CH), 2.78 (t, J= 7.5 Hz, ,CH2CH2C =CH), 7.37-7.70 (m, 5H, Ar), 8.06 (bs, 1H, 
C=NOH). 
13C NMR (75 MHz) 0 16.0 (CH2C=CH), 34.4 (ClhCH2C 69.4 (C =CH), 82.7 
(C 127.7,128.3, 129.1, 132.6 (Ar), 156.7 (C=N). 
(E)-Methyl-6-(hydroxyimino )-6-phenylhex-2-ynoate (5.37) 
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The aryl alkynyl ketone (590 mg, 2.73 mmol), hydroxylamine hydrochloride (402 mg, 
6.8 mmol) and pyridine (610 JlL, 7.6 mmol) were stirred in EtOH (30 mL) at rt fOJ 5 h 
according to general procedure B. The crude oxime (single isomer, based on analysis of IH 
NMR spectrum) mixture was purified by column chromatography using (HIEA 90/10) to 
elute 441 mg (70%) ofE-5.37 as a white solid. 
IH NMR (300 MHz) 82.66 (t, J = 7.9 Hz, 2H, CH2C=CC02), 3.09 (t, J 7.9 Hz, 2H, 
CH2CH2C (s, 3H, CH3), 7.36-7.43 (m, 2H, Ar), 7.58-7.65 (m, 2H, Ar), 8.10 (bs, 
IH, C=NOH). 
(E)-1-Phenylpent-4-yn-l-one O-pentatluorobenzoyl oxime (5.38) 
To a solution ofE-5.36 (640 mg, 3.69 mmol) and TEA (1.0 mL, 7.38 mmol) in DCM (20 
mL) at 0 °c was added C6F5COCI (1.36 mg, 5.91 mmol) in DCM (5 mL) and stirred for 1.5 
h aceording to general procedure C. The crude oxime was purified by silica 
chromatography (H/EA 95/5) to give 1.16 g (88%) of E-5.38 as a white solid. 
Data for 
IH NMR (500 MHz) 8 1.99 (t, J = 2.5 Hz, 1H, C=CH), 2.50 (dt, J 7.5,2.5 Hz, 2H, 
CH2C 3.15 (t, J= 7.5 Hz, 2H, CH2CH2C=CH), 7.40 (t, J Hz, 2H, Ar), 7.49-
7.52 (m, 1H, 7.77 (d, J 8 Hz, 2H, Ar). 
BC NMR (75 MHz) 8 15.9 (CH2C=CH), 27.6 (CH2CH2C 69.9 (C=CH), 81.4 
(C =CH), 107.0 (m, C-F), 127.4, 128.7, 131.2, 132.5 CAr), 135.8-139.6 (m, C-F), 141.6-
145.4, 143.6-147.4, (m, C-F), 156.2 (OCOC6FS), 166.6 (C=N). 
TOFMS [MH]+: Found: 368.0637; Cal cd for C18HllFsN02: 368.0710. 
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(E)-Methyl-6-(pentafluorobenzoyloxyimino )-6-phenylhex-2-ynoate (5,39) 
To a solution of E-5.37 (292 mg, 1.26 mmol) and TEA (350 p,L, 2.53 mmol) in DCM (20 
mL) at 0 °C was added C6FsCOCI (554 mg, 2.40 mmol) in DCM (5 mL) and stirred for 1.5 
h according to general procedure C. The crude oxime was purified by recrystallization 
(H/EA) to give 420 mg (75%) of E-3.39 as a white solid. 
IH NMR (500 MHz) (52.64 (t, J= 7.5 Hz, 2H, CH2C=CC02), 3.21 (t, J= 7.5 2H, 
CH2CH2C=C), 3.72 (s, 3H, CH3), 7.46 (t, J= 7.5, 2H, Ar), 7.51 (t, 7.0,lH, Ar), 7.76 (d, 
7.5 Hz, 2H, Ar). 
I3C NMR (75 MHz) (5 16.14(CH2C =CC02), 26.50 (CH2CH2C =C), 52.53 (C02CH3), 73.86 
(C CC02CH3), 85.97 (C =CC02CH3), 127.4, 128.9, 131.4, 132.1 (Ar), 135.8-136.3, 
139.2-139.7, 141.7-142-2, 143.6-143.9, 145.0-145.6, 147.0-147.6 (m, 
(C02CH3), 156.0 (C02C6F5), 196.7 (C=N). 
153.6 
Micro. Found: C, 56.41; H, 3.02; N, 3.33%. Calcd for C2oH12N04Fs: C, 56.48; 2.84; N, 
3.29%. 
2-methyl-5-phenyl-lH-pyrrole (5.40)22,23 
a) A-H reaction of 5.38 
Pd(PPh3)4 (31 mg, 0.027mmol) was added to a solution of E-5.38 (100 mg, 0.27 mmol) and 
TEA (190 p,L, 1.3 mmol) in dry DMF (0.05 M) under argon atmosphere at Ii and stirred at 
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80°C for 1 h according to general procedure 1. The residue was purified by preparative thin 
layer chromatography (H/EA = 8/2) to give 14.7 mg (35%) of 5.40 as a dark red oil. 
lH NMR (500 MHz) 8 3.33 (s, 3H, CH3), 5.94 (bs,IH, CH3CCH), 6.39 (t, J = 3 Hz, 
PhCCH, IH), 7.15 (t, J= 7.4 Hz, IH, Ar), 7.34 (t, J= 8 Hz, 2H, Ar), 7.43 (d, J= 7.8 Hz, 
2H, Ar), 8.09 (bs, IH, NH). 
l3C NMR (125 MHz) 8 13.2, 106.1, 107.9, 123.3, 125.6, 128.8, 129.0, 130.5, 141.7. 
b) Preparation via A-H reaction followed by Transmetallation with PhSnBu3 
Pd(PPh3)4 (30.5 mg, 0.026 mmol) was added to a solution of E-5.38 (97 mg, 0.26 mmol), 
TEA (180 f-tL, 1.32 mmol) and PhSnBu3 (170 f-tL, 0.53 mmol) in dry DMF or THF (0.05 M) 
at rt and stined at 70°C for 11 h according to general procedure J. The residue was purified 
by preparative thin layer chromatography (H/EA = 85/15) to give 3 mg (7%) of 5.40 as a 
dark red oil. 
Data for 5.40 as above. 
c) Preparation via A-H reaction followed by Intermolecular Heck Reaction with 
methyl acrylate 
Pd(PPh3)4 (39 mg, 0.034 mmol) was added to a solution of E-5.38 (124 mg, 0.34 mmol), 
TEA (230 f-tL, 1.69 mmol) and methyl acrylate (60 f-tL, 0.68 mmol) in dry DMF (0.05 M) at 
rt and stirred at 80°C for 5 h according to general procedure K. The residue was purified by 
preparative thin layer chromatography (H/EA = 83/17) to give 1.5 mg (6%) of 5.40 as a 
dark red oil. 
Data for 5.40 as above. 
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via reaction followed by Carbonylation/Nudeophile Insertion 
Pd(PPh3)4 (38 mg, 0,033 mmo) was added to a solution of E-5.38 (122 mg, 0,33 mmol) 
TEA (230 ILL, 1.65 mmol) and C2HSOH (90 ILL, 1.65 mmol) in dry DMF (0.05 M) at rt and 
stirred at 80°C for 5 h according to general procedure L. The residue was purified by 
preparative thin layer chromatography (HIEA = 82120) to give 3 mg (6%) of 5.40 as a dark 
red oil as well as 20 mg (26%) of5.42. 
Data for 5.40 as above. 
2-Methylene-5-phenyl-3,4-dihydro-2H-pyrrole (5.41)9,22 
PhZnBr (170 ILL, 0.53 mmol) was added over 20 min to a solution of E-S.38 (144 mg, 0.40 
mmol) and Pd(PPh3)4 (46 mg, 0.04 mmol) in dry THF (0.05 M) at rt and stirred for 3 h 
according to the general procedure J. 1be residue was purified by preparative thin layer 
chromatography (HIEA = 9812) to give 12 mg (28%) of5.41 as a dark red oil as well as 21 
mg of a mixture containing (16%) of 5.32 and (11%) of the starting material 5.38 
determined by 1 H NMR. 
lH NMR (500 MHz) 8 2.63 (t, J = 7 Hz, 2H), 2.74 (t, J = 7 Hz, 2H), 4.16 (s,lH), 4.62 (s, 
1H), 7.39-7.41 (m, 3H), 7.65-7.69 (m, 2H). 
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Ethyl (5-phenyl-1H-pyrrol-2-yl)acetate (5.42)9,22,23 
Preparation as for 5.40 (d) above. 
246 
IH NMR (500 MHz) 8 1.30 (t, J= 7.2 Hz, 3H, CH2CH3), 3.71 (s, 2H, CH2C02), 4.20 (dd, J 
= 14.3 Hz, 7.1 Hz, 2H, CH2CH3), 6.06 (t, J= 2.8 Hz, 1H, C02CH2CCH), 6.41 (t, J= 3 Hz, 
PhCCH, IH), 7.18 (t, J= 7.4 Hz, 1H, Ar), 7.34 (t, J= 7.6 Hz, 2H, Ar), 7.46 (d, J= 7.8 Hz, 
2H, Ar), 9.01 (bs, 1H, NH). 
13C NMR (75 MHz) 8 14.2 (CH2CH3), 33.3 (CH2CH3), 61.2 (CH2C02), 105.8 (NHCCH), 
109.1 (C02CCH), 123.6 (Ar), 124.5 (PhCCH), 126.0, 128.8 (Ar), 132.1 (C02CH2CCH), 
132.7 (Ar), 171.1 (CO). 
TOF MS ES+ [MHt: Found: 230.1154; Calcd for C14H16N02: 230.1181. 
Methyl (5-phenyl-1H-pyrrol-2-yl)acetate (5.43)23 
Pd(PPh3)4 (27 mg, 0.023mmol) was added to a solution of E-5.39 (100 mg, 0.23 mmol) and 
TEA (160 ilL, 1.17 mmol) in dry DMF (0.05 M) at rt and stirred at 80°C for 2 h according 
to general procedure 1. The residue was purified by preparative thin layer chromatography 
(H/EA = 82/20) to give 18.3 mg (37%) of5.43. 
IH NMR (500 MHz) 8 3.71 (s, 2H, CH2C02), 3.73 (s, 3H, CH2C02CH3), 6.07 (t, J= 2.5 
Hz, 1H, C02CH2CCH), 6.41 (t, J= 3.5 Hz, 1H, PhCCH), 7.18 (t, J= 7.4 Hz, 1H, Ar), 7.33 
(t, J = 8 Hz, 2H, Ar), 7.46 (dd, J= 8 Hz, 1.5 Hz, 2H, Ar), 9.00 (bs, 1H, NH). 
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I3C NMR (75 MHz) 8 .1 (C02CH3), 52.2 (CH2C02), 105.8 (NHCCH), 109.2 (C02CCH), 
123.6 (Ar), 124.3 (PhCCH), 126.0, 128.8 (Ar), l32.2 (C02CH2CCH), l32.6 (Ar), 171.6 
(CO). 
TOF MS ES+ [MHt: Found: 216.1125; Cal cd for C13H14N02: 216.1025. 
Ethyl rnethy1 (5-phenyl-1I1-pyrrol-2-yl)rnalonate (5.45) 
C02Me 
C02Et 
Pd(PPh3)4 (32.6 mg, 0.028 mmol) was added to a solution of E-5.38 (122 mg, 0.28 mmol), 
TEA (190 p,L, 1.41 mmol) and C2HSOH (80 p,L, 1.41 mmol) in dry DMF (0.05 M) at rt and 
stirred at 90 °C for 1 h according to the general procedure L. The residue was purified by 
preparative thin layer chromatography (HIEA = 85115) to give 25 mg (52%) ofa mixture as 
a dark red oil containing as well as 5.43 (2:5, determined by analysis of IH NMR 
spectrum). 
IH NMR (500 MHz) 8 1.30 (t, J 7.2 Hz, 3H, CH2CH3), 3.78 (s, 3H, C02CH3), 4.20-4.27 
(m, 2H, CH2CH3), 4.78 (s, lH, CH(C02Me)C02Et), 6.19 (t, J= 3 Hz, IH, NHCCH), 6.43 
(t, J = 3 Hz, IH, PhCCH), 7.16-7.21 (m, 3H, Ar), 7.46-7.49 (m, 2H, Ar), 9.29 (bs, 1H, 
NH). 
l3 C NMR (125 MHz) 8 l3.9 (CH2CH3), 50.9 (CH(C02Me)C02Et), 53.1 (C02CH3), 62.3 
(CH3CH20CO), 105.8 (PhCCH), 110.6 (NHCCHCH), 123.9, 126.3, 128.8 (Ar), 132.5 
(CHCCH), 133.2 (Ar), 167.6, 168.1 (CO). 
TOF MS ES+ [MHt; Found: 288.1250; Calcd for CL6HlSN04:288.1236. 
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8.6 Experimental Work Described in Chapter Seven 
Acid24 7.37, amine25 7.46, and N-allyl benzyl amine8 were prepared by literature methods. 
(±)-tert-Butyl (1-{[ allyl(benzyl)amino Jcarbonyl} but-3-en-l-yl)carbamate (7.29) 
EDCI (1.11g, 5.80 mmol), HOBT (1.57g, 11.61 mmol), and NMM (1.67 mL, 17.42 mmol) 
were added to a solution of (±) N-t-Boc allyl glycine (1.248g, 5.80 mmol) and N-allyl 
benzyl amine (795 mg, 5.80 mmol) in DMF (30 mL) under argon with stirring at rt for 16 h 
according to the general procedure M. The crude product (a 2:5 mixture ofrotamers, based 
on analysis of IH NMR spectrum) was purified by flash column chromatography (PEIEA = 
911~ 7/3) to give the 1.77g (88%) of the desired diene (±)-7.29 as a cream solid. 
Data for mixture (2:5) 
FTIR (KBr): 3365,2983,2331, 1728, 1689, 1521, 1433, 1296, 1244, 1170, 1022,912, 850, 
786,698. 
IH NMR (500 MHz) 8 1.42 (s, 9H, t-Bu, minor), 1.44 (s, 9H, t-Bu, major), 2.31-2.42 (m, 
3H, CHCHABCHCH2, 2H, minor and CHCHACHCH2, 1H, major), 2.43-2.54 (m, 1H, 
CHCHACHCH2, major), 3.89 (dd, J= 18 Hz, 5 Hz, 2H, NCHABCH, major), 3.97 (dd, J= 
18 Hz, 6 Hz, 1.5 H, NCHABCH, minor), 4.08 (dd, J = 16 Hz, 5.5 Hz, 0.5 H, NCHBCH, 
minor), 4.48 (d, J = 14.5 Hz, 1H, NCHAPh, major), 4.61 (s, 2H, NCHABPh, minor), 4.64-
4.68 (m, 1H, CHex, major), 4.71 (d, J = 15.5 Hz, 1H, NCHBPh, major), 4.72-4.75 (m, 1H, 
CHcx, minor), 5.07-5.21 (m, 4 H, NCH2CHCH2, CHCH2, minor & major), 5.67-5.81 (m, 
2H, NCH2CHCH2, CHCH2, minor & major), 7.19-7.36 (m, 5H, Ar, minor & major). 
l3 C NMR (75 MHz) 8 28.3 (t-Bu), 37.7, 37.8 (CHCH2CH), 47.9 (NCH2CH), 48.2 
(NCH2Ph), 49.03 (NCH2CH), 49.8, 49.9 (CH ex), 50.05 (NCH2Ph), 79.5 (C(CH3)3), 117.6, 
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117.7 (CHCH2CHCH2), 118.57 (NCH2CHCH2), 126.8, 127.4, 127.7, 128.0, 128.5, 128.8 
(Ar), 132.3, 132.5 (CHCH2CHCH2), 132.7, 132.8 (NCH2CHCH2), 136.2, 136.9 (Ar-C), 
155.1, 155.2 (OCOt-Bu), 172.0, 172.2, (NCO). 
TOF MS ES+ [MHt: Found: 345.2178; Calcd for C2oH29N203: 345.2178. 
Anal found: C, 69.70; H, 8.15; N, 7.95%; calcd: C, 69.74; H, 8.19; N, 8.13%. 
(±)-tert-Butyl (1-benzyl-2-oxo-2,3,4, 7-tetrahydro-1H-azepin-3-yl) carbamate (7.30) 
PCy Ck, I 3 
Ru ........ 
~ I Ph 
CI PCY3 
o BOOHNZ:fD 
6.2 
Catalyst 6.2 (16 mg, 0.02 mmol), dissolved in dry degassed DCM (3 mL) was added to a 
solution of the diene 7.29 (95 mg, 0.25 mmol), dissolved in dry degassed DCM (20 mL) 
under argon, according to the general procedure O. The mixture was refluxed for 24 h. The 
crude product was purified by flash column chromatography (PE/EA = 911 then 8/2) to give 
66 mg (76%) of the desired olefinic lactam 7.30 as a brown solid. 
FTIR (KBr): 3249, 2850, 2391, 1703, 1647, 1527, 1487, 1392, 1361, 1226, 1164, 1047, 
1002,968,929,798,702,626. 
IHJ'l"MR (500 MHz) 0 1.38 (s, 9H, t-Bu), 2.20 (m, 1H, CHCHACH), 2.60 (dd, J= 18 Hz, 4 
Hz, IH, CHCHBCH), 3.27 (dd, J = 7.5 Hz, 17.5 Hz, IH, NCHACH), 4.21 (td, J = 17.5 Hz, 
3 Hz, 1H, NCHBCH), 4.53 (d, J= 15 Hz, 1H, NCHAPh), 4.63 (d, J= 15 Hz, 1H, NCHBPh), 
4.86-4.91 (m, 1H, CHNH), 5.53 (m, 1H, CHCH2CHNH), 5.64 (m, 1H, CHCH2N), 5.82 (bd, 
J= 7 Hz, 1H, NH), 7.14 (d, J= 7 Hz, 2H, Ar), 7.17-7.24 (m, 3H, Ar). 
l3C NMR (75 MHz) 0 28.3 (t-Bu), 33.3 (CHCH2CH), 45.1 (NCH2CH), 49.94 (CHl\JH) , 
51.4 (NCH2Ph), 79.4 (C(CH3)3), 124.1 (CHCH2CHNH), 127.4, 127.7, 128.5 (Ar), 130.0 
(CHCH2N), 136.7 (Ar), 154.9 (OCO I-Bu), 172.4 (NCO). 
TOFMS ES+ [MHt Found: 317.2242; Calcd for C18H2SN203: 317.1856 
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(3-benzyl-4-oxo-8-oxa-3-azabicyco[5,1,0]oct-5-yl] carbamate (7.31) 
The olefinic lactam 7.30 (138 mg, 0.44 mmol) in acetone (12 mL) and water (10 mL) was 
treated with sodium hydrogen carbonate (1.24 g, 14.80 mmol) and Oxone® (2.68g, 4.35 
mmol) as described in the general procedure P. The resulting crude epoxide was purified by 
column chromatography (PE/EA = 70:30) to give 91 mg (63%) of 7.31 (-1:1) as a white 
solid. 
Data for mixture of diastereoisomers (~I : 1) 
FTIR (KEr): 2977,2343, 1712, 1652, 1606, 1490, 1434, 1365, 1328, 1226, 1166, 1055, 
1022,977,869,742,702. 
IHNMR (500 MHz) 8 1.45 (s, 9H), 1.91 (t, J = 12.5 Hz, 1H, CHCHACH), 2.03 (t, J 12.5 
1 H, CHCHBCH), 2.52 (dddd, J = 11 Hz, 6.5 Hz, 4.5 Hz, IH, CHCHACH), 2.65 (d, J 
Hz, IH, CHCHBCH), 2.90 (dd, J = 6 Hz, 11 Hz, IH, OCHCH2N), 3.01 (m, lH, 
OCHCH2CH), 3.04 (t, J= 4.5 Hz, IH, OCHCH2N), 3.18 (t, J 5.5 IH,OCHCH2CH), 
3.62 (dd, J= 4.5 Hz, 17 Hz, 2 H, CHCHABN), 3.65 (d, J= 6.5 lH, CHCHAN), 3.92 (d, 
J 15.5 Hz, 1H, CHCHBN), 3.96 (d, J = 17 Hz, tH, NCHAPh), 4.33 (d, J 14.5 Hz, IH, 
NCHAPh), 4.40-4.43 (m, lH, NHCH), 4.55-4.59 (m, tH, NHCH), 4.95 (d, J= 14.5 Hz, IH, 
NCHBPh) , 5.27 (d, J = 15 Hz, IH, NCHBPh), 5.73 (bd, J 7 IH, NH), 5.86 (bd, J = 
6.5 Hz, IH, NH), 7.23 (t, J= 7.5 Hz, 2 H, Ar), 7.26-7.35 (m, 3H, Ar). 
13CNJvIR (CDCh, 75 MHz) 828.2,28.3,30.4,31.3,44.2,47.2,47.7,48.27,50.0,51.1, 
51 52.2, 52.4, 52.7, 127.6, 127.8, 128.0, 128.2, 128.6, 128.8, 136.2, 136.8, 154.9, 171.3, 
172.2. 
TOF MS ES+ [MHt: Found: 333.1811; Calcd for ClsH2SN204: 333.1814. 
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tert-Butyl [(3S,5R,6S)-1-benzyl-5,6-dihydroxy-2-oxoazepan-3-yl]carbamate (7.32) 
and tert-butyl [(3R,5R,6S)-1-benzyl-5,6-dihydroxy-2-oxoazepan-3-yl ]carbamate (7.33) 
7.32 
o 
BOCHNVlN~ h uP 
7.33 
Potassium osmate (3 mg, 0.008 mmol), olefinic lactam 7.30 (52 mg, 0.16 mmoI) , t-butyl 
alcohol (3 mL), water (3 mL), potassium carbonate (68 mg, 0.49 mmol) , potassium 
ferricyanide (162 mg, 0.49 mmol), ligand 7.21 or 7.22 (6.4 mg, 0.0016 mmol) and methane 
sulphonamide (31 mg, OJ3 mmol) were reacted according to the general method Q with 
stirring for 48 h. The crude product, obtained as a mixture (9: 1 based on analysis of iH 
NMR spectrum) was purified by flash column chromatography (PE/EAlacetone 5:1:4) to 
give 41 mg (71 %) of a mixture of diols 7.32 and 7.33. Separation of the major isomer 7.32 
was then achieved by recrystallisation (CHCh/PE) to give the major isomer as a white solid. 
FU11her separation of7.33 from the mixture could not be achieved. 
Data for major isomer 7.32 
IHNMR major isomer (CD3CN, 500 MHz) 8 1.23 (s, 9H, t-Bu), 1.53 (dd, J= 11.5 Hz, 23.5 
Hz, 1H, CHuCHACHOH), 1.67 (dd, J= 12.5 Hz, 4.0 Hz, lH, CHuCHBCHOH), 2.94 (d, J= 
4 Hz, lH, NCH2CHOH), 3.04 (d, J= 5.0 Hz, 1H, CHCH2CHOH), 3.14 (dd, J= 15.5 Hz, 6 
Hz, 1H, NCHACHOH), 3.23-3.26 (m, lH, NCHBCHOH), 3.54 (bd, IH, CHuCH2CHOH), 
3.65 (bs, IH, NCH2CHOH), 3.71 (d, J= 15.0 Hz, lH, NCHAPh), 4.01-4.05 (m, 1H, CHu), 
5.16 (d, 15 Hz, 1H, NCHBPh), 5.72 (bs, IH, NH), 7.03-7.08 (m, 3H, Ar), 7.12-7.14 (m, 
2H, 
Chapter 8 252 
I3C NMR (CDCb, 75 MHz) 8 28.4 (t-Bu), 34.60 (CHuCH2CH), 46.93 (NCH2CH), 48.99 
(CHa), 53.14 (NCH2Ph), 68.41 (CCH2CHOH), 72.28 (NCH2CHOH), 79.87 ( C(CH3)3), 
127.64, 128.08, 128.72, 136.90 (Ar), 155.22 (OCO ), 171.63 (NCO). 
Anal calcd: C, 61.52; H, 7.74; N, 7.9%. Found: C, 61.40; H, 7.43; N, 7.86%. 
TOF MS ES+ [MHt: Found: 351.1922; Calcd for ClsH27N20S: 351.1920. 
tert-Butyl [(3R,5R,6S)-1-benzyl-5,6-dihydroxy-2-oxoazepan-3-yl] carbamate (7.33) 
Data for minor isomer 7.33: 
lHNMR (500 MHz, CDCb) 8 1.44 (s, 9H, t-Bu), 1.83 (t, 1 H, J = 12.5 Hz, 
CHuCHACHOH), 2.23-2.35 (m, 1 H, CHuCHBCHOH), 2.92-3.09 (m, 2H, NCH2CHOH), 
3.31-3.34 (d, 1 H, J= 5.0 Hz, NCH2CHOH), 4.12 (bs, 1 H, CHCH2CHOH), 4.48 (d, 1 H, J 
= 15.0 Hz, NCHAPh), 4.75 (d, 1 H, J = 14.5 Hz, NCHBPh), 4.84-4.87 (m, 1 H, 
NHCHaCH2), 6.06 (bd, J= 5.5 Hz, 1 H, NH), 7.16-7.34 (m, 5H, Ar). 
I3C NMR (CDCh, 75 MHz) 8 28.3 (t-Bu), 38.7 (CHuCH2CH), 46.1 (NCH2CH), 51.7 
(CHa), 68.1 (NCH2Ph), 68.4 (CCH2CHOH), 69.9 (NCH2CHOH), 79.9 ( C(CH3)3), 127.8, 
128.2,128.7,136.6 (Ar), 167.8 (OCO), 172.7 (NCO). 
(S)-benzyI2-«2R, 3R)-2-(tert-butyloxycarbonyl)-3-phenylpent-4-enamido)propanoate 
(7.38a) 
H ° \r /N 0, 
Boc ~N Bn 
. H ° 
Ph'" ;/ 
7.38a 
EDCI (66 mg, 0.34 mmol), HOBT (92 mg, 0.68 mmol) and NMP (10 p,L, 1.03 mmol) were 
added to a solution of the acid 7.37 (100 mg, 0.34 mmol) and (S)-alanine benzyl ester 
hydrochloride (73 mg, 0.34 mmol), using the general procedure M. The crude mixture 
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containing 7.38a by IH NMR < 10% of a second diastereoisomer tentatively assigned as the 
epimer 7.38b of the acid, which was Purified by column chromatography (PE/EA = 85115) 
to give 90 mg(58%) of7.38a as a white solid. 
Data for 7.38a: 
IH NMR (500 MHz) (3 1.30 (d, J 7 Hz, CH3NHa), 1.39 (3 CH3, t-Du), 3.98 (t, J= 6.5 Hz, 
IH, PhCH), 4.46 (m, 1H, PhCHCHaNH), 4.51-4.56 (m, IH, CH3CHa), 4.96 (bd, J= 6 Hz, 
IH, Ph CHCHaNH) , 5.14-5.19 (m, 4H, PhCHCHCH2, C02CH2Ph), 6.04-6.11 (m, IH, 
PhCHCHCH2), 6.26 (d, J 7.5 Hz, PhCHCHaNH), 7.22-7.39 (m, lOH, Ar). 
l3C NMR (CDCh, 75 MHz) (3 18.3 (CH3CHa), 28.2 (t-Bu), 48.2 (CH3CH~), 51.1 (PhCH), 
58.2 (NHCHaCHPh), 67.1 (OCH2Ph), 80.2 (C(CH3h), 118.1 (PhCHCHCH2), 127.2, 128.1, 
128.2, 128.3, 128.4, 128.5, ]28.6, 128.7, 130.9 (Ar) , 136.0 (PhCHCHCH2), 139.1 (Ar) , 
155.3 (OCO t_Bu), 169.8 (OCOBn), 172.2 (NCO). 
TOF MS ES+ [MHt: Found: 451.2437; Calcd for C27H3SN204: 451.2597. 
Data for 7.38b: 
'H NMR (500 MHz) (31.27 (d, J 10 Hz, CH3NHa), 1.38 (3 CH3, t-Bu), 3.94-3.99 (m, IH, 
PhCH), 4.48 (bm, IH, PhCHCHaNH), 4.54 (t, J = 7 Hz, IH, CH3CHa), 5.06 (bd, J = 6 Hz, 
IH, PhCHCHaNH), 5.13-5.41 (m, 4H, PhCHCHCH2, C02CH2Ph), 6.04-6.11 (m, lH, 
PhCHCHCH2), 6.23 (bs, IH, PhCHCHaNH), 7.20-7.38 (m, lOH, Ar). 
tert-Butyl «(1R, 2S)-1-{[ aHyI(benzyl)amino ]carbonyl}-2-methylbut-3-en-l-yl] 
carbamate (7.39) 
/~~o V Boc N I ~ Ph\\"~ <- h-
EDCI (200 mg, 1.03 mmol), HOBT (334 mg, 2.47 mmol), NEM (258 mg, 2.06 mmol) and 
N-allyl benzyl amine 7,28 (2.06 mg, 5.80 mmol) were added to a solution of the acid 7.37 
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(300 mg, 1.03 mmol) in DCM (30 mL) under argon with stirring at 1't for 72 h according to 
the general procedure M. The crude product was purified by flash column chromatography 
(PE/EA = 90110--;.. 85115) to give 183 mg [44%, 2:1 (based on analysis of IH NMR 
spectrum)] of the desired diene 7.39 as a white solid. 
Data for (2: 1) rotameric mixture. 
FTIR(KBr): 3319,2977,2360, 1710, 1697, 1647, 1496, 1434, 1367, 1249, 1168, 1047,921, 
700. 
IHNMR (500 MHz) IH NMR (500 MHz) 8 1.28 (s, 9H, t-Bu, minor), 1.30 (s, 9H, t-Bu, 
major), 3.66-3.76 (m, 2H, CHc;PhCH, minor, NCHACH, minor), 3.80 (t, 1H, CHc;PhCH 
major), 3.88 (dd, J= 16.5 Hz, 6.0 Hz, 1H, NCHACH, major), 4.18 (dd, J= 15 Hz, 6.0 Hz, 
2H, NCHBCH, major), 4.33-4.37 (m, 1H, NCHAPh, major and minor), 4.49 (d, J= 16.5 Hz, 
1H, NCHBPh, minor), 4.75 (d, J = 16.5 Hz, 1H, NCHBPh, major), 4.75-4.78 (m, 1H, 
NCHBCH, minor), 4.94 (t, J = 9 Hz, CHc;PhCH, major), 5.04 (t, J = 9 Hz, CHc;PhCH, 
minor), 5.08-5.20 (m, 4H, PhCHCHCH2, NCH2CHCH2, major and minor), 5.63-5.77 (m, 
1H, NCH2CHCH2, major and minor), 5.92-6.90 (m, 1H, PhCHCHCH2, minor), 6.06-6.13 
(m, IH, PhCHCHCH2, major), 7.16-7.34 (m, 10H, major and minor). 
l3C NMR (CDCh, 75 MHz) 828.1,28.3,47.9,48.3,49.2,50.0,53.1,53.2,53.7, 53.7, 79.6, 
117.7, 117.9, 126.9, 127.2, 127.4, 127.6, 128.4, 128.5, 128.6, 132.4, 132.7, 136.3, 136.6, 
136.7, 136.9, 139.4, 139.4, 154.7, 154.8, 171.3, 171.5. 
[a]20o +50.0 (c 1.0 CHCh) 
TOF MS ES+ [MHt: Found: 421.2498; Calcd for C26H33N203: 421.2491. 
tert-Butyl [(3R,4S)-1-benzyl-4-phenyl-2-oxo-2,3,4, 7 -tetrahydro-1H-azepin-3-yl] carba-
mate (7.40) 
PCy C}'" I 3 
Ru " <I" I Ph 
Cl PCY3 
6.2 
H 0 BOc/N6N~ 
Phi'" _ ~ 
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Catalyst 6.2 (68.5 mg, 0.08 mmol), dissolved in dry degassed DCM (3 mL) was added to 
solution of the diene 7.39 (175 mg, 0.42 mmol), dissolved in dry degassed DCM (20 mL) 
under argon, according to the general procedure O. The mixture was refluxed for 24 h. The 
crude product was purified by flash column chromatography (PE/EA = 812) to give 139 mg 
(85%) of the desired olefinic lactam 7.40 as a white crystalline solid. 
FTIR(KBr): 3315, 2976, 2929, 1701, 1641, 1535, 1492, 1444, 1365, 1340, 1319, 1170, 
1056,1018,937,698. 
lH NMR (500 MHz) 8 1.10 (s, 9H, t-Bu), 3.36 (dd, J = 18.0 Hz, 8.0 Hz, 1H, PhCHCH), 
3.42 (d, J = 11.5 Hz, 1H, NCH2CH), 4.45 (d, 1H, J = 17 Hz, NCH2CH), 4.62 (s, 2H, 
NCH2Ph), 5.16 (t, 1H, J = 10.5 Hz, NHClIa), 5.41 (d, IH, J = 9 Hz, NHCHa), 5.64-5.67 
(bm, 1H,CH2CHCH), 5.70-5.74 (m,lH, PhCHCH), 7.12-7.27 (m, 10 H, Ar). 
l3C NMR (CDCh, 75 MHz) 8 27.8 (C(CH3)3), 44.6 (NCH2CH), 49.4 (PhCHCH), 51.4 
(NCH2Ph), 53.7 (NHCH), 79.0 (C(CH3)3), 124.4 (CH2CHCH), 126.9, 127.5, 127.9, 128.1, 
128.58, 129.2 (Ar), 134.5 (PhCHCH), 136.6, 140.1 (Ar) , 154.6 (OCO-t-Bu), 172.1 (NCO); 
Anal found: C = 73.23, H = 7.36, N = 7.05; calcd: C = 73.44, H = 7.19, N = 7.13. 
TOF MS ES+ [MHt: Found: 393.2204; Calcd for C24H29N203: 393.2178. 
tert-Butyl [(SR,6R)-3-benzyl-6-phenyl-4-oxo-8-oxa-3- azabicyclo-[S.1.0]oct-S-yl] 
carbamate (7.41) 
J~QlV Boe N I '-'::: 
Phi'" ~ 
o 
The olefinic lactam 7.40 (40 mg, 0.10 mmol) in acetone (6 mL) and water (5 mL) was 
treated with sodium hydrogen carbonate (291 mg, 3.46 mmol) and Oxone® (627 mg, 1.02 
mmol) as described in the general procedure P. The resulting crude epoxide was purified by 
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column chromatography (PE/EA = 70:30) to give 36 mg (87%) of 7.41 (5:4, based on 
analysis of IH NMR spectlUm) as a white solid. 
Data for mixture of isomers (5:4) 
IH NMR (500 MHz) 0 1.16 (s, 9H, t-Bu, major), 1.26 (s, 9H, t-Bu, minor), 3.00-3.28 (m, 
3H, NCH2CHCH, major & minor, PhCHCH, major & minor, PhCH, major), 3.69-3.76 (m, 
1H, NCHACH, major & minor), 3.94 (dd, 1H, J= 15.5 Hz, 5 Hz, PhCH, 1H minor), 4.00 (d, 
J = 15.0 Hz, 1H, NCHAPh, major), 4.22 (d, J = 16.5 Hz, 1H, NCHBCH, major & minor), 
4.34 (d, J= 15 Hz, 1H, NCHAPh, minor), 4.82-4.90 (m, 1H, CHaCHPh, major & minor), 
5.05 (d, J= 14 Hz, 1H, NCHBPh, minor), 5.24 (d, J= 10 Hz, 1H, NH, minor), 5.33 (d, J= 
15.5 Hz, 1H, NCHBPh, major), 5.41 (d, J= 9 Hz, 1H, NH, major), 7.26-7.53 (m, 10 H, Ar, 
major & minor). 
13C NMR (CDCh, 75 MHz) 028.0,29.7,43.9,47.3,47.6, 50.4,51.3, 52.1, 52.2, 54.5, 56.4, 
57.0, 68.4, 79.3, 80.4, 127.3, 127.7, 128.5, 128.7, 129.0, 129.6, 136.2, 136.9, 139.3, 154.6, 
155.2, 169.4, 171.4. 
TOF MS ES+ [M+Ht: Found: 409.2124; Calcd for C24H29N204: 409.2127. 
tert-Butyl [(3R,4R,5S,6R)-1-benzyl-5,6-dihydroxy-4-phenyl-2-oxoazep an-3-yl]-
carbamate (7.42) 
Boc N I '-':::: /~QlV
Phi'" ~ 
RO OR 
Potassium osmate (2.2 mg, 0.003 mmol), olefinic lactam 7.40 (25 mg, 0.06 mmol), t-butyl 
alcohol (3 mL), water (3 mL), potassium carbonate (26 mg, 0.19 mmol), potassium 
ferricyanide (63 mg, 0.19), ligand 7.21 or 7.22 (2.5 mg, 0.0003 mmol) and methane 
sulphonamide (12 mg, 0.13 mmol) were reacted according to the general method Q with 
stirring for 48 h. The clUde product (obtained as a single isomer, determined by analysis of 
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lH NMR spectrum) was purified by flash column chromatography (PE/EA 1I1-l> 20180) 
to give 14 mg (51 %) of 7.42 (14 mg, 51%) as a colorless oil, along with recovered 9 mg 
(36%) of 7.40. 
lHNMR (500 MHz) 8 1.21 (s, 9H, t-Bu), 1.70 (bs, IH, (NCHzCHCHOH), 1.90 (bs, 0.5 H, 
CHzCHCHOH), 2.74 (bs, 0.5 H, CHzCHCHOH), 3.09 (t, 10 lH, CHa.CHPh), 3.56 
(dd, J= 16.5 Hz, 6.0 1H, NCHACH), 3.67 (m, 1H" NCHBCH), 4.02 (d, 15 Hz, 1H, 
NCHAPh), 4.07 (dd, J 11 Hz, 3.5 Hz, IH, PhCHCHOH), 4.16 (d, J 6 Hz, 3.5 Hz, IH, 
CHzCHCHOH ), 4.76 (t, J 9.5 Hz, IH, CHa.), 5.43 (d, J = 9 Hz, 1H, NH), 5.59 (d, J = 
14.5 Hz, lH, NCHBPh), 7.27-7.36 (m, 10 H, Ar). 
13CNMR (75 MHz) 8 28.11 (3 CH3), 46.39 (NCHzCH), 49.82 (CHa.CHPh), 51.29 (CHa ), 
53.03 (NCHzPh), 68.48 (NCHzCHOH), 76.66 (CHzCHCHOH), 79.32 (C(CH3)3), 127.56, 
127.76, 128.24, 128.67, 128.71, 136.60, 136.88 (Ar), 155.09 (OCO), 171.81 (NCO) 
TOF MS ES+ [MHt: Found: 427.2309; Calcd for CZ4H31NzOs: 427.2233. 
tert-Butyl «1S)-1-({benzyl[(1S)-1-benzylprop-2-en-l-yl]amino}carbony1) but-3-en-l-yl 
carbamate (7.47) 
(5)-N-Boc allyl glycine (250 mg, 1.16 mmol) , Bop coupling reagent (513 mg x 5, 1.16 
mmol) and DIPEA (620 f.1L, 3.48 mmol) were added to a solution of the amine (275 
mg, 1.16 mmol) in DCM (20 mL) under argon according to the general procedure N with 
stirring at rt for 72 h. The crude residue (3:2, based on analysis of IH NMR spectmm) was 
purified by flash column chromatography (PE/EA = 9/1) to give 336 mg (67%) of (3:2) 
as a clear oil. 
Data for 7.47 (3:2 mixture) 
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FTIR (KBr): 2977, 2856, 2360, 1697, 1647, 1633, 1497, 1434, 1367, 1249, 1168, 1047, 
921, 700. 
IH NMR (500 MHz) (5 1.42 (s, 9H, t-Bu, major), 1.43 (s, 9H, minor), 1.96-2.00 (m, 
CHaCHACH, IH, major), 13-2.17(m, CHaCHBCH, 1 H, major), 2.21 (t, J = 7.0 Hz, IH, 
CHCHAPh, major), 2.72-2.75 (m, CHaCHACH, IH, minor), 2.84-2.85 (m, CHaCHBCH, IH, 
minor), 2.89 (dd, J 13.5 Hz, 7.0 Hz, IH, CHCHBPh, major), 2.94 (d, J = 7.5 Hz, IH, 
CHCHAPh, minor), 3.01 (dd, J 13.5 Hz, 7.0 Hz, IH, CHCHBPh, minor), 4.26 (d, J= 15 
Hz, IH, NCHAPh, major), 4.42-4.51 (m, 3H, NCHAPh, minor, CHCH2Ph, major), 4.51-
4.60 (m, IH, CHCH2Ph, minor), 4.83 (d, J = 16 Hz, NCHBPh, major), 4.85-4.87 (m, IH, 
NHCHa, major & minor), 4.95-5.31 (m, 5H, NCHCHCH2, CHCH2CHCH2, major & minor, 
NCHBPh, minor), 5.53-5.63 (m, tH, NCHCHCH2, major), 5.76-5.87 (m, 2H, NCHCH, 
CH2CHCH2, minor), 5.94-6.01 (m, IH, CH2CHCH2, major), 7.05 (d, J 7.0 Hz, IH, Ar), 
7.14-7.29 (m, major & minor). 
l3C NMR (CDCh, 75 MHz) (5 28.3 (i-Bu, major), 29.6 (i-Bu, minor), 37.3 (CHaCH2CH, 
minor), 37.6 (CHCH2Ph, major), 38.4 (CHaCH2CH, major), 38.6 (CHCH2Ph, minor), 46.5 
(NCH2Ph, minor), 49.7 (NCH2Ph, major and CHa , minor), 50.7 (CHa, major), 60.9 
(CHCH2Ph, major), 61.1 (CHCH2Ph, minor), 79.5 (C(CH3)3, major), 79.6 (C(CH3)3, 
minor), 117.6, 118.0 (CH2CHCH2, major and minor), 118.1, 118.2 (CH2CHCH, major & 
minor), 126.4, 126.7, 126.8, 127.0, 127.3, 127.5, 128.3, 128.6, 128.7, 129.3 (Ar, major & 
minor), 133.0, 133.2 (CH2CHCH, major), 135.7, 136.2 (CH2CHCH2, major and minor), 
137.1, 137.4, 138.1, 138.4 (Ar) , 155.1, 155.2 (OCOt-Bu, major & minor), 172.7, 172.9 
(NCO, major and minor); [a,fOD -66.2 (c 1.0 CHCh). 
TOF MS ES+ [IVIHt: Found: 435.2635; Calcd for C27H35N203: 435.2648. 
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tert-Butyl [(3S, 7 S)-1-bellzyl-7-benzyl-2-oxo-2,3,4, 7-tetrahydro-l H-azepin-3-yl] 
carbamate (7.48) 
n 
MesNyNMes 
_ L",Cl 
Ru~ 
CI<f" I Ph 
PCY3 
6.4 
o 
BOCHNllcY~ , N Ph 
Ph 
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Catalyst 6.4 (46 mg, 0.05 mmoI) , dissolved in dry degassed DCM (3 mL) was added to 
solution of the diene 7.47 (291 mg, 0.67 mmol), dissolved in dry degassed DCM (20 mL) 
under argon, according to the general procedure O. The mixture was refluxed for 36 h. The 
crude product was purified by flash column chromatography (PE/EA 911 then 812 ) to 
give 250 mg (92%) ofthe desired olefinic lactam 7.48 as a brown oil. 
IR (KBr): 3062, 2977, 1737, 1649, 1458, 1471, 1440, 1365, 1325, 1172, 1055, 1029, 985, 
871,702. 
IHNMR (500 MHz) () 1.48 (s, 9H, t-Bu), 2.30 (dt, J = 14.5 Hz, 2 Hz, 1H, NHCHCH2), 2.66 
(dd, J = 18 Hz, 4 Hz, 1H, NHCHCH2), 3.03-3.11 (m, 2H, CHCH2Ph), 3.56 (d, J 15.5 Hz, 
1H, NCHAPh), 3.92 (dd, J 14 6.5 Hz, 1H, CHCH2Ph), 4.82-4.86 (m, 1H, NHCH~), 
5.07 (d, J= 15 Hz, 1H, NCHBPh), 5.46 (t, J= 10 Hz, 1H, NCHCH), 5.77 (dd, J 11.5 Hz, 
6 Hz, 1H, CHaCH2CH), 6.03 (bd, J 6.5 Hz, IH, NHCH~), 7.09-7.15 (m, 2H, Ar), 
7.35 (m, 3H, Ar). 
l3C NMR (CDCb, 75 MHz) () 28.4 (t-Bu), 32.5 (NHCHCHz), 42.4 (CHCH2Ph), 52.3 
(NCHzPh), 52.4 (NHCHu), 61.4 (CHCH2Ph), 79.5 (C(CH3)3), 126.9 (CHaCH2CH), 127.4, 
127.4, 127.5, 128.2 (NCHCH), 128.6, 128.6, 129.1, 136.9, 137.5 (Ar) , 155.1 (OCO' 
172.1 (NCO); [a]2oD -29.8 (c 1.0 CHCb). 
TOF MS ES+ [MHt: Found: 429.2157; Calcd for CZSH31N2Na03: 429.2154. 
Chapter 8 
tcrt-Butyl [(2S,5S)-3-benzyl-2-benzyl-4-oxo-8-oxa-3-azabicyclo 
carbamate (7.49) 
o 
BOCHNI'(r/'--... h ' N P 
Ph 
o 
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The olefinic lactam (80 mg, 0.197 mmol) in acetone (12 mL) and water (10 mL) was 
treated with sodium hydrogen carbonate (562 mg, 6.70 mmol) and Oxone® (1.21 g, 1.97 
mmol) as described in the general procedure P. The resulting crude epoxide 01: 1, based on 
analysis of IH NMR spectrum) was purified by column chromatography (PE/EA 70/30) 
to give 70 mg (84%) of 7.49 (~1: 1) as a white foam. 
Data for mixture of diastereomers: (~1: 1) 
FTIR (KBr): 3030,2972,2979,2856,2360,2343, 1708, 1645, 1602, 1542, 1473,1440, 
1365,1240,1166,1053,1028,941,869,736,698. 
IHNMR (500 MHz) (5 1.45 (s, 9H, t-Bu), 2,01 (d, J = 14.5 Hz, 1H, CHCHACH), 2.09 (d, J 
= 13.0 Hz, IH, CHCHACH), 2.55 (m, IH, CHCHBCH), 2.69 (d, J 14.5 Hz, IH, 
CHCHBCH), 2.89-2.93 (m, 2H, CHCHABPh), 2.98 (dd, J = 13 Hz, 6 Hz, 1H, OCHCHN), 
3.11 (dd, J= 7.5 Hz, 4 1H, OCHCHzCH), 3.17 (dd, J= 14 Hz, 8 Hz, 1H, OCHCH2C'H), 
3.27 (bm, 1H, OCHCHN), 3.30 (t, J 5 Hz, 2H, CHCHABPh), 3.63 (d, J 14.5 Hz, 1H, 
NCHAPh), 3.92 (dd, J 14.5 7 Hz, 1 H, CHCHN), 4.11 (m, 1 H, CHCHN), 4.40 (s, 2H, 
NCHABPh), 4.55 (t, J 9 1H, NHCH), 4.62 (m, 1H, NHCH), 5.05 (d, J 15 Hz, 1H, 
NCHBPh), 5.79 (bd, J 6.5 Hz, IH, NH), 5.97 (bd, J= 6.5 Hz, 1H, NH), 6.92 (d, J 7.5 
Hz, 2 H, Ar), 7.14 (d, J Hz, 2 H, Ar), 7.18 (d, J= 7.5 Hz, 2 H, Ar), 7.22-7.36 (m, 4H, 
Ar). 
I3C NMR (75 MHz) (5 28.4 (C(CH3)3), 29.8, 32.2 (CHCHzCH), 37.5, 38.6 (CHCHzPh), 
46.9, 50.6 (NHCH), 52.4, 53.1 (NCHzPh), 53.3, 53.7 (CHCHCHzPh), 54.8, 55.3 
(CHCHzCH), 58.8, 58.9, (CHCHzPh), 79.8, 80.4 (C(CH3)3), 126.9, 127.1, 127.8, 127.9, 
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128.5,128.7,128.9, 129.0, 129.3, 136.2, 137.0, 137.2, 137.5 (Ar) , 1 .0 (OCOI-Bu), 171.2, 
172.2 (NCO). 
TOFMS 
tert-Butyl[ (3S,5R,6S, 7 S)-1-benzyl-5,6-dihydroxy-7-benzyl-2-oxoazepan-3-yl] 
carbamate (7.50) 
o 
, N Ph BOCHNllry 
Ph 
HO bH 
(a) Potassium osmate (2mg, O.OOS mmol), olefinic lactam 7.48 (20 mg, O.OS mmol), t-butyl 
alcohol (3 mL), water (3 mL), potassium carbonate (21 mg, O.lS mmol), potassium 
ferricyanide (49 mg, O.lS), ligand 7.21 or 7.22 (4 mg, .002 mmol) and methane 
sulphonamide (10 mg, 0.1 mmol) were reacted according to the general method Q with 
stirring for 48h. The crude product 7.50 (obtained as a single diastereoisomer, based on 
analysis of IH NMR spectrum) was purified by flash column chromatography (PE/EA 
SO/SO-;. 20/80) to give 11 mg (S2%) of 7.50 as a white oily solid. 
IH NMR (CD3CN, 500 MHz) 0 1.30 (s, 9H, t-Bu), 1.64-1.74 (m, 2H, CHCH2CHOH), 2.49 
(dd, J 13.S 6Hz, 1 H, CHCHAPh), 2.76 (bs, 1H, CHCHOH), 2.86 (dd, J = 13.5 Hz, 10 
Hz, Hr, CHCHBPh), 2.99 (bs, 1H, CH2CHOH), 3.S1 (bs, 1H, CHCHOH), 3.61-3.66 (m, 
IH, CHCHOH), 3.96 (d, J 14.S Hz, 1H, NCHAPh), 4.01-4.03 (m, IH, CH2CHOH), 4.1 
4.18 (m, lH, CHCH2CHOH), 4.69 (d, J 14.S Hz, 1H, NCHBPh), S.82 (bs, 1H, NH), 6.77 
(d, J 7.0 Hz, 2H, Ar), 7.02-7.09 (m, 3H, Ar), 7.13-7.19 (m, SH, Ar). 
l3C NMR (CDCb, 75 MHz) 0 28.43 (t-Bu), 33.98 (CHuCH2CH), 37.16 (NCHCH2Ph), 
50.04 (CHuCH2CH), 54.79 O'l"CH2Ph), 63.41 (NCHCHOH), 68.64 (CH2CHOH), 69.69 
(CHCHOH), 79.83 (C(CH3)2, 127.0, 128.0, 128.55, 128.79, 128.84, 129.21, 137.06, 137.33 
(Ar), 155.21 (C02t-Bu), 171.44 (NCO); [a]2oD + 18.1 (c 1.0 CHCb). 
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TOF MS ES+ [MHt; Found: 441.2389; Calcd for C25H33N205: 441.2389. 
(b) Potassium osmate (2mg, 0.005 mmol), olefinic lactam 7.48 (20 mg, 0.05 mmol), t-butyl 
alcohol (3 mL), water (3 mL), potassium carbonate (21 mg, 0.15 mmol), potassium 
felTicyanide (49 mg, 0.15), and methane sulphonamide (10 mg, 0.1 mmol) were reacted 
according to modified general method Q in the absence of ligands with stirring for 48 h. 
The crude product 7.50 (obtained as a single diastereoisomer, based on analysis of IH NMR 
spectrum) was purified by flash column chromatography (PE/EA 50/50~ 20/80) to give 
12.5 mg (59%) of 7.50 as a white oily solid. 
Data for 7.50 as above 
Benzyl (1 (RS)-{[ (1-benzyl-2-oxo-2,3,4, 7-tetrahydro-1H-azepin-3-yl)amino I 
carbonyl}-2(S)-methylpropyl)carbamate (7.57) 
Compound 7.30 (200 mg, 0.63 mmol) was treated with 1 N HC} (aqueous, 2 mL) in EA (6 
mL) at rt with stirring for 4 h. The progress of the reaction was monitored by was 
evaporated in vacuo, MeOH was added (x2) and the solvent was evaporated in vacuo. The 
crude free amine was dried in vacuo and used without further purification. 
(S)-N,Cbz Valine (137 mg, 0.55 mmol) was added to the crude free amine (118 mg, 
0.55 mmol), EDCI (104 mg, 0.55 mmol), HOBT (147 mg, 1.09 mmol) and DIPEA (190 flL, 
1.09 mmol) in dry DCM (20 mL) and the mixture was stined at It for 16 h. Water (4 mL) 
and EA (8 mL) were added to the mixture, the organic phase separated and the aq. phase 
extracted with EA (x3). The combined organic fractions were washed with H20 (x2), 
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NaHC03, brine) dried (MgS04) and evaporated in vacuo. The residue (a mixture of 1: 1 
diastereoisomers by analysis of lH NMR spectrum) was purified by flash column 
chromatography (PEIEA 50:50) to give 160 mg (66%) of 
solid. 
Data for 7.56 (1: 1) mixture of diastereoisomers 
(12 mg, 52%) as a white 
lH NMR (CDCh) 500 MHz) 0 0.92 (dd, J= 7 Hz, 2.5 Hz, 3H, (CH3)zCH), 0.98 (dd, J= 7 
Hz, 2.5 Hz, 3H, (CH3)2C), 2.04-2.26 (m, 2H, (CH3)2CH, CH=CHCHACH), 2.23-2.26 (m, 
IH, CH=CHCHBCH), 3.34-3.39 (m, IH, NCHACH), 4.14 (dd, J 13 Hz, 7 Hz, lH, 
NHCHuCH2), 4.27-4.33 (m, lH, CH=CHCHBCH), 4.60 (d, J 14.5 1H, NCHAPh), 
4.73 (d, J= 14.5 Hz, IH, NCHBPh), 5.08-5.21 (m, 3H, (CH3)2CHCHa, PhCH20), 5.43 (bm, 
IH, NHCHCH2), 5.45-5.59 (m, lH, CHClbCH), 5.60-5.69 (m, IH, NCH2CH), 7.20-7.36 
(m, lOH, Ar) 
l3C NMR (CDCh, 75 MHz) 0 17.5,17.6 (CH3), 19.1,19.2 (CH3), 31.3, 31.4 «CH3hCH), 
32.3, 32.5 (CHCH2CH), 45.1 (NCH2CH), 49.1 «CH3)2CHCHu), 51.7 (NCH2Ph), 60.1, 
60.2 (NHCHuCH2), 67.0 (PhCH20), 124.1, 124.2 (NCH2CH), 127.6, 127.8, 128.0, 128.1, 
128.5, 128.7 (Ar), 129.9 (CH2CHCH), 136.2, 136.5 (Ar), 156.3 (OCOBn), 170.1, 170.2 
(NCO), 171.8, 171.9 (NHCO). 
TOF MS ES+ [MHt: Found: 450.2394; Calcd for C26H32N304: 450.2393. 
tert-Butyl «lR, 2S)-1-({benzyl[(1S)-1-benzylprop-2-en-l-yl]amino}carbony1)-2-
phenylbut-3-en-l-yl)carbamate (7.53) 
o 
BOCHN~l ~ N Ph 
Ph"" /, ~Ph 
Pyridine (50 j1L, 0.69 mmol) was added to a soln. of the acid 7.37 (200 mg, 0.69 mmol) in 
dry DCM (15 mL). The solution was cooled to -20 °C, cyanuric fluoride (500 j1L, 3.43 
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mmol) was added and the mixture stirred for 2 h at the same temperature. DCM was 
evaporated in vacuo, dry toluene (20 mL) was added to the residue and filtered. The solvent 
was evaporated in vacuo and dried to give the acid fluoride 7.52 as a pale yellow oil which 
was used in the next step without purification. 
To a solution of the amine 7.46 (150 mg, 0.63 mmol) in DCM (15 mL), was added DIPEA 
(60 ILL, 0.64 mmol) and stirred for 30 min at that temperature. A soln. of the crude 7.52 in 
DCM (5 mL) was added slowly to the reaction mixture and stirred for 2 hat ° °C and 16 h 
at rt. Water was added to dilute the reaction mixture, organic layer was separated and 
aqueous layer back extracted with DCM (x3). The combined organic extracts were washed 
with sat. NaHC03 soln and brine, dried (MgS04) and evaporated in vacuo. The residue was 
purified by flash column chromatography to give 40 mg (12%) of 7.53 as a colourless 
viscous oil as well as 75 mg (50%) of the recovered amine 7.46. 
IH NMR(CDCh, 500 MHz) 8 1.23, 1.25, 1.28, 1.33 (s, 9H), 2.81-2.86 (m, IH), 2.90-2.98 
(m, 2H), 3.16-3.20 (m, 0.5 H), 3.70-3.77 (m, IH), 3.81-3.84 (m, 0.5 H), 4.08 (d, J = 17.5 
Hz, 0.5 H), 4.36-4.55 (m, 1.5 H), 4.77-4.85 (m, IH), 4.97-5.25 (m, 4H), 5.53-6.07 (m, 2H), 
7.01-7.18 (m, 15 H). 
l3C NMR (CDCh, 75 MHz) 8 28.0, 28.0, 28.1, 28.1, 38.4, 38.5, 38.7, 39.6, 46.1, 48.5, 51.0, 
53.2, 53.3, 53.6, 53.7, 54.0, 54.1, 55.5, 59.7,61.0,61.1,62.9, 79.4, 79.5, 115.0, 117.3, 
117.4, 117.5, 117.6, 117.8, 118.6, 126.2, 126.3, 126.5, 126.6, 126.7, 126.7, 126.8, 126.8, 
126.9, 127.2, 127.3, 127.4, 127.4, 127.8, 127.9, 128.1, 128.2, 128.3, 128.4, 128.4, 128.5, 
128.6, 128.7, 128.7, 129.2, 129.3, 129.4, 135.6, 135.7, 135.8, 136.6, 136.7, 136.8, 137.0, 
137.2, 137.6, 137.9, 138.2, 138.4, 138.5, 139.3, 139.5, 154.5, 171.8, 171.9. 
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N-allyl-N-benzyl-3-phenylbu t-3-enamide (7.58) 
EDCI (279 mg, 1.45 mmol), HOBT (397 mg, 2.91 mmol) and NMP (420 f-LL, 4.37 mmol) 
were added to a solution of the acid 7.57 (236 mg, 1.45 mmol) and N-allyl benzyl amine 
(213 mg, 1.45 mmol), using the general procedure M. The clUde mixture containing 7.58 
by lH NMR 35% of a by product 7.59, which was purified by column chromatography 
(PE/EA = 90110) to give 150 mg of 7.58 (35%) as a colorless oil as well as 7.59 (15%) as a 
yellow oil. 
Data for 7.58 (2:3) 
lH NMR (acetone-d6, 500 MHz) 8 3.52 (s, 2H, PhCCH2, minor), 3.56 (s, 2H, PhCCH2, 
major), 3.83 (s, 2H, NCH2CH, major), 3.86 (s, 2H, NCH2CH, minor), 4.43 (s, 2H, NCH2Ph, 
major), 4.49 (s, 2H, NCH2Ph, minor), 4.97-5.14 (m, 3H, NCH2CHCH2, CH2 C(Ph) CH2, 
major and minor), 5.42-5.43 (m, 1H, CH2C(Ph)CH2, major and minor), 5.63-5.69 (m, 1H, 
NCH2CHCH2, minor), 5.70-5.79 (m, 1H, NCH2CHCH2, major), 6.8-7.4 (m, 10H, Ar). 
(2E)-N-allyl-N-benzyl-3-phenylbut-2-enamide (7.59) 
Data for 7.59 (~1:1) lHNMR(acetone-d6, 500 MHz) 8 2.94, 2.51 (s, 3H, CH3), 4.15-4.25 
(m, 2H, NCH2CH), 4.76-4.84 (m, NCH2Ph), 5.34-5.41 (m, 2H, NCH2CHCH2), 5.97-6.11 
(m, 1H, NCH2CHCH2), 6.64 (s, 1H, PhCCHCO), 7.44-7.75 (m, 10H, Ar). 
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